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Abstract 
 
African trypanosomiasis is a protozoan infection affecting tens of thousands of people 
and millions of livestock animals across sub-Saharan Africa. In humans the disease is 
fatal without chemotherapeutic intervention and in animals it causes a severe anaemia 
that greatly impairs productivity. Available drug compounds are difficult to administer 
and unacceptably toxic.  
A natural product, ascofuranone, inhibits a key trypanosome specific respiratory 
enzyme, trypanosome alternative oxidase, and was shown over a decade ago to be 
trypanocidal using both in vitro and in vivo experiments. The compound suffers from 
rapid metabolism and contains several functionalities undesirable in a drug compound. 
Despite the promising activity the lack of applicable synthetic methods available 
hampered the development of chemotherapeutics from ascofuranone.  
In this work, novel synthetic routes were completed to explore the lead compound. New 
synthetic methods were successfully developed using palladium catalysed Suzuki 
couplings and Lewis acid catalysed rearrangements. 
Ortho-lithiation approaches also afforded potent novel inhibitors. Of particular note is a 
benzisoxazole, which is expected to alleviate many of the metabolic issues associated 
with ascofuranone. Alternate heterocycle analogues were explored and an interesting 
indazole analogue obtained. 
Finally, chemical methods were developed towards the benzisoxazole and indazole 
motifs with carboxylic acids, amenable to diversification by amide coupling. A 
preliminary range of novel amide containing 5, 6-heterocycles were synthesized to begin 
SAR exploration of these structures. 
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RNA 
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T3P propylphosphonic anhydride 
TAO trypanosome alternative oxidase  
TbAT1 trypanosoma brucei adenosine transporter 1 
TbCatB Trypanosoma brucei cathepsin B  
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TgsGP T. brucei gambiense-specific glycoprotein 
THF tetrahydrofuran 
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Chapter 1 - Literature Review 
Introduction 
African trypanosomiasis is a disease caused by specific members of the genus 
trypanosoma. There are a diverse range of trypanosome species, and all are unicellular 
parasites that have developed elaborate mechanisms for survival within their hosts. An 
essential feature of these adaptations is the ability to continuously alter the expression 
of the antigens exposed on the cell's surface. This constant antigenic variation effectively 
conceals the parasitic infection from the host immune response, and this capacity to 
evade host immune systems has allowed trypanosomes to propagate in many species 
across the world. In Africa, some organisms have developed trypanosomal lytic factors 
(TLF) to combat these parasites. They are proteins specific to humans, apes and some 
monkeys that circulate in the blood and lyse trypanosomal cells on contact.  
Two species of trypanosomes, Trypanosoma brucei rhodesiense and Trypanosoma 
brucei gambiense, have developed separate novel adaptations that negate the effect of 
the lytic factors and these species cause human African trypanosomiasis (HAT). In 
contrast, animal African trypanosomiasis (AAT), which affects important livestock 
species lacking lytic factors, is caused by different trypanosome species: T. Congolese, T. 
vivax, and T. b. brucei.  
Trypanosomal diseases greatly impact Africa in terms of lives lost, suffering endured and 
livelihoods compromised. In animals, the major detrimental effect is chronic anaemia: 
however in humans, the disease is debilitating and fatal without chemotherapeutic 
intervention.   
HAT has two distinct stages. In phase 1 it infects the blood and lymph; in phase 2 it 
penetrates the central nervous system (CNS), leading to neurodegeneration, coma and 
death. Drug treatments available for HAT are limited to five compounds, none of which 
are ideal: apart from their varying effectiveness, many are also overly toxic and difficult 
to administer. The development of novel therapeutics are underway, and an excellent 
candidate for drug development is trypanosomal alternative oxidase (TAO).  
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TAO is a parasite-specific respiratory enzyme: inhibiting this with a natural product, 
ascofuranone (AF), has been shown to be trypanocidal both in vitro and in murine 
models. AF inhibits TAO in picomolar concentrations and is a lead compound from which 
drug development can commence. With inhibition proven, AF represents an exciting 
opportunity for HAT treatment: however, there are several functionalities present on AF 
that are metabolically undesirable and require alteration. To date, the limited synthetic 
methods available to access AF-like compounds have impeded exploration of this lead 
compound. The development of novel methods and synthesis of drug-like AF analogues 
is the subject of this thesis. 
 
Trypanosomes 
Trypanosoma are a genus of kinetoplastids, a unicellular eukaryotic class of protozoa.1,2 
There are dozens of species of trypanosomes, all of which are obligate parasites in 
nature, requiring a host organism for survival.  
The genus has several characteristic features. All trypanosomes have misshapen or 
modified mitochondria3 that contain kinetoplastid deoxyribonucleic acid (DNA) loops in 
a combination of minicircle and maxicircle structures.4 These unique circular DNA 
agglomerations encode the mitochondrial respiratory enzymes on their maxicircles and 
the regulation of maxicircle gene expression appears to be controlled in part by the 
minicircles, via guiding RNA.5 They are monoflagellate6 and have a cytoskeleton7 
primarily composed of microtubules and distinctly lacking in the other major eukaryotic 
cytoskeletal protein, actin.7 Finally, flagellar rotation and cytoskeletal undulation 
contribute to permit them a distinctive corkscrew-like motility, which is observable by 
confocal microscopy. 
The obligate parasitic life cycle of trypanosomes makes them the cause of many serious 
diseases. They are ubiquitous across the majority of vertebrate life forms including 
mammals,8 amphibians,9 birds10, fish11 and are likewise observed in various insects12 and 
flora.13 
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Trypanosomes have evolved sophisticated immune-evasion mechanisms that allow 
them to perpetually reside alongside host immune systems and therefore become highly 
pervasive parasites. These adaptations are multifarious14–18but the trypanosomes' 
variant surface glycoprotein (VSG) is pre-eminent, easily surpassing its other virulent 
adaptations.19,20 VSG is an example of antigenic variation, a changing of the proteins 
expressed on the cell’s surface. It is a 58-kDa glycophosphatidylinositol (GPI)-anchored 
glycoprotein, predominantly α-helical in secondary structure, which has its C-terminus 
embedded in the membrane and sequentially varied N-terminus exposed to the 
extracellular medium of the host.19  
VSG represents a huge proportion of the overall protein synthesized by the cell. There 
are an estimated 107 copies21 comprising approximately 90% of cell surface 
polypeptides,22 requiring 20,000 VSGs to be formed, modified and distributed to the cell 
surface every minute.23 The VSG changes at a rate of up to 10-3 switches/cell/division24 
with each cell cycle taking 8 hours19 and peak parasitic load being 106/mL (in murine 
models).25  
Such frequent modification of the VSG during infection is enabled by various genetic and 
epigenetic mechanisms. VSG genes are >1600 in number,26 existing internally on the 11 
diploid chromosomes,27 in non-expressed genes at the telomeres28 and on hundreds of 
aneuploid mini-chromosomal units.29 At any one time however only 5-10% of these VSG 
genes are expressed26 and there are several ways in which a VSG gene present at an 
expression site can be transformed into another. Most commonly, after DNA damage 
upstream of the VSG expression site, one of several DNA damage repair mechanisms is 
utilized to replace the initial gene with the that of the recombinant VSG.30 By this 
method, which accounts for about 80% of VSG replacement, the whole gene is 
exchanged. 31  
A less observed method also exists which consists of mixing various parts of several VSG 
genes and pseudogenes to create completely new VSGs.32 This creates many non-viable 
proteins but importantly also a viable minority that are novel and affords the VSG a 
virtually inexhaustible variability.32 This is further enhanced by the potential for post-
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translational modification of the N-terminus by oligosaccharide glycan formation in the 
endoplasmic reticulum and Golgi apparatus.33,34  
In combination, the variation and profligate production of VSGs outpaces the immune 
system's ability to identify and match the antigens on these pathogens. Consequently, 
even the adaptive immune system is permanently lagging and only ever able to act on 
parasites with the oldest antigens that it has had time to recognize and mobilize a 
response against. Meanwhile it remains continuously "blind" to the new antigen-
expressing parasites, allowing sufficient time for this subset to further replicate and 
diverge, ad infinitum.    
With their exceptional immune evasion capabilities, trypanosomes have successfully 
colonized much of the world, with specific species of the genus having adapted to 
particular hosts. This specification is true too for human hosts. There are two particularly 
striking examples of human infection. The first is Chagas Disease, which is native to 
South America and caused by Trypanosoma cruzi,35 and the second, which is the main 
focus of this doctoral research, is Human African Trypanosomiasis (HAT) or sleeping 
sickness, caused by Trypanosoma brucei.36  
 
Epidemiology and History of African Trypanosomiasis 
The first unequivocal display of trypanosomes in human blood was made by the British 
Colonial surgeon Robert Michael Forde in 1901 when examining a steamboat captain in 
The Gambia.37 Forde initially mistook the trypanosomes as worms38 but was corrected 
a few months later by the English physician Joseph Everett Dutton, who also gave the 
species its name, Trypanosoma gambiense (now T. b. gambiense).39 In the same year, 
the Italian physician and pathologist Aldo Castellani suggested that trypanosomes cause 
sleeping sickness, having identified them in the cerebrospinal fluid of patients.38,40 
HAT is a debilitating disease with a severe social and economic impact across Africa 
(Figure 1). The parasite's transmission vector is the tsetse fly, as observed by Scottish 
pathologist and microbiologist David Bruce in 1903.38,41 As such it is exclusively found in 
sub-Saharan Africa between 14°N and 20°S in the so-called "tsetse belt" where the 
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insect is endemic. Across the 36 affected countries an estimated 60 million people are 
at risk of contracting HAT.42  About 70,000 people are thought to be currently infected, 
with approximately 30,000 new infections a year43 and 10,000 deaths.44  
The burden of the disease is measured not only in mortalities but also as the impact on 
community life and the contribution of individuals to food production and community 
support. This morbidity function is regularly measured in terms of disability-adjusted life 
years (DALYs),45,46 where one DALY can be thought of as one lost year of "healthy" life. 
HAT exhibits high morbidity, currently resulting in 1.78 million DALYS with the 60 million 
at risk.47 This magnitude is better understood when compared with the related 
trypanosomal disease leishmaniasis, which causes only slightly more DALYs, 2.06 million, 
despite being more widespread and affecting significantly more people, 350 million at 
risk in 88 countries.47  
 
Figure 1 - Distribution of HAT with incidences and risk for travelers. The black line divides the areas in which 
Trypanosoma brucei gambiense prevails and those in which Trypanosoma brucei rhodesiense predominates.36 
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The history of human sleeping sickness has been characterized by the interspersion of 
disease epidemics with long periods of endemicity. Three major epidemics have been 
recorded in the 20th century: 1900-20, 1940-50 and 1970-80. Positively, HAT is currently 
experiencing a trend towards reduction of incidences and is in one of its endemic 
phases, but a resurgence is all but inevitable, especially as the co-ordinated national and 
pan-national monitoring and treatment can easily collapse when stressed: be it by 
governmental collapse, financial collapse, civil war or large-scale population migrations, 
which have been unfortunately common across sub-Saharan Africa over the decades.   
Trypanosomes also cause sleeping sickness in animals, and in animals it is called 
‘nagana’, or Animal African Trypanosomiasis (AAT). The disease affects animals in a 
similar way to humans, which is discussed at length below, however animals also suffer 
an onerous anemia48 which has a major impact on livestock productivity be it in meat, 
dairy or breeding.48   
Wild mammal species endemic to sub-Saharan Africa have largely developed a 
resistance to trypanosomiasis, termed trypanotolerance.49 This ability allows the 
animals to remain healthy, active and gain weight whilst enduring parasitemia.49 Native 
cattle species also display some trypanotolerance and substantial work has been done 
to identify its genetic origin.50–53 Genes affording resistance have been identified across 
several quantitative trait loci in the trypanotolerant African N'dama (Bos taurus) and 
even in some breeds more recently arrived to Africa like the trypanosuceptible Boran 
(Bos indicus).52   
Two phenotypes have been linked to possession of these trypanotolerant genes. The 
first is a better capacity to control parasitemia and is mediated by haemopoietic cells (T 
lymphocytes or antibodies). The second is a better capacity to limit anaemia 
development and is mediated by haemopoietic cells, but not by T lymphocytes or 
antibodies.53 Weight gain has been linked to the latter mechanism, implying that 
anaemia control is more important for survival and productivity than parasite control.53 
The majority of cattle reared across sub-Saharan Africa are not trypanotolerant and 
work continues to see if selective breeding of these traits can be coupled to the 
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economically necessary traits of livestock and if successful this could represent a low-
cost method to battle AAT.52  
As it stands, however, AAT is a widespread problem, causing about three million deaths 
in cattle and requiring approximately 35 million doses of trypanocidal drugs to be 
administered54 every year. The economic losses in cattle production alone are in the 
range of US$1-1.2 billion per annum and AAT is the single largest infectious disease of 
cattle in Africa.54,55 This is a particularly high relative cost when the current states of sub-
Saharan economies, which are largely primary economies with low GDPs, are taken into 
consideration. The full cost can be assumed to be higher as this figure doesn't take into 
account less measurable impacts such as the effect of reduced nutrition and income 
from meat and dairy loss, or the effect of increased manual labour, decreased area 
farmed and yield of crops due to unhealthy draught animals.   
For example, the Democratic Republic of Congo (DRC) has accounted for roughly 70% of 
total HAT cases in the last ten years.42 It also has 70% of citizens living below the 
international poverty line. A one billion dollar loss would represent a substantial portion 
of the national economy, lowering household incomes and retarding socio-economic 
development. Taking these figures in context further demonstrates the devastating 
impact African trypanosomiasis is having on the sub-Saharan region and the DRC in 
particular.  
 
 Trypanosomal lytic factor 
Four species of trypanosomes cause the majority of trypanosomal disease in mammals 
and these have distinct infection profiles across Africa (Figure 1). There is a clear 
distinction in infective capabilities of different species due to the evolution of 
trypanosome lytic factors (TLFs) unique to humans, gorillas and Old World monkeys, 
which afford an innate immunity to a subset of trypanosomes.56  
Two different serum complexes have been identified as TLFs.57 TLF1 is the densest 
fraction of high density lipoprotein (HDL) particles. It contains a lipid core with an outer 
hydrophilic layer of phospholipids, cholesterol and several apolipoproteins (APO), 
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including APOA1, the major component of HDL in serum.58 TLF2 is a distinct complex 
that has few lipids, instead comprising mostly of natural immunoglobulin Ms, together 
with APOA1 amongst other proteins.59 Common to both complexes are the haptoglobin-
related protein (HPR) and APOL1, which has been shown to be trypanocidal.57  
As a result of the different compositions of the TLF1 and TLF2 complexes, the methods 
by which the two interact with trypanosomes are understandably divergent. In human 
serum, the TLF1-HPR complex binds to hemoglobin60 and only then does it have a high 
affinity for the trypanosomal receptor TbHpHbR.61 The ligand-bound complex 
undergoes receptor-mediated endocytosis62 at a region known as the flagellar pocket, 
which is responsible for concentrating cell surface receptors, including TbHpHbR, 
around the base of the flagellum. This flagellar pocket is an ingenious parasitic evasion 
strategy, restricting most endo/excocytosis and exposed receptors to 0.5% of the cell 
surface.63 This drastically limits the area of cell surface displaying foreign antigens, which 
if recognised would induce an immune response, and thus decreases the parasite’s risk 
of detection. The mechanism of action of TLF2 is currently unknown, but is known to 
occur independent of the trypanosomal receptor TbHpHbR.64 
APOL1's N-terminal domain is an analogue of bacterial pore proteins, colecins.65 The 
exact molecular mechanism requires further elucidation but irrespective of the origin it 
appears APOL1 dissociates from the HDL complex and mediates trypanolysis via the 
transmembrane flux of chloride anions, osmotic swelling and rupture of the 
lysosome.66,65  
APOL1 is also known to cause kidney damage and is well studied in African-American 
people,67 whose inherited trypanosomal immunity from increased APOL1 levels in HDL 
conferred a 35-60% risk of impaired renal filtration, particularly in late stage chronic 
nephropathy.68  Clearly trypanosomes exerted a powerful selective pressure on our 
hominid ancestors to afford evolution of this specific resistance in spite of the associated 
renal detriment.  
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Causative species of trypanosomiasis 
T. congolese, T. vivax and T. b. brucei are the main causative species of AAT, all of which 
are susceptible to TLFs and, as such, not pathogenic in humans. Just two subspecies of 
trypanosomes can infect humans, T. brucei gambiense and T. brucei rhodesiense. These 
have distinct epidemiologies and pathologies, and have evolved different solutions to 
negate the human TLFs. These strategies are an excellent example of a host-parasite 
molecular "arms-race", where each party develops consecutively more complex 
methods to overcome any advance made by the other.69 Domestic and wild animals can 
also become infected with T.b. gambiense and T.b. rhodesiense. Although they do not 
fall ill, they have an epidemiological role as carriers or reservoir animals from which 
tsetse flies can acquire an infection.70  
3% of HAT infections are caused by T. brucei rhodesiense.71 Particularly aggressive, this 
causes fast-onset acute trypanosomiasis in humans with infection periods measured in 
weeks, or at most months, and >80% mortality at six months.72 It is most common in 
southern and eastern Africa where wild game animals and livestock are thought to be 
the primary reservoir73,74,75. Interestingly, a progressive increase in severity of infection 
is observed moving from south to north Africa,76 however extrapolating the cause from 
genetic variation in host or parasite populations has proven difficult. T. b. rhodesiense  
has been the causative species of the three trypanosome epidemics in the 20th 
century.77,78  
Investigations into the genetic differences in APOL1-sensitive and -tolerant  T. b. 
rhodesiense clones have established the means by which the parasite has evolved to 
survive in normal human serum.69 The trypanosome employs a version of its VSG to 
create an expression site-associated gene known as serum resistance-associated (SRA) 
which is able to neutralize the effects of APOL1.79 SRA protein is a truncated form of 
VSG, lacking the antigenic loops exposed to the extracellular media.80,81 Whereas 
correctly formed VSG is trafficked at a great rate to the cell surface, malformed proteins 
are shuttled to the endolysosomal system for degradation by proteases82,83. It is likely 
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that it is in this endolysosomal system that SRA co-locates with APOL1 given that a range 
of shortened VSGs were all shown to result in endocytic processing.84  
The truncated SRA protein has two associating alpha helices, A and B, which ordinarily 
form a hairpin structure. However, when SRA and APOL1 are in close proximity the    N-
terminal A helix of the SRA interacts more strongly with the C-terminal helix of APOL1, 
thereby displacing the native helix B.57,85 This SRA-APOL1 binding neutralizes the pore-
forming ability of the TLF agent and without the lysosome's swelling and subsequent 
rupture the SRA-APOL1 proteins are degraded by proteases via normal lysosomal 
activity (Figure 2). In agreement, APOL1 C-terminus mutants that disrupt this coiled-coil 
SRA-APOL1 interaction were shown to restore the trypanocidal activity of APOL1 to T. b. 
rhodesiense.85  
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Figure 2 - VSG-derived adaptive proteins in human-infective Trypanosoma brucei subspecies.  a| The structure of 
the variant surface glycoprotein (VSG) amino-terminal domain highlights the two long amphipathic helices, helix 
A (in green) and helix B (in grey), which form a hairpin structure with the inter-helical peptide (in red) that is 
located at the bottom. b| Helix A of the VSG-derived serum resistance-associated (SRA) protein of Trypanosoma 
brucei  rhodesiense neutralizes apolipoprotein L1 (APOL1) by a coiled-coil interaction; SRA is targeted to the 
endocytic compartment instead of being anchored to the cell surface, probably as a result of the absence of 
surface-exposed loops. c| In Trypanosoma brucei gambiense, the inter-helical peptide of the VSG-derived protein 
T. b. gambiense-specific glycoprotein  (TgsGP) protects trypanosomes from APOL1 toxicity in a process that is 
associated with membrane lipid stiffening involving antiparallel peptide organization; as TgsGP lacks a carboxy-
terminal domain, the inter-helical peptide is expected to be located close to the membrane. The boxes represent 
the endocytic compartments, and a colour gradient illustrates the endosomal acidification that takes place 
between the beginning (that is, the flagellar pocket) and the end (that is, the lysosome) of the endocytic 
pathway.69 (Image and caption from reference) 
These laboratory-developed C-terminal mutants have posed the question as to whether 
these changes may have also developed in nature. Indeed, they have since been 
observed in baboons,86 which are known to be resistant to T. b. rhodesiense, and most 
fascinatingly, in subpopulations of western African people.67 Unfortunately however 
even a single allele of this mutant gene not only affords resistance but greatly increases 
the likelihood of end-stage kidney disease.67 This is not completely dissimilar to other 
parasite-associated conditions in Africa, particularly sickle cell anaemia and malaria, 
whereby the negative impact on the sufferer is overcome by the resistance to the 
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parasite,87 such that the disease allele represents a net gain in fitness and remains 
pervasive in sub-Saharan African gene pools.    
The remaining 97% of HAT infections71 are by T. brucei gambiense, which causes a slow-
onset chronic trypanosomiasis in humans with infection averaging around three years88 
but some recorded persisting over three decades.89 It is most common in central and 
western Africa, where humans are thought to be the primary reservoir,90 with only small 
pockets residing in livestock.90,91 .  
Identification of the SRA VSGs in T. b. rhodesiense inspired a search for unique truncated 
VSGs that might mediate the resistance of T. brucei gambiense to TLFs. A screen 
identified the T. brucei gambiense-specific glycoprotein (TgsGP).92 Deletion of this gene 
re-establishes vulnerability to APOL1 in T. brucei gambiense and exposure to normal 
human serum is trypanocidal.92,93 TgsGP is located in the endocytic system,94 much like 
SAR, but does not interact with APOL1 directly. Rather it induces membrane stiffening 
via a hydrophobic β-sheet interaction that is thought to hamper APOL1 membrane 
insertion and thus pore lytic formation.94 This TgsGP is one of three changes that 
combine to confer resistance (Figure 2). In addition, more rapid acidification of 
endosomes results in increased degradation of APOL1 94 and a point mutation of the 
TbHpHbR95–97 inactivates it to TLF1 binding. Both of these serve to lower the volume of 
active APOL1 which reaches the lysosome. These factors in concert with TgsGp allow the 
lysosomal proteases time to disassemble the APOL1 before it acts.  
VSGs are truly remarkable and have proven to be highly multifunctional tools. Not only 
do they afford immunological evasion but here have been repurposed in divergent 
manners to address an evolved trypanotolerance factor in normal human sera, HDL-
TGFs. The power of pathogenic highly recombinant DNA motifs is also clearly evidenced. 
The VSG expression sites allow for the generation of completely novel adaptive solutions 
for the trypanosomes and are clearly a critical factor in the evolutionary success of the 
genus. 
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T. Brucei lifecycle 
T. brucei is heteroxenous, requiring both mammalian and tsetse fly (Glossina) hosts at 
different stages of its lifecycle (Figure 3). The trypanosome has distinct developmental 
forms in each of these hosts. The stumpy bloodstream trypomastigote is ingested by the 
blood-sucking tsetse fly and develops in the fly’s midgut into the procyclic 
trypomastigote before reproducing asexually by binary fission. The parasite then 
migrates to the salivary gland of the fly where it develops into the metacyclic 
epimastigote and waits to be injected into the next mammalian host. The full process in 
the fly takes three weeks.98 The bloodstream trypomastigote develops in the 
mammalian extracellular fluid again reproducing by binary fission where it waits to 
infect another tsetse fly.  
 
 
Figure 3 - Complete heteroxenous trypanosomal lifecycle98                              
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Human African trypanosomiasis pathology 
Haemolymphatic Phase 1     
In haemolymphatic Phase 1, immediately after a bite from an infected tsetse fly, the 
parasite infects all intracellular fluids of the body with the exception of cerebrospinal 
fluid. Initial symptoms include fever, headaches, joint pains, and characteristic swollen 
lymph nodes on the back of the neck, termed Winterbottom’s sign.99 Usually a painful 
red sore called a chancre will develop at the location of the tsetse fly bite five to 15 days 
after the incident. Pathogen attacks come in waves and can fall into remission for 
periods of days or months in between each episode.  
The symptoms of acute HAT caused by T. brucei rhodesiense naturally reoccur with much 
greater frequency than those in the chronic T. brucei gambiense infection.99 If left 
untreated the pathogen can cause damage to any or all organ systems. Patients might 
develop various features including: lymphadenopathy; enlargement of the spleen 
and/or liver; cardiac features such as myocarditis, pericarditis, and congestive cardiac 
failure; ophthalmological features such as iritis, keratitis, and conjunctivitis; endocrine 
dysfunction including menstrual abnormalities, impotence, alopecia, and 
gynaecomastia; and fertility problems including sterility, prematurity and abortion.36,100–
102 However, it is also possible that patients present with only basic flu-like symptoms, 
giving the disease a whole spectrum of possible symptoms and severities.103  
 
Neurological Phase 2 
In neurological Phase 2, which can be several weeks to several months after infection, 
the parasite penetrates the blood brain barrier (BBB). Pathologically, the late stage is 
characterized by a meningoencephalitis, with extensive cerebral white matter 
infiltration by lymphocytes, macrophages, and plasma cells.100,104 A multitude of 
symptoms result from this encephalitic degeneration of the central nervous system. 
Those clinically observed include: motor disturbances, with motor weakness reported in 
35% of cases; gait disturbance in 22%; tremor in 21%; abnormal movements in 11%; 
speech disturbances in 14%;105 myelitis, myelopathy, muscle fasciculation, and 
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peripheral motor neuropathy;106 psychiatric disorders, with 25% of patients displaying 
behavioural disturbances, lassitude, hallucinations, delirium, anxiety, irritability, and 
excessive sexual impulses;105 headache, which occurs in 79% of patients in one study;105 
sensory disturbances such as deep hyperaesthesia, pruritus, anaesthesia and 
paraesthesia and seizures; and finally visual problems such as optic neuritis, double 
vision, optic atrophy, and papilloedema.100,106  
Characteristically, patients experience severe lethargy, insomnia and disruption to their 
diurnal cycle as the disease progresses. According to an extensive study on 2,541 
patients with late-stage HAT, sleep disturbances occur in 74% of patients,105 which, 
without treatment, invariably progress to coma and death. It is these typical sleep 
disturbances that give rise to the name ‘sleeping sickness’. Sleep abnormalities consist 
of a reversal of the normal sleep/wake cycle, with nocturnal insomnia and daytime 
somnolence, uncontrollable episodes of sleep, and an alteration of the structure of sleep 
itself, with the early onset of rapid eye movement sleep rather than this occurring at the 
end of Stage 4 sleep.107  
The vast scale of potential maladies highlights how profoundly debilitating HAT is for its 
sufferers, at 1.5 million DALYs per year108 across sub-Saharan Africa. Coupled with the 
near 100% mortality109 without medical intervention, this emphasizes the need for new 
effective treatments. 
The blood-brain barrier 
The central nervous system (CNS) and the brain are regarded as an immuno-privileged 
space, removed from the regular leukocyte mediated inflammation and immune 
response.110 This is achieved via tight regulation of permeability across the blood-brain 
barrier (BBB), blood-cerebrospinal fluid barrier and arachnoid barrier. The BBB is 
particularly tightly regulated and investigations are ongoing to determine how 
trypanosomes are able to traverse it, though some key factors have been elucidated.  
The BBB is complex, but essentially it is comprised of a barrier of tightly functioned 
endothelial cells with a protective basal membrane, perivascular space, parenchymal 
basement membrane and a large number of supporting structures and cells, particularly 
astrocytes and neurons.111,112 The initial tight junctions of the endothelial barrier are 
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weakest and often fenestrated113 in circumventricular organ regions of the brain. This 
improved contact allows rapid and accurate assessment of the composition of the sera, 
which can then be adjusted as necessary by the osmoregulation,114 cardiovascular 
regulation,115 and energy homeostasis115 mechanisms. It is also at this region that 
important endocrine regulators such as oxytocin,116 vasopressin117 and melatonin118 are 
secreted into the sera. 
It remains unclear whether the parasites are better able to breach the BBB at these 
positions or whether this is still prevented by the remaining post endothelial barriers.119 
The constituents of these barriers appear to be of relevance. The endothelial and 
parenchymal membranes are composed of the protein laminin in association with type 
IV collagen networks via entactin, fibronectin, and perlecan.120 Laminin comprises an α, 
β, γ trimer of proteins, where α, β and γ are variable. Trypanosomal CNS translocation 
of the endothelial basement membrane was found to be laminin alpha dependent. This 
membrane contains either α4 or α5. α5 has been shown to restrict parasite movement 
whilst α4 is permeable to CNS infection.121 
γ-Interferon (IF-γ) has been shown to mediate trypanosomal crossing of the BBB. In 
mouse models with IF-γ knocked down or inhibited by RNAi, trypanosome translocation 
to the CNS was greatly diminished.122 This is in interesting contradiction with the normal 
role of IF-γ as a potent activator of cell-mediated protective immunity against 
intracellular infections, where it activates different microbicidal effector mechanisms of 
macrophages and non-professional phagocytes.123 In these experiments, the control 
mice with native IF-γ levels experienced reduced severity of parasitaemia but at the cost 
of greater parasite penetrance.122 Further investigation is required to explain this effect.   
Lacking its own immune response, the CNS must recruit leukocytes from the blood to 
fight infection. It does this by displaying cytokines on the BBB surface that are recognized 
by white blood cells, which initiates a translocation process.124 Recombination-
activating gene 1 (RAG-1) deficient mice lack B and T cells and are also largely resistant 
to trypanosome CNS phase 2 infection.122 This suggests that trypanosomes utilize 
mechanisms similar to that of leukocytes to penetrate the BBB and invade the CNS or, 
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more likely, that translocation of the leukocytes could alter the structural integrity of 
the basement membranes paving way for subsequent penetration by the parasites.121  
The trypanosome constantly secretes proteins and chemicals to manage its immediate 
environment. Two that have been shown to be of particular import are cysteine 
proteases cathepsin B and cathepsin L (brucipain). In one study, doxycycline induction 
of RNAi  targeting cathepsin B led to parasite clearance from the bloodstream and 
prevented a lethal infection in the mice,125 while all mice infected with T. brucei 
containing the uninduced Trypanosoma brucei cathepsin B (TbCatB) RNA construct died 
by day 13. The mechanism mediating this virulence is still under investigation. Brucipain 
has been shown and confirmed to mediate the translocation of trypanosomes across 
BBB models in vitro. It does this in a calcium dependent manner. Both calcium 
scavengers and brucipain RNAi removed penetrance in the BBB model126 and although 
brucipain RNAi induced in murine models did not cure mice from infection, 50% of these 
mice survived 60 days longer than uninduced controls.125 
It is now understood that in HAT infections the tight junctions of the brain-endothelial 
barrier are not disrupted and damage to the barrier is minimal, making it difficult to 
correlate CNS invasion with parasite-endothelium interactions. The exact mechanism of 
parasite CNS migration therefore remains uncertain. The factors outlined above 
demonstrate clearly that BBB penetrance in HAT is likely a multifactorial  process which 
requires substantial further investigation.  
 
Current Treatments for HAT 
Due to the biphasic nature of HAT, chemotherapeutic treatments can be separated into 
two categories. The first aims to treat the haemolymphatic phase prior to BBB 
penetrance and involves intravenous or intramuscular injections of one of two drugs. 
Pentamidine is used to treat against T.b. gambiense infections and suramin against T.b. 
rhodesiense. The second is used at the neurological phase and therefore must overcome 
the challenge of BBB penetrance, ruling out the trypanocidals used at Phase 1. Three 
drugs are available: melarsoprol; eflornithine; and nifurtimox. 
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Despite HAT having been known since the turn of the 20th century, there are only these 
five drugs available to treat it, all of which have major limitations. The disease has 
affected millions of people and tens of millions of animals over decades but has received 
little attention until recently. As such it has been designated a neglected tropical disease 
(NTD) by the World Health Organization and will likely remain as such until new 
treatments make the current therapeutics redundant. 
Phase 1 treatments 
 
Figure 4 - Pentamidine 
Pentamidine (1) (Figure 4) has been in use since the 1960s for Phase 1 infection in T.b. 
gambiense. The two phenyl amidine motifs make the molecule dicationic at both 
intestinal and plasma pH, restricting migration across the intestinal membranes as well 
as the CNS barriers. As a result, oral administration and Phase 2 HAT administration are 
impossible and the seven-day, once daily 4 mg/kg dosing must typically be given by 
intramuscular injection.127 Pentamidine is trypanocidal and highly active at IC50 1-10 nM.  
Its exact mechanism is still debated, but interestingly its localisation to the mitochondria 
has been observed to precede mitochondrial kinetoplastid DNA degradation.128 
Pentamidine has specific transporters that act to increase its cellular concentrations to 
μM levels and the mutation of these transporters confers melarsoprol-pentamidine 
cross resistance (MPXR) which is detailed below. In addition, there are particular toxicity 
issues, with severe pain at the site of injection, nephrotoxicity, leukopenia and liver 
enzyme abnormalities, as well as the risk of hypoglycemia.129  
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Scheme 1 - Synthesis of Pentamidine 
The synthesis of pentamidine (1) is straightforward (Scheme 1); it involves the double 
SN2 displacement of bromide on 1,5 dibromopentane (3) by two para-
hydroxybenzonitriles130 (2) followed by a Pinner amidine synthesis where the nitriles are 
converted first to ethyl benzimidates and then to amidines by the addition of 
ammonia.131    
 
 
Figure 5 - Suramin 
Suramin (5) (Figure 5) has been utilized as a trypanocidal since 1922 and is now the only 
Phase 1 treatment for T.b. rhodesiense. It is a very large molecule, with poor membrane 
permeability and high (>99%) serum protein binding. The serum binding extends the 
half-life of the drug to an extremely high 44-54 days.132 The normal treatment course 
comprises intravenous (IV) injection of 20 mg/kg (no more than 1 g per injection) in a 
series of five injections at five-to-seven day intervals.133 Suramin is also effective against 
T. b. gambiense infections, but due to the risk of sudden shock in case of infection by 
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Onchocerca volvulus, treatment with pentamidine is preferred.129 Again the mechanism 
of action is not well understood but is linked to inhibition of glycolysis enzymes.134  
Suramin resistance has been characterized by genome wide RNAi studies.135 Links have 
been drawn to eight genes with the strongest suggestive of suramin uptake via a major 
facilitator superfamily (MFS) transporter. Suramin resistance is rarely seen in patients 
despite long-term use and is therefore not considered a threat to its continued 
application.132 The main side-effects are fever, mucocutaneous eruptions, nausea, 
vomiting, polyneuropathy and haematological toxicity.133  
 
Scheme 2 - Synthesis of suramin 
The synthesis of suramin136 (Scheme 2) involves two consecutive amide couplings and 
nitro reductions. The nitro groups serve to both activate the acid chlorides for aniline 
attack and as a masked amine equivalent that is liberated by reduction. Two equivalents 
of compound (10) are then reacted with phosgene to form the symmetrical urea and 
this is acidified to give the neutral compound suramin (5).  
 
Phase 2 treatments  
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Figure 6 - Nifurtimox 
Nifurtimox (11) (Figure 6), a 5-nitrofuran pro-drug, was initially used in small-scale last-
resort trials in the 1980s and 1990s to treat melarsoprol refractory patients.137 It was 
only in 2009, with its implementation in nifurtimox-eflornithine combination therapy 
NECT, that it came into common use. Before this it existed as a monotherapy 
administered thrice daily at a dose of 15 mg/kg for two-three weeks.138 It is readily 
metabolized at the liver resulting in a short half-life of two hours,139 but as it remains 
the only orally available drug for HAT it is the most commonly prescribed.  
 
Figure 7 - Conversion of nitrofuran pro-drug to the active Michael acceptor nitrile compound 
Trypanosomatids are unusual in that they possess a bacterial-like type I nitroreductase 
(NTR)140 which is absent in the mammalian genome. This type 1 NTR can reduce 
nifurtimox to the nitrile compound 13 by introducing four electrons (Figure 7).141 This 
nitrile has been synthesized and unfortunately is equally as toxic in mammalian cells.142 
The mechanism of toxicity is unknown but hypothesized to result from its Michael 
acceptor capabilities (Figure 7).141 The IC50 of nifurtimox is 1.5 μM for both T.b. 
rhodesiense and T.b. gambiense forms of HAT,143,144 and is below the maximum 
achievable concentration of 2.6 μM measured in healthy subjects. It appears to perfuse 
easily into the CNS, independent of BBB breakdown.145 In fact, in mouse models 
[35S]nifurtimox appears to concentrate in the CNS, with higher levels observed in both 
the frontal cortex (6.0 μM) and CSF (12 μM).145  
Resistance to nifurtimox has been observed particularly in the treatment of T. cruzi for 
Chagas Disease where 20-25% of cases are refractory.146 In both T. brucei and T. cruzi 
resistance is easily developed by reducing the expression of the type 1 NTR.147 This 
reduced expression does however have a negative impact on rate of trypanosome 
proliferation and null Tbntr mutants were shown to be non-viable.147 If the tenfold 
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decrease in drug sensitivity seen in vitro is reflective of the in vivo effect in T. brucei, this 
would result in an IC50 above the achievable CNS concentration. Nifurtimox also suffers 
toxicity problems. Due to its ability to penetrate the CNS and its susceptibility to redox 
reactions, administration is associated with a range of neurological side effects and 
gastrointestinal issues that end upon cessation of treatment.148,149  
 
Scheme 3 - Synthesis of nifurtimox 
There are several ways with which the components 18 and 20 that combine to form 
nifurtimox (11) can be synthesized and a possible route is illustrated (Scheme 3). The 
dihydroxy sulfide (16) is formed by epoxide opening150 and is then oxidized to the 
sulfone (17).151 Interestingly the formation of compound 18 requires catalytic sodium 
hydroxide, the mechanism is not discussed but presumably formation of the desired 6 
membered ring (18) is kinetically favored over the available 7 membered diazepane.  
Compound 19 is achievable by direct nitration of furfural.152 The drug is synthesized by 
the chemical company Bayer and they have patented the synthetic methods only for the 
formation of the cyclic hydrazine (18) from the 1-((2-hydroxyethyl)sulfonyl)propan-2-
ol153 (17) starting material and for the final hydrazone formation to arrive at nifurtimox 
(11).154     
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Figure 8 - Eflornithine 
Eflornithine (21) (Figure 8), an analogue of ornithine, is a suicide inhibitor of the enzyme 
ornithine decarboxylase (ODC). ODC is the first biosynthetic step in production of 
polyamines such as putrescine, spermidine and spermine.155 These polyamines are 
involved in the repair of DNA damage but they also play a key role in maintaining a 
normal cell cycle.156 Cyclin dependent kinases are considered the drivers of cell cycle 
processes and changes.157 Key signal molecules, cyclins, are reduced during polyamine 
inhibition,158 resulting in cessation or retardation of cell growth.  Both mammalian and 
parasitic ODC are inhibited but selectivity is achieved from the divergent enzyme 
turnover rates. Rates in the parasite are very slow compared to mammals thus the 
human cells only experience ODC inhibition for a short time whereas the parasite must 
endure the detrimental ODC inhibition for longer.159  
Eflornithine does not kill trypanosomes but induces a shift from the reproductively 
active, long slender form to the non-profligate stumpy form.160 As it is not a trypanocidal 
drug, the host’s innate immune system is still necessary to clear the static infection 
throughout the body.161 Eflornithine monotherapy regimen usually involved 100 mg/kg 
IV infusions at six-hour intervals for 14 days. Adverse effects include fever, headache, 
hypertension, macular rash, peripheral neuropathy, tremor, gastrointestinal problems 
and bone marrow suppression but these all recover post-treatment.129,132   
Unfortunately eflornithine resistance is easily generated in vitro, with resistant cells 
reported in the 1980s.162 The mechanism of this resistance is thought to result from the 
deletion of the TbAAT6 gene that encodes an amino acid transporter.163 Much like that 
of MPXR, eflornithine resistance results from diminished cell uptake as opposed to any 
specific intracellular target protein.163 Resistance leaves the cell 40 times less sensitive 
to the drug.163 It is important to note that use of eflornithine was limited until NECT was 
introduced164 so the fact that resistant infections have yet to be observed is somewhat 
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unsurprising and it remains to be seen if this mutation will impact fitness in wild 
trypanosomes. Eflornithine IC50 growth inhibitory values are 81–693 μM165 in vitro, with 
average plasma levels of 234–528 μM and CSF levels at 22.3–64.7 μM in patients 
receiving standard doses of 100 or 125 mg/kg. C 
Clearly there is a disconnect between these values – and perhaps the in vivo inhibitory 
reality is different – but the situation is complex, especially considering eflornithine is 
trypanostatic not trypanocidal and therefore requires CNS recruitment of leucocytes. At 
present eflornithine remains curative but could easily fall victim to a mutation that 
would confer a 40-times reduction in efficacy, which could have a particularly dramatic 
impact given that laboratory studies have shown it already to be at its upper limit of 
efficacy at achievable CNS concentrations.  
Eflornithine and melarsoprol monotherapies were for decades the clinical standard for 
T.b. gambiense but since 2009 these have been rejected in favor of NECT.166 By 2010 
NECT was utilized in 59% of treatments because although it doesn't improve patient 
outcomes compared to eflornithine, it allows for reduced dosing, resulting in greater 
patient compliance.167 Additionally, a NECT kit costs one-third as much as an eflornithine 
monotherapy kit and that is without accounting for cost of longer treatment times. 
Indeed, a multi-centre, randomized, Phase III trial found the best course of treatment to 
be intravenous eflornithine (400 mg/kg per day, every 12 hours) for seven days with oral 
nifurtimox (15 mg/kg per day, every eight hours) for ten days.167 Toxicity is also reduced 
by half when compared to the severe and very severe reactions of eflornithine 
monotherapy.  
NECT is now the highest standard of care and is an important improvement for HAT 
treatment. Combination therapies are also less likely to enable the development of 
resistance. It is very important that resistance to eflornithine and nifurtimox is limited 
whilst new trypanocidals are developed, especially in light of melarsoprol refractory 
trypanosome strains vide infra and the ease of developing resistant trypanosome strains 
in vitro. 
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Scheme 4 - Synthesis of eflornithine 
The synthesis of eflornithine168 (21) (Scheme 4) unsurprisingly starts from the 
biologically-available ornithine (22). The protection of the carboxylic acid as a methyl 
ester and of the amines as benzylidines (23) facilitates the deprotination of the alpha 
carbon and allows for the addition of the difluoro group. Deprotection of both the ester 
and imines gives the desired product eflornithine (21).  
 
 
Figure 9 - Melarsoprol pro-drug and the active malrsen oxide 
Melarsoprol (24) (Figure 9) is a melaminophenyl based organo arsenide pro-drug, 
introduced as a treatment for HAT in 1949. It is administered by IV injection, 2.2 mg/kg 
for ten days, as a 3.6% solution in propylene glycol, as it is immiscible with water.169 
Cellular metabolism produces the melarsen oxide, compound 25, which has < 10 nM 
activity170 and acts by sequestering trypanothione (N1,N8-bis(glutathionyl)spermidine) 
to form a melarsen oxide-trypanothione adduct (Mel-T).171  
Mel-T both directly removes trypanothione and inhibits trypanothione reductase (Ki = 
9.0 μM) such that trypanothione is removed from use in its normal role of mediating 
cellular response to reactive oxygen species (ROS).172 The trypanocidal affect is thought 
to be mediated through increased ROS but Mel-T could itself be toxic and complement 
the ROS increase.172 Melarsoprol is not only toxic to trypanosomes, it is extremely toxic 
in humans, resulting in severe reactive encephalopathies in 10% of patients and 5% 
fatality.132 Other adverse events include convulsions, pyrexia, headache, pruritus, 
thrombocytopenia and heart failure.129 It is incredibly painful to administer and it so 
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badly damages the veins that consecutive treatment requires new sites for 
administration.132 The fact that this drug was accepted as the best treatment for Phase 
2 HAT between 1950 and 1990, when eflornithine was introduced, and even then was 
only really replaced in 2009 by NECT, serves to emphasize how severely this disease has 
been neglected. 
 
Scheme 5 - Synthesis of melarsoprol 
The synthesis of melarsoprol (24) involves the substitution of the aniline (26) in place of 
the chlorine of the triazine (27).173 2-Mercaptoacetic acid is then utilized to reduce the 
arsenic from Ar(V) to Ar(III) and also forms compound 29 which easily undergoes 
displacement with 2,3 dimercaptopropan-1-ol to give melarsoprol (24).174  
Interestingly, the first observed example of drug resistance was of trypanosomes with 
arsenical compounds by Paul Ehrlich. Subsequently arsenical–diamidine cross-resistance 
was first observed over 60 years ago.175 Despite its toxicity melarsoprol is the least 
harmful of the arsenical drugs for HAT, and it and pentamidine have been in use since 
the 1940s and 1930s respectively.176 It was not until the 1990s that the mechanism of 
resistance for both pentamidine and melarsoprol began to be elucidated and linked to 
the membrane protein P2 (purine transporter 2), encoded by the TbAT1 gene.176  
Expression of TbAT1 in Saccharomyces cerevisiae enabled adenosine uptake and also 
conferred susceptibility to arsenicals.177 TbAT1 gene deletion and loss-of-function 
mutations were then identified in drug-resistant trypanosomes generated in the 
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laboratory178 and these mutations were also found in "wild" T. brucei field samples179 
including in cases of melarsoprol treatment failure.180,181 Loss of the P2 transporter 
cannot explain melarsoprol-pentamidine cross resistance (MPXR) in its entirety. 
Laboratory generated resistance was substantially higher than observed for the mutated 
TbAT1 and the existence of a high-affinity pentamidine transporter (HAPT1) was 
postulated.  
Recently, two closely related aquaglyceroporins, AQP2 and AQP3, were linked to MPXR 
in a high-throughput loss-of-function screen.135 aq2-aq3 null strains were created and 
the AQ2 absent mutants were insensitive to melarsoprol and pentamidine, while 
restoring AQ2 re-established wild type sensitivities.182 This is a particularly worrying 
scenario for HAT as detailed examination showed no fitness cost in aq2-aq3 null strains 
in cells at neither the developmentally distinct bloodstream stage or insect stage,135 nor 
the transition between them.  
Specific mutations in AQPs have been identified that correlate to reduced drug 
sensitivity in field-isolated trypanosomes: particularly common in the cited study was a 
completely novel AQP2/AQP3 chimera.183 AQP2 alteration in melarsoprol insensitive 
and relapsed HAT patients was first reported in 2014. 45 T.b. gambiense strains were 
obtained from patients with 41 arising from relapse post-melarsoprol. In all these 
strains, irrespective of the patient treatment outcome, AQP 2 and 3 genes are replaced 
by chimeric AQP2/3 genes. 
MPXR has been shown to arise from two specific transporter proteins, with the greatest 
resistance conferred by their concomitant expression, and worryingly (though as 
expected) these mutants bear no cost to fitness.184 Both resistant alleles have been 
observed independently in patient population field isolates, so it can be assumed that 
these genes are now present in the parasite reservoirs and that genetic exchange in 
parasite populations could result in a trypanosome becoming almost completely 
resistant to melarsoprol. Even though uptake is reduced for pentamidine, the potency 
is so high (IC50 ~1 nM) that it remains lethal at patient blood concentrations, which peak 
at one-hour post injection at around 0.42-13 μM, even in the most resistant varieties 
observed in laboratories (IC50  ~100 nM).183  
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Melarsoprol however is already poorly CNS-penetrant, with the maximum obtainable 
CNS concentration just 1-2% of its plasma concentration of 5-10 μM.185 This 50-100 nM 
CNS concentration might not be enough for complete clearance when just a single 
resistant TbAQP2 allele increased the IC50 50 nM from 5 nM.183 Given the complex multi-
barrier structure of the CNS and the likely occurrence of reduced local concentrations, 
this increase in drug resistance might not allow for full clearance.  
If concomitant expression were to develop in trypanosomes, melarsoprol, the only 
available treatment for T.b. rhodesiense, would become essentially redundant. 
Enhancing the risk is the existence of a multi-drug-resistant protein A (MRPA) present in 
some trypanosomes. In vitro studies have shown that over expression of this protein, 
which is responsible for exporting the active Mel-T agent from the cell, increased the 
drug resistance by ten-fold. 170. The particular disadvantages of each treatment is 
summarised (Table 1):186 
Table 1 - Summary of available HAT treatments186 
 
 
Poor oral adsorption – All chemotherapeutics, with the exception of nifurtimox, must be 
intravenously or intramuscularly administered by a trained professional, all requiring 
multiple doses over a course of days. Melarsoprol requires daily treatments for ten days, 
whilst eflornithine necessitates a very intensive regime of 56 IV doses over 14 days. NECT 
has shown some improvement187 and is currently the best treatment strategy available. 
However, NECT still requires seven days of single IV eflornithine doses. IV administration 
is a substantial problem in HAT treatment particularly regarding logistics and 
affordability, as the disease is widespread across a poor, rural demographic. The 
affected individuals are unlikely to be able to afford to travel the necessary distances to 
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treatment centres for the days or weeks required to receive the available drug 
treatments. 
Acute toxicities – While Phase 1 drugs are generally tolerated, traditionally treatments 
for Phase 2 have proven highly toxic. Melarsoprol is extremely painful to administer, is 
associated with severe reactive encephalopathies in 10% of cases and kills 5% of 
patients.188,189 Eflornithine monotherapy has a 2.1% mortality190 and toxicity problems 
result in gastrointestinal distress, bone marrow toxicity and seizures.191 The high level 
and long duration (two months) of dosing in nifurtimox monotherapy was deemed 
unacceptably toxic.192 Fortunately NECT has halved the toxicity compared to eflornithine 
but it remains unacceptably high. 
Limited therapeutic spectrum – Eflornithine and pentamidine are only active against T.b. 
gambiense whilst suramin acts only on T.b. rhodesiense. The massively toxic 
melarsoprol, referred to as “arsenic antifreeze” by clinicians193, is the only course for 
CNS-implicated illnesses involving T.b. rhodesiense, and the evolution of refractory 
parasite strains is affording it increasingly limited application. Indeed this development 
of melarsoprol resistance poses a serious risk, particularly if it becomes increasingly 
prevalent in acute T. b. rhodesiense HAT, as here treatment options would be completely 
limited to nifurtimox monotherapy. 
Pharmacokinetics – Rapid metabolism and clearance of pentamidine, eflornithine, 
melarsoprol and nifurtimox necessitates increased dosings of these HAT trypanocidal 
agents to maintain the high serum concentrations necessary to minimize the high 
relapse rates observed in low dosing. 194 In contrast, the serum binding suramin, with a 
half-life of >50 days, is arguably at the other undesirable extreme, although toxicity from 
this appears limited.  
Uncertain availability and price – In the past there have been zero-cost charity 
agreements between the World Health Organization (WHO) and the producers of anti-
trypanosomal drugs, Sanofi and Bayer, as the patients are typically poor and unable to 
pay for treatment. However, long-term availability of such loss-making drugs is always 
precarious,195 and in fact, for a period in the late 1990s, eflornithine became completely 
unavailable. Even with heavy international and government subsidies, if one member of 
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a household is infected with HAT the cost of treatment is calculated at roughly five 
months of the total family income. 196 
Parasite drug resistance - HAT chemotherapy began in the 1900s 197 and has been 
prevalent in animals and humans since. Partial treatment of animals or humans with 
anti-trypanosomal agents, due to incomplete application resulting in only semi-
clearance of the parasite, unsuccessful treatments, or prophylactic use, have allowed 
the parasite to coexist in a host with non-lethal drug concentrations. These non-curative 
concentrations have provided a selective pressure in response to which anti-
trypanocidal drug resistance has evolved for both melarsoprol and pentamidine. In vitro 
studies have shown that eflornithine and nifurtimox are similarly vulnerable to the 
development of resistance.140,163 
 
African animal trypanosomiasis 
 
Figure 10 - Isometamidium chloride, ethidium bromide and diminazene aceturate  
There are three main veterinary trypanocidal drugs administered, with isometamidium 
chloride (30) (ISM), diminazene aceturate (31) (DA) and ethidium bromide (32) (EB) 
(Figure 10) estimated to represent 40%, 33% and 26% respectively of the total 
trypanocidal drug market by value.198 Despite being introduced in the 1950s the 
mechanism of action for both DA and ISM remain unclear.199,200 DA is used primarily as 
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an active treatment199 whilst ISM and EB are mainly prophylactic, but EB is a powerful 
mutagen and a poor trypanosomal prophylactic.198 Inappropriately toxic treatments are 
thus common to AAT and HAT, as in fact is drug resistance. Drug resistance has been 
reported in 17 countries. Resistance to ISM is more widespread than to DA,201 but 
increasingly often there are reports of multiple drug resistance. The challenge of 
multiple resistance is particularly well illustrated by a study of 800 cattle in south-east 
Mali.202 Of the cattle tested across the area 125 (16%), were-trypanosome-positive. This 
subgroup was split in two, and half treated with ISM and half with DA. Any which 
remained infected after treatment were then retreated with a double dose of DA. 49% 
and 30% respectively of the ISM and DA treated cattle failed to clear the parasite and 
the doubled dose of DA failed to clear 26% of both the ISM and DA infections. Roughly 
a quarter of diseased animals were therefore deemed refractory to ISM and DA.  
35 million doses of trypanocidals are given every year to animals.54 This very high 
treatment rate is the result of ineffective treatments and high levels of resistance. The 
need for an effective, orally available, CNS-penetrant and non-toxic drug is evidently 
equally critical for AAT as HAT, with particularly incumbent issues of economics, 
livelihood, human nutrition and animal welfare.  
 
Drug development  
Advances towards new HAT treatments have received new attention in the past two 
decades with some compounds reaching clinical trial but none able to progress further. 
Therapies can be derived from alteration of known drugs, the re-ignition of old hits or 
from entirely new scaffolds and targets. 
Development from the amidine agents has been common. These compounds have been 
known for a long period and have proven potent inhibitors, for example pentamidine 
with nM affinity. Most efforts have been in whole cell trypanosomal activities with no in 
vivo, pharmacokinetic or toxicology data with the exception of a study showing 
mammalian cell-line LD50,203 thereby representing only preliminary drug discovery 
efforts.203  
42 
 
 
Figure 11 - An example 2-phenyl-imidazopyridine compound developed by Novartis 
High throughput screens reported early in 2014204 by Novartis identified 2-phenyl-
imidazopyridines as a new scaffold (Figure 11) from their 700,000 compound library. 
Exploration around these gave compound 33, which inhibits T.b. brucei with IC50 <5 nM, 
has good CNS penetrance and dosing orally twice a day at 5 mg/kg for five days cured 
mice of Phase 1 infection. This compound requires further study but it seems promising 
and will hopefully become a candidate for clinical trial in the near future. 
All of the issues discussed above clearly illustrate the urgent need for new African 
trypanosomiasis treatments. Ideally such a treatment should be targeted, non-toxic, 
orally bioavailable, and not require a complex dose regimen or administration by a 
professional clinician.205,206 Despite the dire state of current treatment there has been 
some promising progress towards much-needed new drug treatments. NECT is an 
excellent breakthrough in comparison to the previous standards and the two potential 
treatments now in clinical trials represent genuine hope for some appropriate 
treatments. 
 
Figure 12 - Fexinidazole and SCYX-7158: novel drug candidates 
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Fexinidazole and SCYX-7158 
Fexinidazole (34) (Figure 12) was a preclinical antimicrobial developed in the 1970s and 
resurfaced in a profile of 700 nitroheterocyclic compounds.113 It is oxidised from sulfide 
to sulfone in the body but an in vitro IC50 of ~2.3 μM has been observed for both of the 
two compounds against both variants of HAT. It successfully cleared mice infected with 
T.b. brucei in both Phase 1 and Phase 2 of the disease at 100 mg/kg/day. Extensive ADME 
(Absorption, Distribution, Metabolism, Excretion) studies, pharmacokinetic studies, 
repeated dose studies and toxicology studies (genetic, developmental and reproductive) 
were undertaken and the compound and its metabolized derivatives showed no 
markedly negative results. It is distributed well in the body and although, as mentioned, 
it is readily metabolised, it has a half-life of one to four hours. The drug is currently in 
Phase II/III studies, which are taking place in the Democratic Republic of the Congo and 
Central African Republic under the direction of the Drugs for Neglected Diseases 
Initiative in collaboration with the Swiss Tropical and Public Health Institute.  
SCYX-7158 (35) (Figure 12) was identified in a screen of a library of boron-based 
compounds by Anacor Pharmaceuticals.207 The lead was optimized to SCYX-7158 with 
IC50 800 nM. It cures both forms of HAT infection in mice, is 55% orally bioavailable, CNS 
penetrant and metabolically stable. Preliminary toxicology is clean in Ames and hERG 
assays, and it is currently awaiting Phase II/III completion.208 
Despite the promise of drugs currently in clinical trials, it would be imprudent, foolhardy 
and irresponsible for the scientific and medical community to ignore continued research 
into alternative treatments. Clinical trial failures are commonplace and even if both 
drugs are able to proceed to market, two drugs would represent a very limited 
pharmacological arsenal for the treatment of HAT and AAT, especially given their 
propensity to develop resistance.  
In this regard we examined target proteins and lead compounds with potential for the 
rational design of new drugs against HAT and AAT. A trypanosomal protein, 
trypanosomal alternative oxidase (TAO), which emerged 30 years ago, shows promise 
for targeted treatment. 
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Trypanosomal alternative oxidase function 
A number of desirable features make TAO a particularly promising target for drug 
development. Firstly, there is a published protein isolation procedure209 that allows the 
production of the protein for established biological assays and drug potency 
measurements. There is also a published crystal structure of TAO,210 which allows for 
increased understanding of the target's active site. TAO has been illustrated to be 
necessary for survival of the parasite.211 Natural products have been identified that 
inhibit TAO, which can be used as lead compounds for further exploration,212–214 and 
finally the trypanocidal activity of these natural products has been studied both in vitro 
and in vivo on the mammalian parasites.215,216 Taken together, all of these factors make 
TAO an excellent focus for the development of a new chemotherapeutic to help address 
the dearth of acceptable and appropriate AT treatment options.        
TAO function is the cytochrome-independent terminal oxidase of the mitochondrial 
electron-transport chain in the mammalian bloodstream trypanomastigote (Figure 
13).217 Unlike cytochrome-dependent oxidases (COXs), TAO is not sensitive to cyanide 
poisoning but is inhibited by salicylic hydroxamic acid (SHAM).218 TAO transfers electrons 
from ubiquinol to oxygen, reducing the oxygen to water. It is not coupled to proton 
translocation but rather adenosine triphosphate (ATP) synthesis and heat production.219 
The bloodstream trypanosome must derive all its energy from the glucose of the host 
and as such has developed the glycosome organelle which undertakes glycolysis in 
addition to performing various other functions including purine salvage, beta oxidation 
of fatty acids, and ether lipid synthesis.220 The mitochondrial TAO is ultimately coupled 
via the glycerol 3-phosphate/dihydroxyacetone cycle to the reoxidation of NADH to 
NAD+ for use in aerobic respiration to afford the net gain of two ATP per glucose. 
Inhibition of the aerobic process leaves the parasite dependent on the less productive 
anaerobic process, where the net gain is only one ATP per glucose, but this does also 
produce glycerol 3 phosphate (G3P). This G3P can be processed into glycerol by glycerol 
kinasein an incredibly rare backward enzymatic activity. Glycerol kinase activity 
equilibrates however as glycerol levels rise, removing the net ATP gain. This inhibition 
by mass action can starve and kill the trypanosome. 
45 
 
 
 
 
 
TAO structure 
TAO enzyme is a monomer221 located in the mitochondrial organelle. It consists of α 
helices with a non-haem di-iron centre held by two conserved EXXH (Glutamic acid-X-X-
Histidine) motifs at residues 162–165 and 266–269. It has two hydrophobic stretches, 
similar to other alternative oxidases.222 The iron, which is crucial to function,223 was 
detected initially by the EPR signal of the mixed valence reaction intermediate224 and 
visualized recently via protein crystallisation.210 TAO is an interfacial protein embedded 
only in the inner leaflet of the mitochondrial lipid bilayer210,225 with its ubiquinol binding 
site opening into the mitochondrial cytoplasm. 
Figure 13 - Glucose metabolism in bloodstream form of T. b. brucei under aerobic and anaerobic conditions. (1) Glycerol 
kinase, (2) glycerol-3-phosphate424 
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Figure 14 - Dimeric crystalised structure of TAO226  
The recent publication of TAO's crystal structure at a resolution of 2.8 Å210 is a great 
advance in understanding the nature of the protein however the crystal structure 
contains four monomers per asymmetric unit that associate to form homodimers 
(Figure 14) and so unfortunately data must be interpreted across these mildly divergent 
protein units not just a single monomer (Figure 15).  
 
Figure 15 - Homodimeric crystalysed form of AOX monomer (left). Five co-ordinate diiron centres at TAO active 
site (right)210 
All subunit’s are convergent in their general structure. They each consist of a long N-
terminal arm, six long α helices (α1–α6) and four short helices (S1–S4) (Figure 14). The 
long helices are arranged in an antiparallel fashion with α2, α3, α5, and α6 forming a 
four-helix bundle that accommodates the diiron centre. The diiron active site was 
confirmed as an oxidized Fe(III)-Fe(III) form with a single hydroxo-bridge (Figure 15), 
which agreed with predictions from existing spectroscopic evidence.224  
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The active site, which is located in a hydrophobic environment deep inside the TAO 
molecule (Figure 17), is composed of the diiron centre and four glutamate (E123, E162, 
E213, and E266) and two histidine residues (H165 and H269), all of which are completely 
conserved across alterative oxidases (AOXs).223 These residues bind the diiron centre in 
a five co-ordinate manner possessing a distorted square pyramidal geometry, observed 
across all four crystallized units (Figure 15 and Figure 16).  
 
Figure 16 -  The structure of diiron sites. Interaction between the diiron molecule and TAO with sigma-A weighted 
electron density map (Fo-Fc) calculated from the refined model of ligand-free TAO with the diiron molecule 
omitted from the phase calculation. The diiron molecules bound to (A) chain A, (B) chain B, (C) chain C and (D) 
chain D are shown as yellow sticks with nitrogen and oxygen atoms colored in blue and red. The diiron (Fe-OH--
Fe) is drawn as magenta spheres. Contour levels are 1.0 σ (blue) and 3.0 σ (orange).210 
CAVER protein-analysis software210 predicted another possible hydrophobic cavity near 
the membrane surface and indeed this can observed in the crystal structure (Figure 17). 
This second cavity connects the di-iron active site with the membrane and interacts with 
the inhibitor-binding cavity on the opposite side of the di-iron core to the known 
ubiquinol binding site (green and orange respectively in Figure 17). 
Although the exact four electron reduction mechanism is unknown, the mutation of the 
tyrosine 220 (Y220), which is entirely conserved across all known AOXs, abolishes 
enzymatic activity223 (Figure 15). It is hypothesized that each hydrophobic cavity binds 
one ubiquinol close to the active site with the quinol rings located at the bottom of each 
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cavity, in a manner similar to that observed in known crystal structures for other 
proteins.210 
 
Figure 17 -  Putative ubiquinol binding channels in CCB-TAO complex. Two hydrophobic cavities found by CAVER 
protein-analysis227 software  are shown in green and orange. Proposed residues involved in electron transfer are 
shown as orange sticks. 
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Figure 18 - The mitochondrial electron transport system in the bloodstream and procyclic forms of T. brucei. (a) 
The bloodstream form of T. brucei depends exclusively on TAO for respiration. (b) In the procyclic form TAO 
branches from the primary cytochrome-dependent pathway at the site of ubiquinol. Sub-mitochondrial 
localization of the enzymes and enzyme complexes are represented by their position in the outer mitochondrial 
membrane, inner mitochondrial membrane, intermembrane space, and mitochondrial matrix. Abbreviations: C, 
cytochrome c; COX, cytochrome oxidase; DHAP, dihydroxyacetone phosphate; Gly-3-P DH, glycerol-3-phosphate 
dehydrogenase; QH2, ubiquinol; Q, ubiquinone.211 
 
Role of TAO across trypanosome lifecycle  
TAO is expressed at nearly all stages in the life-cycle of the parasite and is 
developmentally regulated. In the Tsetse fly it is thought to allow for respiratory 
plasticity such that it can survive the harsh environment in the gut,211 as it is expressed 
alongside COX and all citric acid cycle (CAC) proteins (Figure 18). The bloodstream form 
in mammals does not express COX or CAC proteins228 but rather up-regulates TAO in a 
post-transcriptional manner so that the steady-state level of TAO transcript is about five-
fold greater and the TAO protein level is 100-fold greater than in the Tsetse procyclic 
form.229 TAO is the terminal oxidase in pyruvate producing glycolysis.205 TAO inhibition 
induces anaerobic respiration,230 whereby one glucose produces only one ATP, along 
with pyruvate and glycerol.211 ATP is used in the cell, pyruvate exported into the 
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extracellular host medium, and glycerol, as described above, is itself an inhibitor of 
anaerobic ATP synthesis by mass action.216 The combination of TAO inhibition and 
increasing cellular glycerol therefore derails bloodstream T.brucei's only respiratory 
pathway.  
 
Trypanosome alternative oxidase as a drug target 
As discussed, TAO seems an excellent chemotherapeutic target. In addition to the 
plethora of advantages features already acknowledged, there is no mammalian 
homologue,211 increasing the plausibility of designing a specific drug with minimal side 
effects. A genotypic assay has been used to screen for candidate molecules able to 
inhibit TAO and this assay has also been established in the Ward lab allowing rapid 
assessment of compound affinities. The published crystal structure allows also for 
computer-aided rational drug design and computational-chemical modelling of 
potential compound-protein interactions.      
 
Potentially most encouraging is the existence of lead compounds from which medicinal 
chemical and synthetic exploration can begin. Trypanocidal inhibition of TAO by the 
natural products SHAM (36), colletochlorin B (37) and ascofuranone (38) (Figure 19) has 
been demonstrated.215,231-233 All developmental stages of the bloodstream 
trypomastigotes in humans are crucially dependent on TAO for aerobic respiration 
making inhibition trypanocidal, rather than trypanostatic as with eflornithine.234 
Ascofuranone represents an exciting starting point on the journey towards a cure for 
African trypanosomiasis.   
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Figure 19 - Established TAO inhibitors 
 
Ascofuranone 
Ascofuranone (38) (AF), a polyprenyl phenolic antibiotic, was first isolated from 
phytopathogenic fungus Ascochyta visiae in 1973.235 Initially of interest was its 
hypolipidemic236 effects and tumor-suppression237 ability, thought to be mediated 
through activation of macrophages by respiratory inhibition.238 However, in 1996 AF was 
shown to inhibit T.b. brucei with a Ki = 2 nM. It was later demonstrated that this affect 
was the result of incredibly potent inhibition of TAO. The compound exhibits mixed-type 
inhibition,239 binding at the ubiquinol active site with picomolar activity (Ki = 0.13 ± 0.04 
nM).212 The trypanocidal activity of AF is orders of magnitude more potent than that of 
known concentrations for other trypanocidals like suramin (Ki= 4.1 μM),240 n-propyl 
gallate (Ki = 6.3 μM)241 and even melarsoprol (Ki = <10 nM).  
 
Orientation of ascofuranone analogues in published crystal structure 
AF analogues AF2779OH and colletochlorin B (37) (CCB) (Figure 19) were co-crystallized 
with TAO with resolution 2.6 Å and 2.3 Å respectively, which is not sufficiently high to 
draw very specific conclusions but is discussed below. 
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The structure indicates that AF2779OH is located close to the diiron active site and that 
the C2–OH forms hydrogen bonds with R118 and T219 (Figure 20). In addition, in the B 
and D subunits, the aldehyde oxygens at the C1 position interacts with E123 through a 
hydrogen bond network (Figure 20), whereas for the A and C subunits, the aldehyde 
oxygens form an intramolecular hydrogen bond with C2–OH ortho-phenol. While 
structural information is desirable, these crystal structures are not of sufficiently high 
resolution and the lack of consistency between the ABCD units makes determining the 
exact binding mode of the aldehyde head group futile. It is possible that the compound 
might bind to Fe, the bridging OH, outer-sphere water or H-bond amino acid (AA) 
residues near the iron. 
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Figure 20 - Interaction between TAO and the bound AF2779OH molecules and their electron density maps. 
Interaction between the bound AF2779OH molecule and TAO with sigma-A weighted electron density map (Fo-
Fc) calculated from the refined model of TAO-AF2779OH complex with theAF2779OH molecule omitted from the 
phase calculation. AF2779OH molecules bound to (A) chain A, (B) chain B, (C)chain C and (D) chain D are shown as 
pink sticks with nitrogen, oxygen and chlorine atoms coloured in blue, red and green, respectively. The diiron (Fe-
OH--Fe) is drawn as magenta spheres. Contour levels are 1.0 σ (blue) and 3.0 σ (orange)226 (Image and caption 
from reference) 
 
Anti-trypanosomal evidence for AF 
AF has been shown eradicate the parasite from bloodstream of mice with a high parasitic 
load, with curative dosings of 25 mg/kg AF and 3 g/kg glycerol for one day216 or 100 
mg/kg AF without glycerol for four days.233 These results indicate that AF and AF-like 
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compounds show promise as non-toxic agents for mammalian trypanosomiasis. 
However, there are a number of drawbacks. For best effect the compounds must be 
administered intraperitoneally (IP), maintaining the need for a clinician. Curative oral 
doses were considerably higher with 100 mg/kg for one day AF and 3 g/kg glycerol, or 
400 mg/kg for eight days with AF alone. Such doses are incredibly high considering that 
AF exhibits picomolar potency against TAO in genotypic and phenotypic assays, 
indicating that improving the pharmacokinetics (PK) could markedly improve prospects 
for TAO specific HAT inhibition.   
 
Other known AF interactions 
AF shows activity against a number of interesting targets including mitogen activated 
protein kinases,242 G1 cell cycle arrest,243 AMP activated protein kinases,244 cytochrome 
bc1 complex,213 and EGFR-mediated cell signaling.245 It is also indicated as an antitumor 
agent by way of inhibiting MMP-9, which is implemented in tumour invasion and 
metastasis.245   
The non-toxic clearance of trypanosomes in mice models indicates that AF is TAO-
specific in vivo, however in its natural form there are a number of factors which make it 
unlikely that AF could be useful as a drug. Instead, TAO is adopted as a tantalizing lead 
compound for diversification.  
 
Shortcomings of AF as a potential drug 
AF has a number of structural features which should be addressed to make it more drug-
like. The structure can be divided in 3 sections: 1) the aromatic head group; 2) prenyl 
linker; and 3) furanone tail group (Figure 21).  
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Figure 21 - Division of AF structural motifs 
1) The crystal structure of TAO shows that the head group of AF analogues, with 
salicylaldehyde motif, interacts with the diiron active site. There are a number of 
potential problems in this region which must be addressed.210 
The benzaldehyde is a prime target of metabolism in vivo via oxidation or attack by 
endogenous scavenging nucleophiles such as glutathione.246 
The bisphenol moiety greatly increases the likelihood that AF-derived compounds would 
act as indiscriminate redox cycling agents. Redox cycling could potentially interfere with 
a plethora of electron transfer proteins, including, most critically, the human 
mitochondrial respiratory complex. Additionally, phenols have an innate toxicity for a 
wide variety of reasons.247–250  
The hexa-substituted aryl motif is undesirable as these compounds tend to have poor 
solubility. They can also be synthetically idiosyncratic in both general reactivity and 
potential for side reactions because each addition, removal or substitution on any 
position will interact electronically and likely sterically with every other position on the 
ring.           
2) The prenyl linker is a long hydrocarbon chain, and as such is likely to have poor 
metabolic stability. Cytochrome P450s (CYPs) are a superfamily of monooxygenases that 
account for ~75% of drug metabolism.251 They add single hydroxyl/epoxy functionalities 
to a molecule which often deactivates it and increases its renal excretion from the body. 
The prenyl linker is particularly vulnerable to such oxidation and substitution for a 
shorter chain would be optimal, especially if that chain included a heteroatom. It would 
also be interesting to explore diverse linker and tail replacements by changing the linker-
aryl bond from a carbon-carbon bond to a carbon-heteroatom bond. 
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3) The furanone tail group should have reasonable metabolic stability. However, 
analogues with simpler functionality and no chirality would be synthetically desirable. It 
is proposed that the furanone tail may help to afford selectivity because while AF is not 
toxic in mouse models, colletochlorin B is.210 
 
Literature of the structure-activity relationship (SAR) around AF 
It has been known since the 1990s232 that AF is a TAO inhibitor, but it wasn’t until 2013 
that the structure-activity relationship (SAR) was explored.212 As a result, most of the 
investigation detailed in this report was conducted prior to understanding of the SAR.  
The synthetic alternatives explored in the study fall into several groups: 1) altered linker 
and tail group; 2) altered aldehyde functionality; 3) alteration and removal of remaining 
aryl substituents.  
1) Extensive changes were made to the linker and tail group. These include: 
removing the furanone or substituting it for various ethers, esters, and hydroxyl groups; 
saturating, partially saturating, branching, debranching, shortening or lengthening the 
linker.  
 
Figure 22 - Most potent inhibitor to date: Ki= 0.06 nM 
The changes illustrated that the furanone is not necessary for potency, in fact the most 
potent compound (39) (Figure 22), Ki= 0.06 nM, had no tail group, the optimum chain 
length is eight carbons, and a prenyl functionality beside the head group is mildly 
preferred. In summary, the chain appears to affect potency only non-specifically by 
lipophilic interactions. 
2) Aldehyde replacement was studied less extensively and unfortunately not 
conducted with matching tail groups, making direct comparison impossible, but seems 
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to indicate that substitution for the methyl ketone and nitro has little effect on potency 
(<10-fold), while introducing a nitrile, methyl ester or oxime moderately decreases 
potency (~10-fold) and chlorine and proton replacements had decidedly negative effects 
(100,000-fold and 40,000-fold respectively). 
3) Single changes on the ring at either the Me or Cl positions have negligible effect, 
both maintaining picomolar activity, but if both groups are removed potency decreases 
by 40-fold. These point changes do not confirm whether it is steric or electronic effects 
that are affecting potency but it is clear that these are non-essential functionalities. 
Methylation of the para-phenol decreases potency 100-fold and deletion results in 
almost complete loss of activity.  
 
Figure 23 - SAR published by Kido et al. 
To summarize (Figure 23), the nature of the tail is unimportant and the chlorine and 
methyl are not vital to function, but the para-phenol and potentially the ortho-phenol 
are necessary.  
The exploration of chemical space in the study seems strangely directed. Only limited 
alterations were made to the headgroup, which would seem likely to have greater effect 
on potency given that ubiquinol is known to interact via its aromatic head group and 
SHAM only has this region. While hydrophilic interactions might be possible in the 
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channel leading to the active site, the linker is not an obvious starting point for 
diversification. 
Positively, this exploration indicated that many desirable changes are viable, which 
should make AF more drug-like and tractable for analogue exploration. The linker and 
tail can be modified extensively, the aldehyde can be replaced with more suitable drug-
like equivalents while retaining nM potency, and the Cl and Me can be removed, 
allowing space for possible SAR and growing off the ring. The necessity of the 4-hydroxy 
is clear but unfortunately the 2-hydroxy was not explored, although SHAM contains this 
2-hydroxy and is efficacious, so it was assumed that the overall phenolic character of the 
lead compound is important. However, understanding can be improved by testing the 
effect of para-hydroxy methylation. Given that AF is mimicking electron-transferring 
ubiquinol it is understandable that the aldehyde and ortho, para phenolic character is 
necessary. 
This work in combination with headgroup exploration undertaken in house prior to the 
commencement of this work unfortunately concluded that every position on the hexa-
substituted aromatic group is required to give maximal potency. This greatly increased 
the synthetic challenge in producing novel analogues and severely limited the synthetic 
methods available. A thorough discussion of the synthetic difficulty involved in hexa-
substituted aromatics and the literature around this topic is discussed in chapter 2.    
 
 
Synthetic approaches to AF 
There are several routes to AF and its analogues. There are numerous publications 
dedicated to synthesis of the furanone tail,252–254 however, as it is irrelevant to AF's 
action, focus will be on preparation of the headgroup and how this is attached to the 
linker.  
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Scheme 6 - Penta-substituted headgroup synthesis from aliphatic staring materials 
The headgroup, in almost all syntheses, is pre-formed as the 3-chloro-4,6-dihydroxy-2-
methylbenzaldehyde (47) or the bromo methylbenzoate (44). This is obtained either by 
cyclisation (Scheme 6) or functionalization of orcinol (45) (Scheme 7). Unfortunately, in 
both of these routes the electrophilic carbonyl is installed early, limiting nucleophilic 
possibilities for later addition of the isoprenoid linker.    
 
Scheme 7 - Penta-substituted headgroup synthesis from aromatic staring materials 
There are two main routes for linker attachment from these two cores (44) and (47). For 
the free phenolic reagent (47), KOH and geranyl bromide enable electrophilic aromatic 
addition of the linker. The bromine of compound (44) is subjected to lithium-halogen 
exchange forming a nucleophile which attacks geranyl bromide via Sn2 displacement.    
Prior to the commencement of this work, both of these methods had been tested in the 
Ward group but were found unsuccessful. The KOH method had been tried by several 
different labs and chemists at the University of Sussex and all had < 10% yields, much 
lower than the published 29%.255 The second method involving lithium-halogen 
exchange, transmetallation to the cuprate and then Sn2 displacement with the geranyl 
bromide, reported a 70% yield,256 but again this could not be repeated by post-doctoral 
fellows or students in the Ward lab.  
This particular method does call for concern as it employs n-butyl lithium (n-BuLi) to 
exchange with the bromine, creating the aryl lithium intermediate in the presence of a 
methyl benzoate. Both of these could be expected to react with the methyl benzoate 
60 
 
and indeed this affect was observed in the Ward lab even when temperature, dilution 
and equivalents were carefully controlled. The choice of n-BuLi is also contrary to the 
recommendation in Victor Sneickus's comprehensive lithiation review,257 where it is 
outlined that a tert-butyl benzoate, sec or tert-BuLi and low temperatures are needed 
to obtain yields comparable to those claimed for the AF synthesis.258 This synthesis also 
requires SEM protecting groups which cannot be deprotected utilizing any of the various 
methods typically employed, including those quoted by the author. This deprotection 
problem was also identified by another group attempting to follow this synthesis of 
AF.259  
 
Scheme 8 - Synthesis employing late stage headgroup functionalisation258 
In the only remaining published route258 to AF the linker is attached early and the aryl 
headgroup functionalized afterwards by a chlorination, aromatization and formylation 
(Scheme 8). The yield for the complete 11-step synthesis was 0.8%, or omitting the 
formation of the tail group and linker, the 4 steps for simply attaching and 
functionalizing the headgroup, 2%. This is clearly not a viable route to AF for further 
derivatisation and SAR exploration.  
Unfortunately none of the syntheses of AF have thus far proven to be high yielding, 
quick, reproducible or easily amenable to the diversity-orientated synthesis required for 
exploration of SAR. In spite of this AF represents an interesting and worthwhile subject 
for investigation because of its remarkable potency against an exciting protein candidate 
for the treatment of African trypanosomiasis. If a method could be developed for the 
diversification of this structure and/or the synthesis of the natural product improved, 
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this would be novel, constructive and important towards alleviating the suffering caused 
by the parasite T.Brucei.   
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Aims 
The ultimate goal of this project was the development of the potent lead compound 
ascofuranone to produce a clinical candidate for the treatment of African 
trypanosomiasis. Towards this, three specific aims were determined which would 
become the focus of this work (Figure 24): 
1) The existing chemistry around ascofuranone was limited in scope and not amenable 
to diversification of key functionalities. New synthetic routes were required which would 
enable improved exploration of chemical space and modification of metabolically labile 
features. 
2) Once synthetic routes had been established, compounds could be developed which 
would afford enhanced drug-like properties, compared to AF, whilst retaining TAO 
activity. Pertinent to improving the drug-like properties of ascofuranone analogues was 
the removal of the headgroup aldehyde and bis phenols, which are particularly 
metabolically labile. 
3) If a suitable alternate headgroup was discovered, which retained TAO activity, focus 
would shift to exploration at the tail. This would ideally involve substitution of the 
metabolically active geranyl motif with a variety of other tails with an aim to determine 
the optimum combination of pharmacodynamic and pharmacokinetic properties. 
 
Figure 24 - Aims for developing ascofuranone towards a more drug-like analogue 
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Chapter 2 - Palladium cross-coupling and Fries-type rearrangement  
The existing synthetic methods to synthesise ascofuranone (AF) and AF-analogues were 
limited. In addition, those methods reported had in large been tested by other chemists 
in the Ward group, prior to the commencement of this work, with little success. Several 
different methods were examined with the hope of developing an improved route to AF 
analogues. In particular, Suzuki coupling and Lewis acid catalysed Fries-type 
rearrangements were attempted as a means of installing the geranyl tail on to the 
aromatic headgroup. Also included in this chapter is a synthetic route to another AF 
analogue that had been designated as an interesting target.  
 
Hexasubstituted arenes 
When commencing this work there was no SAR around AF with which synthetic 
strategies could be directed and even when SAR was published,212 it served only to 
reinforce the requirement of each of the six arene substituents. Polysubstituted 
aromatic compounds have long been a synthetic challenge260 with the necessary 
presence of many functionalities decreasing the likelihood of obtaining the desired 
product. This is often due to steric or electronic incompatibility of these functionalities 
and the increased risk of side-reactions.  
The functionalisation of aromatic rings is of critical importance in synthesis and nowhere 
more so than in medicinal chemistry where they are nearly ubiquitous across the field.261 
Naturally, by posing such a worthwhile challenge, the synthesis of polyfunctionalised 
arenes has been a massive field of chemical endeavor; these methods can be divided 
into classical approaches based on aromatic substitution of a given arene and 
benzannulation approaches that construct the aromatic backbone from acyclic 
precursors.  
The main methods for decorating aromatic rings include: electrophilic aromatic 
substitution;262 nucleophilic aromatic substitution;263 benzyne reactivity;264 coupling 
reactions catalyzed by transition metals;265 and metalation-functionalisation 
reactions.257  
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Methods of polyfunctional benzannulation are innumerate, some examples of reactions 
classes include: [4 + 2] Diels-Alder cycloaddition,266 particularly impressive when 
deployed to synthesise hexaarylbenzenes with six different aryl substituents;267 the [3 + 
2 + 1] Dotz reaction of Fisher carbene complexes;268 alkyne-cyclobutenone [4 + 2] 
cyclisation;269 [4 + 2] cycloaddition of metalacyclopentadienes and alkynes;270 transition 
metal catalyzed [2 + 2 + 2] and [4 + 2] cycloadditions;271,272 [4 + 2] benzannulation of o-
alkynyl benzaldehyde and alkyne;273–275 [3 + 3] cyclocondensation between 
bielectrophiles and binucleophiles;276,277 1,6-electrocyclization reaction;278,279 [5 + 1] 
benzannulation strategy between alkenoyl keteneacetals and nitroalkane;280,281 
synthesis of acetophenones and methyl benzoates via the reaction of 1,3-dinitroalkanes 
with 2-ene-1,4- dione or 2-ene-4-oxo ester derivatives;282 and [4 + 2] annulation strategy 
from the Baylis-Hillman reaction.283  
Selection of the most appropriate synthetic method to synthesise AF analogues from 
the plethora of potential methods was a daunting prospect. Decisions were based 
primarily on literature precedent284 as compound 51 (Figure 25) and similar compounds 
were available in good yield within three steps, and critically contained the correct 
substitution pattern.  
 
Figure 25 - Correctly hexasubtitued compound 
In general, it was envisaged that the step-wise functionalisations of the ring would be 
more relevant as they potentially allow for greater generation of SAR data. Whereas, 
benzannulations, which would ideally install all functionalities at once, would not allow 
this. 
In addition to this, the benzannulations referenced are often very limited in what 
functionalities can be used and prescriptive of their required position in the final ring. It 
is also common that these reactions have only be shown to work best with multiples of 
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the same functionality, which is unsuitable for AF-like synthesises. Additionally, the 1, 3 
diphenol motif was poorly represented, with the 1, 4 and 1, 2 benzoquinones being 
much more widely available.267 Of those examined the Diels-Alder cycloaddition did 
offer an interesting potential route to a hexasubstituted AF analogue or indeed for a 
total or formal synthesis of AF (Scheme 9). These sorts of annulations were unexplored 
in the course of this work and the methods employed: electrophilic aromatic 
substitution; palladium catalysed cross-coupling reactions; and metalation-
functionalisation reactions are described at length where appropriate.   
 
Scheme 9 - Potential formation of desired hexasubstituted arene via Diels-Alder chemistry  
 
Suzuki coupling  
When this work commenced, there was no published SAR around ascofuranone (AF) and 
as a result all molecules synthesised had to incorporate the geranyl chain so that 
headgroup changes could be compared directly to colletochlorin B (CCB). A useful 
general method to access CCB or AF analogues was not available, but compound 51 
(Figure 25) was known from published work to be synthetically viable. With the aim to 
move away from the low yielding, unpredictable chemistry previously reported in the 
literature and toward more reliable reactions, the decision was taken to explore a 
palladium catalysed Suzuki coupling in an attempt to couple an easily synthesised aryl 
halide such as compound 51 with a boronate ester (Scheme 10). 
The range of possible palladium couplings were considered:  Negishi organozinc;285 
Kumada organomagnesium;286 Hiyama organosilicon;287 Stille organotin288 or Suzuki 
organoboron289 chemistry were all possible candidates for the sp2-sp3 C-C bond 
formation. However, as nucleophilic metalates were likely to attack the methyl ester, 
the Negishi and Kumada methods were inappropriate.  
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Of the remaining options, Stille and Suzuki have been most extensively explored and are 
the most versatile. Of these two, the Suzuki organoboron avoids the use of toxic tin 
which is undesirable in synthetic routes to compounds for biological assay. 
A number of problems were foreseen including: that the possible η3-allylic palladium 
intermediate formed could isomerise the trans geranyl chain; the alkyl boronate would 
be unstable in the reaction; and the lone pair containing functionalities on the aryl 
headgroup could chelate and deactivate the palladium in solution. However, if these did 
develop into issues it was hoped they could be overcome by reaction optimisation.  
 
Scheme 10 – General Suzuki cross-coupling reaction 
The Suzuki-Miyaura coupling reaction (Scheme 10) was first reported for aryl boronic 
acids with aryl halides and has since expanded to a vast range of C-C bond formations. 
The reaction now generally denotes palladium catalysed coupling of a C-BRn molecule 
with any molecule capable of oxidative addition to the palladium catalyst. The reaction 
can proceed with a large range of bases and solvents.290 Typical bases include 
hydroxides, alkoxides, acetates, pivolates, carbonates, and flourides whilst some 
reaction is reported in nearly all organic solvents (polar/apolar, protic/aprotic) and 
additionally in water.   
An assortment of organoboron compounds are used regularly (Figure 26): boronic 
acids291 (61) are commonly used as they are cheap and a huge number of diverse 
compounds are available commercially, however these are the least stable and most 
prone to protodeborylation and oxidation; esters292 (60 and 64) afford greater stability 
from enhanced oxygen lone-pair overlap with the vacant boron p-orbital than the 
boronic acid and enjoy wide commercial availability; 9-BBN borane293 (59) was used 
initially because it was easily installed by hydroboration and remains a reagent of choice 
in alky couplings;  trifluoroborates294 (62), N-methyliminodiacetic (MIDA) boronates295 
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(63) and 1, 8 diaminonaphtyl boronamide296 (65) all act as protecting groups allowing a 
boron moiety to proceed unaffected through various reaction conditions, this increases 
their synthetic utility and additionally allows for iterative Suzuki couplings;297 the 
remaining charged boronates (66 and 67) benefit from requiring no addition of base, are 
crystalline solids to handle and can environmentally more benign, “greener”.298  
 
Figure 26 - Common organoboron reagents used in Suzuki reactions 
When considering choice of palladium catalyst the list is enormous, from simple: 
Pd/C;299 PdCl2;300 and Pd(OAc)2300  to elaborate preformed catalysts affording enhanced 
specific reactivities and/or low catalyst loadings: pincer ligands;301 Buchwald ligands;302 
N-heterocyclic carbenes.303 Palladium Suzuki catalysts is a large field in itself and will not 
be further reviewed here; the catalysts selected in this work were done so based on 
recommendations of reviews specific to the reactions undertaken and will be discussed, 
as appropriate, in line with the synthetic sequences undertaken.       
The Suzuki-Miyaura coupling represents one of the most important synthetic 
transformations developed in the 20th century.304 Palladium cross-coupling of 
alkenyboranes with alkenyl or aryl halides was performed by Suzuki, Miyaura and 
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Yamada and reported first in 1979.289,290 Suzuki’s work built upon the pioneering work 
of the previous 30 years in realising the catalytic potential of palladium: Hafner’s 
development of the catalytic oxidation of ethylene in the Wacker process;305,306 Heck’s 
catalytic cross-coupling of alkenes with aryl halides;307–313 Sonogashira’s progression 
from stoichiometric copper to a catalytic Pd/Cu for coupling aryl halides and 
acetylenes;314 Stille’s coupling of organostannanes and aryl halides;315,316 and Suzuki 
pursued the remaining element of the three previously identified by Negishi (zinc, 
boron, and tin).304  
The Suzuki coupling has since outstripped all other palladium reactions in terms of 
articles published.304 Several factors that have contributed to this success include: 1) 
easily handled and usually air- and moisture-stable organoboron starting materials; 2) 
mild and convenient reaction conditions; and 3) the facile removal of less-toxic inorganic 
byproducts. These aspects make the Suzuki–Miyaura coupling reaction especially useful 
for industrial applications and this compounding factor has acted to further accelerate 
research in this field.304    
Despite its discovery in the late 1970s a definitive elucidation of the mechanism of the 
Suzuki-Miyaura coupling reaction was not reported until the 2010s and even this was 
only under a certain set of common conditions and reagents.317 There were several 
mechanisms proposed (A-D, Scheme 11). All consisted of oxidative addition of the aryl 
halide onto the palladium, transmetalation from boron to palladium, endergonic 
rearrangement of the of trans diorganopalladium (72) to the cis isomer (73), and 
reductive elimination (Scheme 11).  
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Scheme 11 – Proposed role of the base in Suzuki reaction317 (R= H, alkyl) 
The differences between the mechanisms arise from the role of the base in the catalytic 
cycle. Suzuki had observed in 1981 that even cross-couplings undergoing no 
deprotonation required a ‘base’, and in addition that not all bases were adequate with 
Lewis bases such as trialkylamines proving entirely unproductive318 (although that has 
not remained the case).319 Suzuki initially proposed the boronate pathway B318 involving 
the reaction of alkoxides RO (R=Me, Et) with arylboronic acids to generate anionic 
arylborates Ar’B(OH)2(OR)- (71) thought to be more active than Ar’B(OH)2 (70) in the 
transmetalation with the complexes [Pd(Ar)(L)2X] (68) generated in the oxidative 
addition of ArX to [Pd0(L)n] (75). Subsequently Suzuki proposed the oxopalladium of 
pathways D and C as a key intermediate based off the observation that reactions using 
only the preformed [Pd(Ar)(L)2(OR)] (69) with a Ar'B(OH)2 (70) reagent and in the 
absence of base proceeded in good yields.320 Most published work, be it 
experimental321,322 or computational,323–325 demonstrated that pathway B, C or a 
combination was the most probable reaction mechanism. All mechanisms invariably 
arrived at the trans-[Pd(Ar)-(Ar’)(L)2] (72) species.  
An excellent set of experiments by Amatore and Jutand326–328 employed 
electrochemistry and NMR spectroscopy (11B and 31P) to measure in real-time the 
palladium and boron species present throughout the reaction and this allowed the 
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elucidation of the kinetics of simple Suzuki couplings. Through standard investigatory 
methods for probing reactions kinetics they increased and decreased amounts of 
different reagents and measured the rate change for different steps in the reaction, the 
results obtained were interesting. They found that both hydroxide and fluoride ions 
have three antagonistic functions (Scheme 12): 1) formation of the reactive trans-
[Pd(Ar)(L)2(OH)] (69) in the rds transmetallation with Ar’B(OH)2 (70), the rate of which is 
controlled by the ratio: [OH]/[Ar’B(OH)2]; 2) catalysis of the reductive elimination from 
trans-[Pd(Ar)(Ar’)(L)2]; and 3) formation of unreactive Ar’B(OH)3- (71). This evidence 
clearly established pathway C (Scheme 11) as the productive mechanism even 
identifying the proposed active boronate (71) as an inactive reservoir of both boron 
compound and hydroxide. Unprecedented in the Suzuki reaction was the observation of 
a proposed pentacoordinate species (80) (Scheme 12) bypassing the slow classical 
reductive elimination requiring the endergonic trans/cis isomerisation. Finally, the 
cation associated with the base was found to retard the reaction based on its degree of 
conjugation to the oxopalladium complex (79), with larger cations affording greater 
retardation. 
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Scheme 12 – Mechanism accounting for role of the ‘base’ as proposed by Amatore317 
The discussion thus far has been of an assumed homogeneous palladium catalyst and it 
has been suggested that catalysis occurred solely from leaching of low nuclearity 
palladium from metal particles suspended in solution.329–334 However, strong evidence 
exists that Suzuki couplings occur at the five- and six-coordinate defect sites on the edge 
of palladium nanoparticles335 and this was demonstrated adeptly by Fairlamb and 
Wilson using X-ray absorption spectroscopy (XAS). Polyvinylpyrrolidone stabilised 
palladium nanoparticles (PVP PdNP) of definite sizes below 5 nm in diameter were 
synthesised and their activity in Suzuki couplings investigated. The PdNP size and surface 
was monitored continuously by XAS and it was found that the catalytic rate associated 
with these < 5 nm particles was directly proportional to the number of low coordinate 
sites exposed. It was postulated that this could be a factor in the regular observation 
that highly dilute, ‘homeopathic’, quantities of palladium give higher reaction rates.336 
These highly dilute palladium suspensions could be more likely to exist in these active < 
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5 nm PdNPs and increased palladium loading would result only in an increased portion 
of the palladium being trapped in the inactive high coordinated bulk. Whilst this could 
have been assumed before, with this evidence its likelihood is increased. This work 
attempted to further preclude any activity arising from leached palladium atoms by 
adding a palladium binding silica network with pores small enough to exclude the PDNPs 
but not the solubilised palladium. They found only a small decrease in rate which was 
attributed to the adhering of the PdNPs to the exterior of the silica particles, indicating 
that the PdNPs are the drivers of catalysis. The authors stress that these are not generic 
results and alternate mechanisms are certainly taking place with varied solvents, 
temperatures, non PVP PdNPs etc. However, this work and others337–341 indicate that 
both heterogeneous and homogeneous catalysis are possible in Suzuki reactions not 
involving preformed, homogeneous palladium catalysts such as N-heterocyclic carbene 
bound palladium; it suggests that a more complex reaction scheme is required to 
properly envisage the reaction (Scheme 13). Distinctly lacking from discourse of 
heterogeneous Suzuki reaction mechanisms was the requirement and role of the base 
and it appears this requires further elucidation.   
 
Scheme 13 - Proposed mechanism for the PdNP-catalyzed Suzuki cross-coupling involving both homogeneous and 
heterogeneous pathways.342 Note: though only re-deposition is displayed in the scheme, re-clustering to form 
(new) smaller particles and/or formation of palladium black are also feasible but not displayed.  
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The scope of bond formations accessible by Suzuki reactions is truly staggering (only a 
hand-full of the multitudinous references possible will be given): any combination of 
alkyl, alkenyl, alkynyl, or aryl coupling;343–347 synthesis of vinylic sulfides;348 carbon 
ylative coupling;349 decarboxylative coupling reactions;350 and regioselective and 
stereoselective bond formation351 and these reactions can be utilised in: cascade 
reactions;352 aqueous, aerobic, ligand free conditions;353 C-H activation chemistry;354 
masked as stable N-methyliminodiacetic acid boronate and used in iterative 
reactions;355 and amenable to industrially relevant processes like physycally356 or 
magnetically357 recoverable-nanoparticle-supported palladium catalysts. This barely 
touches on the massive field of Suzuki chemistry however fortunately included in this 
field is allylic-aryl cross-coupling which was the desired bond formation in the proposed 
synthesis of ascofuranone analogues.   
Literature precedent existed for Suzuki mediated sp2-sp3 C-C bond formation at the 
allylic position of prenyl, crotyl and allyl boronates.358 The optimum conditions were 
reported as Pd(dppf)Cl2 in dioxane: water with K2CO3 as a base. This research had also 
concluded that potassium trifluoroborates, popularised by Molander,359 gave 
particularly good yields, but simple pinacol boronate esters also performed well. The 
pinacol boronate ester was found to be more readily available and was therefore 
utilised.    
 
Target compounds 
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Scheme 14 - Proposed synthesis utilizing palladium couplings 
An interesting hydroxamic acid target, compound 87 (Figure 27), was generated from 
the combination of the CCB and SHAM motifs. This looked particularly interesting as the 
replacement of the aldehyde would test whether it was possible to remove this 
metabolically unattractive functionality. It would also serve as a target in the exploration 
of palladium chemistry towards AF-like compounds and could potentially have 
reasonable TAO activity given the high ligand efficiency of SHAM.  
 
Figure 27- Hydroxamic acid target compound 
This route also allows for the replacement of the geranyl chain in compound 86 with the 
synthetically simpler shorter prenyl chain compound 85 (Scheme 14). Isomerisation was 
a risk and was thought to have been observed using palladium for installing the geranyl 
in the Ward lab. It was hoped that a compound with this shorter chain would maintain 
sufficiently high potency to enable exploration of headgroup SAR in the event that olefin 
isomerisation could not be controlled for the geranyl chain. 
Headgroup formation 
 
Scheme 15 - Chlorination reaction 
The hexa-substituted headgroup compounds 51 and 82 were synthesised via two 
different routes. 
Compound 82 was synthesized following an available procedure255 (Scheme 16) from 
methyl 2,4-dihydroxy-6-methylbenzoate (88). Chlorination of compound 35 with 
sulfuryl chloride was reported with 75% yield. This yield was not obtained in any of the 
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various test scale and larger reactions attempted. A mixture of mono-chlorinated and 
di-chlorinated compounds 81, 89 and 90 (Figure 28) was obtained.  
These compounds were poorly soluble, poorly purified by recrystallisation and 
ultimately numerous silica column purifications were necessary to prepare the clean 
product. This difficult purification likely resulted in decreased isolated yields however 
even in 1H NMR spectra of crude reaction mixture the observed proportion of methyl 3-
chloro-4,6-dihydroxy-2-methylbenzoate (81) never reached that reported.  
The product (81) was characterised in 1H NMR spectroscopy by the disappearance of an 
aromatic CH and the elimination of 1, 3 proton coupling across the ring. 13C NMR 
spectroscopy and two-dimensional HMBC spectroscopy allowed for accurate 
assignment of the chlorine to the C-5 position by the absence of coupling from the tolyl 
6-CH3.    
 
Figure 28 - Mixture of compounds obtained from chlorination 
The chlorinated product (81) was then iodinated in a straightforward manner with 
benzyltrimethylammonium dichloroiodate (BTMA-ICl2) (Scheme 16). This was evident 
by 1H NMR spectroscopy with the disappearance of the only aromatic CH signal. 
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Scheme 16 - Iodination 
The equivalent bromo headgroup was synthesised by known methods.256 The cyclic ±-
methyl 2-methyl-4,6-dioxocyclohexanecarboxylate (42) was prepared from acyclic 
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reagents (40 and 41) in a single step (Scheme 17). The product was identifiable in 1H 
NMR spectroscopy by the 6-CH3 doublet, the 1-OCH3 methyl ester singlet and the vinylic 
3-CH and by observation of the accurate mass of the molecular ion using HRMS. It also 
converted readily to the desired product compound 43 in the following bromination 
step (Scheme 18), which was fully characterised. The 1H NMR spectrum exhibits only a 
trans proton-proton coupling for the two stereocentres 1-CH and 6-CH formed in the 
reaction and indicates the formation of a racemic mixture of compound 42.    
 
Scheme 17 - Formation of cyclic headgroup precursor 
Compound 42 was brominated and oxidised in a single step using molecular bromine. A 
mixture of the mono and dibromo products was obtained but fortunately, in contrast to 
the chlorination attempted previously, formation of the desired 3-bromo product was 
favoured, affording a 69% yield. Chlorination of compound 43 with sulfuryl chloride 
occurred in excellent yield 98% (Scheme 18). Both products (43 and 51) were easily 
observable by 1H NMR spectroscopy. Compound 43 was identified by the substantial 
simplification of the 1H NMR spectrum in comparison to the staring material and by the 
appearance of distinct aryl and tolyl protons that couple to one another via two-
dimensional HMBC spectroscopy. The chlorination was then observable by the 
disappearance of that aryl 5-CH singlet signal in the 1H NMR spectrum of compound 28. 
 
Scheme 18 - Aromatisation and decoration to the hexa-substituted headgroup 
A similar halogenation and oxidation was attempted with molecular iodine (Scheme 19). 
However, this only partially reacted and the only observed product was the non-
halogenated, oxidised ring (88). This was undesired but somewhat predictable as iodine 
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is a known oxidising agent. As there were already several known two-step methods for 
synthesising this ring and this was given no further attention. 
 
Scheme 19 - Attempted iodination reaction 
It was expected that the phenols would interfere with the palladium coupling reactions, 
so the hexa-substituted headgroup compounds (51 and 82), were methylated with 
dimethyl sulfate (>90%) to give compounds 83 and 84 (Scheme 20) with two new distinct 
singlets for 3H observable in their 1H NMR spectra. The reactivities of the free phenols 
were also assessed in subsequent palladium couplings to test the necessity of the 
protection step. 
 
Scheme 20 - Dimethyl protection of phenols 
 
Palladium catalysed Suzuki couplings 
Coupling of compound 91 (Figure 29) utilising Pd(dppf)Cl2 was reported in literature and 
had been previously employed in house. Encouragingly the protected iodo compound 
84 coupled successfully to 3-methyl-2-butenylboronic acid pinacol ester (92) to give 
compound 85 in a 49% yield (Scheme 21). Although the yields were still not particularly 
high, they compared very favourably with those previously published for C-C bond 
formation between headgroup and linker (< 10%).  
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Figure 29 - Reagents successfully coupled in-house 
The reaction of compound 84 with 3-methyl-2-butenylboronic acid pinacol ester (92) 
using the established method formed two major products, the desired compound 85 
and the deiodinated compound 98. This dehalogenated side product is thought to result 
from beta-hydride elimination of the prenyl group as the allene 95 or diene 96 (Scheme 
22), which would form the palladium hydride (97) that could reductively eliminate with 
the palladium bound aryl group to produce the deiodinated compound observed. 
Compound 85 was characterised only by 1H NMR spectroscopy with the addition of the 
signals of the prenyl chain to those of the staring material (84). The small quantity of the 
product (85) produced was subsequently consumed in attempted deprotections of the 
methyl ethers. Any further resynthesis of compound 85 was deemed unproductive given 
the eventual failures in both deprotection and palladium coupling.  
 
Scheme 21 - Palladium mediated prenyl installation 
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Scheme 22 - Proposed dehalogenation mechanism 
Unfortunately, further Pd reactions proved entirely unsuccessful. Coupling of the bromo 
compounds 83 and 99 was unproductive using any of the applied conditions (Table 3) 
(all conditions were repeated several times and at increased temperatures), and the 
yield from the first attempted reaction with the iodo compound (84) could not be 
improved. Several catalysts were trialed in attempt to couple the free phenolic 
compounds 43, 82 and 51 but this was also unsuccessful. Presumably the conditions for 
the successful Pd(dppf)Cl2 reaction afford either an enhanced relative rate of reductive 
elimination over β-hydride elimination and/or sterically deter the agostic overlap 
required to form the side product. The free phenols seemingly interfered with the Pd 
couplings and even the Buchwald type ligand,302 which donates substantial electron 
density to palladium and often allows previously unreactive substrates to undergo 
oxidative addition, was unable to activate these compounds sufficiently to enable 
successful reaction. Although this is by no means a thorough investigation of Pd catalysts 
and ligands, limited time was committed to further exploration due to the low chance 
of success.  
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Scheme 23 – General reaction scheme for palladium couplings 
Table 2 – Attempted palladium reactions with unprotected phenols  
 Conditions 
   
Pd(dppf)Cl2, dioxane, 
K2CO3, prenyl 
boronate, 100 °C  
No reaction No reaction No reaction 
Pd(acac)2, dioxane, 
K2CO3, prenyl 
boronate, 100 °C 
No reaction No reaction No reaction 
Pd(OAc)2, Ruphos 
toluene/water, 
K2CO3, prenyl 
boronate, 100 °C 
No reaction No reaction No reaction 
 
Table 3 - Attempted palladium reactions with methyl protected phenols  
Conditions 
   
PddppfCl2, dioxane, 
K2CO3, prenyl 
boronate, 100 °C 
49% coupled 
product 
Little reaction 
Major product 
dehalogenated 
No reaction 
Pd(dba)3, dioxane, 
K2CO3, prenyl 
boronate, 100 °C 
< 5% coupled 
Major product 
dehalogenated 
arene 
No reaction No reaction 
Pd(acac)2, dioxane, 
K2CO3, prenyl 
boronate, 100 °C 
< 5% coupled 
Major product 
dehalogenated 
arene 
No reaction No reaction 
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Pd(OAc)2, XPhos 
Toluene/water, 
Cs2CO3, prenyl 
boronate, 100 °C 
Major product 
dehalogenated 
arene 
Little reaction 
Major product 
dehalogenated 
arene 
 
No reaction 
Pd(OAc)2, RuPhos 
Toluene/water, 
K3PO4, prenyl 
boronate, 100 °C 
Major product 
dehalogenated 
arene 
No reaction No reaction 
 
 
Several deprotections of the bis methylated compound 85 were attempted (Scheme 24) 
with BBr3 in DCM at 0 °C or NaSMe heated in both DMF and DMPU but no reaction 
attempted afforded the product. It was hypothesised that with the prenyl and ortho-
phenol in close proximity, there was a likelihood of cyclisation, as in compound 101, in 
the presence of acid, base or potentially high temperatures, resulting in an array of side 
products.  
 
Scheme 24 - Deprotection of methyl ethers unsuccessful 
This exploration of Suzuki couplings for installation of the geranyl linker had therefore 
regrettably come to several impasses: 
1) The stereochemistry of the trans geranyl linker was an isomerisation risk and only one 
of the coupling conditions trialed gave any meaningful product formation, leaving no 
opportunity for improvement.  
2) Most reactions proceeded only when the iodo headgroup was used and the major 
product was invariably the undesired dehalogenated material.  
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3) The coupled product that was formed could not be deprotected to compound 100, 
with the various reactions attempted showing only decomposition.  
At this point, further exploration of Suzuki couplings would have required the repeated 
synthesis of the iodo headgroup (82). In light of the number of serious hindering issues 
this was deemed a poor use of time and the route was abandoned. 
Lewis-acid mediated rearrangement 
 
Scheme 25- Geranyl rearrangement 
In addition to exploring the Suzuki coupling, there were ongoing investigations 
elsewhere in the Ward lab into the use of the Fries-type rearrangement360 to form the 
C-C bond between linker and headgroup. Of all the conditions screened, it was found 
that only florisil (MgO:XSiO2•H2O) effected the transformation and only in 20-30% yield 
(Scheme 25). 
The clay catalysed [1, 3] rearrangement of O-prenylated ethers was first discovered by 
Dauben in 1990.361 The reaction was developed to overcome difficulties faced with the 
Claisen rearrangement,362 which was also initially considered in this synthesis. The [3, 3] 
sigmatropic Claisen rearrangement demands the Sn2' addition of the prenyl equivalent, 
in this instance geranyl bromide (104), to arrive at the product with the desired 
connectivity following a Claisen rearrangement (Scheme 26). Selective formation of 
compound 105 was deemed unnecessarily challenging and therefore not explored. 
Interestingly, evolution has developed an enzyme that can selectively O-prenylate in the 
Sn2’ manner displayed in compound 105 and this then undergoes a [3, 3] Claisen 
rearrangement to afford the appropriately o-prenylated phenol.363 
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Scheme 26 - Improbable Sn2' addition of geranyl bromide required to allow Claisen rearrangement  
Subsequent publications around the clay catalysed [1, 3] shift have further explored the 
range of Lewis acids applicable and utilised the reaction for the synthesis of various 
natural products.360,364,365 The mechanism is thought to involve the destabilisation of the  
C-O etheric bond (107) with the formation of an allylic carbocation and oxyanionic 
phenol (108). This carbocation then is irreversibly incorporated into the aryl ring via 
electrophilic aromatic substitution (109). Dauben rationalised that there must be an 
intermolecular mechanism available in addition to the likely intramolecular reaction 
(Scheme 27) because of the observation of multiply prenylated products. This was later 
explicitly established via crossover experiments.364    
 
Scheme 27 – Proposed mechanism of [1, 3] shift 
This Lewis catalysed rearrangement from a phenol in a [1, 3] manner is very similar to 
work first published by Fries early in the 20th century.366,367 The Fries rearrangement 
entails the creation of o-phenol phenyl ketones from phenyl esters (Scheme 28) and was 
later reported by photochemical368 and anionic369 means. The Fries rearrangement itself 
was an extension of Friedel-Crafts370 chemistry developed in the late 19th century which 
similarly used a Lewis acid to create an acylium cationic reactive intermediate that is 
electrophilically substituted onto an aryl ring. 
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Scheme 28 – Freis rearrangement  
 
Although the yield obtained for linker installation was again poor, 20-30%, it remained 
the most viable route to the hydroxamic acid, compound 87 (Figure 30). Fries-type 
rearrangement was explored in attempt to synthesise the chloro and deschloro 
compounds 87 and 112 (Figure 30). Although the most efficient route to produce 87 and 
112 would require that chlorine was introduced at the final step, it was deemed 
necessary to install the chlorine first. This was in order to avoid complications arising 
from having the acid and electrophile sensitive geranyl chain present at this juncture.  
 
Figure 30 - Target compounds 
 
Para-phenol reactivity and protection  
It was hoped that the 4-geranyl ether (113) could rearrange to the desired product (114) 
as this is the more reactive of the phenols and alkylation preferentially occurs here 
(Scheme 29). This reactivity arises because the 2-OH is the less acidic alcohol due to the 
intramolecular hydrogen bond to the salicylaldehyde moiety. Interestingly, the H-bond 
holds the proton in plane with the aldehyde in a particularly de-shielded environment 
resulting in a characteristically high shift in proton NMR at ~12 ppm in comparison to 
unbound phenols at ~5.5 ppm (Figure 31).  
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Figure 31 - Characteristic downfield ortho-phenol signal 
The 4-O-geranyl compound 57 was available from other investigations within the group, 
and its reactivity was assessed. Unfortunately, even under forcing temperatures no 
rearrangement was observed (Scheme 29). This was not entirely unexpected as previous 
attempts to deprotect the bis-protected phenol would often readily deprotect the 
salicylic phenolic ether but leave the para-phenolic ether untouched. 
 
Scheme 29 - Unsuccessful para-phenol rearrangement 
Rearrangement from the 2-OH had been previously shown in the Ward lab to afford the 
desired product. Presumably the lone-pair of the salicylaldehyde chelates the Lewis 
acidic Mg2+ ion of florisil (Figure 32) to destabilise the etheric O-C bond by polarising it. 
This is similar to the specific ortho directed deprotections of salicylaldehyde moiety with 
AlCl3 reported in literature371 and has been utilised previously in syntheses.371,372 
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Figure 32 - Potential bidentate activation of ortho-ether 
Only a small quantity of the bis phenol methyl ester, compound 88, was available. With 
hindsight it should have been assumed that reaction at this crowded and complex head 
group would be non-trivial and time should have been dedicated to synthesising more 
starting material to enable more extensive exploration. However, although the 
subsequent chlorination of this bis phenol gave low yields of the desired regioisomer, a 
sufficient quantity was produced to attempt the following synthetic steps on small scale 
and the decision was taken to proceed. 
The 4-OH was protected to force geranyl ether formation at the 2-OH position. It was 
decided that a simple acyl protecting group would be utilised (Scheme 30) as this could 
be installed easily and removal should be facile under a variety of conditions. Protection 
of the 4-OH of the des-chloro compound 88, proceeded with good selectivity and very 
good yield, whilst that of the chloro compound 81, was less selective and gave a lower 
yield. Both products were easily observed by 1H NMR spectroscopy with the 
disappearance of a 4-OH phenolic proton and appearance of a singlet CH3 signal. 
 
Scheme 30 - Acylation 
Although the 2-OH geranyl ether formation (Scheme 31) gave a mixture of side products, 
most notably the bis geranyl ether (122) and deacylated geranyl ethers (123 and 124), 
the desired products (118 and 119) were obtained in moderate to good yield. The 
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disappearance of the characteristic phenol signal at ~12 ppm and the appearance of the 
geranyl chain were very clear by 1H NMR spectroscopy.  
 
Scheme 31 - Geranyl ether formation 
The Fries-type rearrangement of the des-chloro compound (116) gave a complex 
mixture of products, which were identified using two-dimensional HMBC and HSQC 
NMR spectroscopy, resulting in a low isolated yield of 21% for the desired compound 
118 (Table 4). 
 
 
Table 4 - Compounds obtained following rearrangement of geranyl chain: R = geranyl chain 
Compound Yield 
 
Trace 
 
21% 
88 
 
 
20% 
 
22% 
 
34% 
 
The desired product (64) was characterised in 1H NMR spectroscopy by the 
reappearance of the salicylic phenol at 12 ppm, the continued presence of the geranyl 
signals and the indicative 1'-CH2 triplet that shifts from 4 ppm to 2 ppm as a result of the 
change in connectivity, from etheric to phenylic. Two-dimensional HMBC NMR 
spectroscopy was utilised to confirm that the correct regioisomer was obtained.  
 
Figure 33 - Compounds obtained from rearrangement of CCB analogue  
Predictably, the corresponding reaction with the penta-substituted chloro compound 
resulted in fewer side products. Three major products were obtained: compound 126, 
having undergone the desired rearrangement and subsequent deacetylation; 
compound 127, in which the protecting groups are swapped (Figure 33); and the bis 
phenolic compound 88.  
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Ester alteration 
Elsewhere in the group, test reactions of the simpler methyl benzoate (88), without any 
tail attached, had been successfully converted to the hydroxamic acid by heating in the 
presence of hydroxylamine. Unfortunately, this did not translate to the more complex 
methyl benzoate (114) which was completely unreactive to these conditions and in 
addition to this, deprotection attempts again proved non-trivial. 1H NMR spectroscopy 
and TLC evidence showed that the NaOH, LiOH and NaSMe deacylated the 4-OH of the 
compounds but no saponification of the benzoate ester was observed.  
If the reaction was heated, or even left at room temperature overnight (under inert 
atmosphere) the compound would degrade to result in a product with indecipherable 
collection of signals by 1H NMR spectroscopy, from which no clean material could be 
purified; use of trimethylsilyl iodide and boron tribromide gave similarly poor results. 
Use of acidic conditions was inappropriate due to the known risk of annulation to give 
compounds such as 128 and 129 (Scheme 32). As a result of this inability to deprotect 
and expose the carboxylic acid motif required to employ any of the myriad of activated 
amide formations and with material low, the route was abandoned. 
 
Scheme 32 - Potential undesired reactivity 
Unfortunately, the routes attempted were low yielding and encountered many 
difficulties however the research did highlight the salicyl ester as unsuitable to late 
modification. This suggested a need for an alternate synthesis, in which, the problematic 
ester/aldehyde functionality is ideally installed at the latest possible stage.   
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Several alternate alpha phenol C-C bond formations were reported in literature. In 
particular, reaction of phenol with NaH and geranyl bromide in toluene had shown 
significant C-C formation over C-O (Scheme 33). This method was trialed several times 
but even at forcing temperatures did not show any formation of the desired product.      
 
Scheme 33 - Failed alternative geranyl addition 
With CCB synthesised and available in the lab there was the possibility of functionalising 
this to the hydroxamic acid, avoiding a lengthy full synthesis. Mild sodium chlorite, 
Pinnick oxidations, were attempted but no carboxylic acid could be obtained.  
Trifluoromethylbenzisoxazole 
While this work does not follow chronologically from the palladium and Fries-type 
chemistry, it represents a brief unsuccessful exploration and so has been included here.  
The benzisoxazole motif of compound 130 was found to be active against TAO and will 
be discussed at length in subsequent chapters. The methyl compound 131 was under 
investigation elsewhere in the Ward group and the trifluoro methy compoundl 132 was 
a desired target (Figure 34). The iodo compound (130) had been shown to undergo Heck 
coupling to varying degrees and therefore we wished to synthesise the direct CF3 
analogue to enable accurate comparison of this point change.  
 
Figure 34 - Target benzisoxazole compounds 
The halogenation of the 5,6-benzisoxazole was considered a liability and therefore the 
preferred synthetic path required iodination prior to isoxazole formation (Scheme 34). 
Acylation was known to occur selectively at the 4 and 6 positions of orcinol (45) and 
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there was precedent in the literature for iodination specifically in the required 2 
position, giving compound 133.373 Unfortunately, despite several efforts, iodination gave 
a mix of the products that proved largely inseparable.  
 
Scheme 34 - Selective iodination unsuccessful 
By reversing the order of reactions the trifluoromethyl ketone could be installed easily 
in excellent yield (83%), however iodination of this ring (135) then proved challenging. 
As seen in previous chlorinations, no selectivity was obtained for the desired 3-C position 
between the two phenols and the ring was susceptible to dihalogenation. Purification 
of products was time consuming and challenging. It was hoped that formation of the 
oxime (137) would be trivial but instead it was quite particular. Typically, oxime 
formation will occur at room temperature, simply by mixing with hydroxylamine 
hydrochloride in methanol, but in this case this was unsuccessful. Higher conversion 
could be obtained by adding dry 3 Å molecular sieves and heating the reaction, but this 
resulted in deiodination. Several reaction conditions were trialed on small scale but with 
no improvement. At this point other avenues were available for exploration and this 
intractable route (Scheme 35) was discontinued in favour of more promising work.   
 
Scheme 35 - Partially completed synthetic route  
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Conclusion 
Unfortunately, the synthetic routes discussed in this chapter were largely unsuccessful. 
The chemistry employed was found to be poorly suited for compound diversification 
and synthesis of novel AF analogues. The palladium chemistry had limited scope with 
only one reaction affording a reasonable yield. With additional problems arising from 
isomerisation of the geranyl chain and difficulties in deprotecting the phenols, the route 
was abandoned. The penta-substituted compound 81 was however still believed to 
represent a valuable starting material.  
Further attempts were made to elaborate compound 81 by Fries-type rearrangement. 
In this approach the geranyl chain was successfully installed without isomerisation. 
However, multiple attempted reactions of the methyl ester (114), with an aim to 
introduce aldehyde alternatives, were unsuccessful and this route was also 
discontinued. 
Whilst these two routes had proven unsuccessful they succeeded in highlighting the 
essential need for a completely new approach to AF-like compounds. In addition, having 
employed the phenolic motif in the rearrangement it was established that this pre-
installed functionality could be exploited. This gave rise to the idea to use ortho-
lithiation to elaborate the headgroup, which paved the way to future success. 
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Chapter 3 - Directed Litiation 
As established, synthetic routes explored so far had not provided an adequate method 
for synthesis of ascofuranone (AF)-type compounds, and therefore others needed 
evaluating. The greatest success had been achieved by utilising the phenolic motif for 
Lewis acid catalysed rearrangement. It was hoped that this idea, in which the phenols 
are employed to direct subsequent reactions, could be exploited in a directed ortho-
lithiation approach to the target compounds. This method was first employed in attempt 
to synthesise an AF analogue lacking the ortho-phenol, compound 138, but was later 
developed to enable installation of the geranyl tail prior to installing functionality at the 
aldehyde position on compound 45 (Figure 35). 
 
Figure 35 - Key compounds in development of lithiation methods  
 
Acetal exploration and ortho-lithiations 
 
 
Figure 36 - Monophenolic target and previously synthesised analogue 
Initially compound 138 (Figure 36) was selected as a primary target. The activity of 
compound 138 could be compared to that of compound 139, previously synthesised in 
the Ward lab, to give some indication of the necessity of the 2-OH for TAO inhibition and 
it was also amenable to synthesis by this proposed synthetic route. The symmetry 
afforded by having the para-phenol benzaldehyde (140) would both benefit the 
lithiation and substitution reactions and selectively direct subsequent chlorination at 
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the desired 3-position by the combined effects of the ortho-para directing phenol and 
the meta directing aldehyde. The intended route (Scheme 36) would also indicate how 
accessible and stable the acetal might be in any future syntheses.  
  
Scheme 36 - Intended synthetic route employing acetal protection and ortho-lithiation 
 
Directing Metal Group chemistry 
 
 
Scheme 37 – General directed ortho metalation 
The key synthetic method in this and subsequent routes in this chapter is directed ortho 
metallation (DoM). This method consists primarily of the application of alkyllithium 
bases to aromatic rings containing a base-stable heteroatomic functionality (147) 
capable of chelating the powerful lithium base and regioselectively deprotonating the 
ortho position. The stabilised aryl lithiate formed can then be reacted with a wide range 
of electrophiles. This chemistry was independently discovered around 1940 by both 
Gilman and Bebb374 and Wittig and Fuhrman375 when anisole was selectively ortho 
deprotonated by n-BuLi. Thorough subsequent development Hauser376,377 and others378 
advanced the scope of the field and this was further accelerated by the commercial 
availability of alkyllithiums arising from their necessity in industrial scale anionic 
polymerization.379 DoM research has expanded vastly since this time thanks to the work 
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countless chemists, with Victor Snieckus preeminent among them, to be a key strategy 
in aromatic functionalisation alongside chemistry such as: cross-coupling; electrophilic 
aromatic substitution; benzyne utilisation; sigmatropic cyclisations; and radical 
reactions.  
 
Scheme 38 – General directed ortho lithiation reaction mechanism 
Mechanistically the reaction is simple (Scheme 38): coordination of the alkyllithium 
aggregate to the heteroatom-containing DMG (147); deprotonation to give the 
coordinated ortho-lithiated species (148); and reaction with electrophile to yield 
product (146). This was established early: thermochemically with the observation that 
quenching (p-anisyl)lithium is 3.6 kcal/mol more exothermic than that of (o-
anisyl)lithium;380 rate enhancement of anisole deprotonation compared to benzene; 
pKa measurement;381 steric effects;382–384 and computational studies.385,386  
The bases used most widely are n-BuLi and s-BuLi both of which exist as aggregates that 
vary greatly depending on the coordination of the chosen solvent. For instance, n-BuLi 
is mainly hexameric in hydrocarbon solvents,387 tetrameric in diethyl ether,388 and a 
tetramer−dimer mixture in THF.389 This propensity to agglomerate reduces the bases 
reactivity through steric cumbrance and enhanced stability relative to disaggregate 
lithiates. This reduced activity has led to the inclusion of cosolvents with lone-pairs 
capable of coordinating the lithium atom. Such electron donation disassembles the 
aggregates to expose the solvated dimeric base and destabilises the C-Li bond, 
increasing its pKa. Examples of such bases are numerous however those routinely used 
include bidentate tetramethylethylenediamine (TMEDA), N,N’-dimethylpropyleneurea 
(DMPU) and the tridentate hexamethylphosphoric triamide (HMPA) and 
hexamethylphosphorous triamide (HMPT) which are significantly more coordinating 
Lewis bases although pose a much greater risk of toxicity and carcinogenicity.390 
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Temperature is also an important consideration in DoM reactions and they are usually 
cooled to –78 °C to minimise side reactions arising from the use of such powerful bases.    
 
Figure 37 – Potential DMGs257 
A wide array of DMGs are available to chemists and these have been ranked based on 
their relative ability to stabilise the ortho lithiate [OCONEt2 > SO2tBu > CONEt2 > OMOM 
~ NtBOC > OMe > Cl]391 (Figure 37). This stabilisation is a composite effect arising from 
factors such as: heteroatom lone-pair donation, sterics and inductive charge 
stabilisation.257 These DMGs have allowed a myriad of synthetic transformations and 
methodologies: electrophile installation and subsequent functional-group 
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interconversion affording various moieties – alkyl,392 allyl,393 formyl,394 silyl,395 
B(OMe)3,396 SnR3,397 OH,398 NH2,399 NHR,400 NR2,400 CO2H,401 CONHR,401 CONR2,397 CN,400 
PR2,257 SH,402 SR,394  Se,402 Br,397 and I;401 heterocycle  functionalisation;403,404 benzyne 
generation;257 2,6 dianion equivalents;405 stabilised o-tolyl anions;406 synthesis of 
heterocycles, including but not limited to, isocumarins,407 3-substituted 3,4-dihydro-1-
(2H)-isoquinolones,408 phthalides,409 isobenzofurans,410 isoquinolones,411 quinolones,412 
and acridones.400 These reactions represent the established chemistry of DoM however 
more current efforts have been to focus on novel DMGs such as O-sulfamates413 and in 
particular DMGs that are amenable to a metal catalysed orthogonal coupling strategy. 
This means to varied arene polysubstitution is exemplified particularly by DMGs capable 
of undergoing subsequent Kumada−Corriu cross-couplings,413 Suzuki cross-couplings,414 
feasible in one-pot,415 and ruthenium catalysed C-O activation/coupling.416  
Whilst the literature reviewed here was not exhaustive, interestingly absent were 
examples of direct transmetallation of an ortho lithiate to palladium in a catalytic cycle 
especially in the light of Feringa’s 2013 high-impact reporting of Li-Pd transmetallation 
in catalytic biaryl cross-coupling in Nature Chemistry.417  
The use of DMGs for DoM in this work was for the relatively facile addition of 
electrophiles, in particular the ascofuranone tail group, and the selection of DMG is 
discussed below as appropriate to the synthetic sequence. 
Acetal formation 
At first it was hoped that ethylene glycol could be used in the synthesis of the cyclic 
acetal, compound 141 (Scheme 39), given that the formation of the five-membered ring 
should be both kinetically favoured and stable. It was necessary that this reaction be 
conducted prior to MOM protection, as these protecting groups are potentially labile 
under the acidic conditions required for acetal formation. Reactions were found to be 
slow, and required multiple equivalents, molecular sieves and heat but the 1H NMR 
spectrum of the reaction mixture showed > 95% conversion overnight, characterised by 
the disappearance of the aldehyde signal (~12 ppm) and appearance of benzyl acetal 
proton signal (~5 ppm). Inconveniently the product (141) had an almost identical Rf to 
the starting material (140) and therefore proved very difficult to purify by column 
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chromatography, and furthermore, 1H NMR spectroscopy showed 20-30% of the acetal 
reverted to aldehyde after silica column chromatography. 
 
Scheme 39 - Attempted five-membered acetal formation 
With an aim to alleviate some of the issues faced in using ethylene glycol, the decision 
was taken to instead use 2,2-dimethyl-1,3-propanediol. This diol reacts to form a stable 
six membered acetal418 with restricted rotational freedom resulting from the Thorpe-
Ingold effect. It was intended that this should afford faster reaction times, increased 
stability in silica column purification and most importantly a substantially different Rf, 
which would simplify purification.  
The six-membered cyclic acetal was formed, as expected, using the same conditions as 
previously (Scheme 40). The increased divergence in Rf served to improve separation 
but did not fully alleviate the problem and as a result compound 149 was carried through 
to compound 150 with impurities present. As such compound 149 was not fully 
characterised.  
 
Scheme 40  - Improved acetal formation 
 
Directing Metal Group selection 
The proposed ortho-lithiation required prior installation of a suitable phenolic DMG. The 
previous literature precedents included -OMe, -OSEM, -OMOM and -OCON(Et)2. The 
OMe and OSEM ethers were discounted, having previously proven difficult to deprotect 
on similar compounds. Of the remaining two options the OMOM ether was selected as 
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there were many reported examples of successful protection and, more notably in this 
work, deprotection with similar compounds with the ortho geranyl motif.419 Of 
particular interest were examples of specific mild deprotections with P2I4256 and 
NaHSO4·SiO2.419 In this work it was found that the para-OMOM benzaldehyde, 
compound 150, could be successfully deprotected with NaHSO4·SiO2. The MOM ether 
therefore appeared to be a reasonable selection for DMG.  
Protection was expediently achieved using NaH and MOMCl (Scheme 41). 1H NMR 
spectroscopy of the crude product showed addition of MOM with minimal reforming of 
the aldehyde (< 5%) however some acetal was again lost during column 
chromatography, lowering the isolated yield.  
 
Scheme 41  - DMG installation 
 
Initial lithiations 
In a test reaction it was observed that compound 150 could be successfully lithiated 
(Scheme 42) and appeared by 1H NMR spectroscopy to afford the desired compound 
151 in good yield. The distinctive shift of the bromide methylene at 3.6 ppm to 3.1 ppm 
in the benzyl methylene became characteristic of successful linker installation in 
subsequent ortho-lithiation reactions. This compound was not fully characterised and 
the work set aside in favour of other research with the intention of it being completed 
at a later date, however, work was never resumed. If the route was continued, the MOM 
ether should first be deprotected using NaHSO4·SiO2 and then chlorinated with NCS to 
afford the desired compound 138. 
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Scheme 42 - Successful geranyl installation 
Although this route was discontinued, it successfully illustrated that the acetal 
compounds 150 and 151 could be obtained in decent yield and that ortho-lithiation is 
amenable to linker installation. Given the difficulties faced using the previous routes, 
this method for lithiation appeared far superior and represented a huge improvement 
in the search for a workable route to linker installation in AF-like compounds.   
Ortho-lithiation for synthesis and diversification of CCB  
Amid attempts to synthesise compound 151 using the ortho-lithiation route described 
another lithiation route to CCB and other AF analogues was proposed. In this route the 
linker would be installed first by ortho-lithiation, prior to the decoration of the aromatic 
ring (Scheme 43). 
 
Scheme 43 - Proposed synthetic route to fully decorated AF analogue using ortho-lithiation 
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Most exciting about this route was the potential to “walk” around the CCB headgroup 
via multiple lithiation steps to fully substitute the ring in one-pot. The first lithiation 
should occur selectively α to both DMG groups at the 2-C position, allowing installation 
of the linker and affording a symmetrical molecule (153), which relieves any potential 
selectivity problems in the following two additions.     
Although less efficient, an alternative step-wise construction of the head group could 
also be executed utilising lithiation to attach the linker and other reactions to install the 
aldehyde and chlorine.  
Literature examples suggested that the protecting group best suited to this chemistry 
would again be the OMOM, which reportedly selectively lithiates at the aryl position 
over benzylic positions.420  
 
Scheme 44 - Bis MOM protection for deprotection condition screen 
Deprotections have proven highly problematic throughout the TAO project. Therefore, 
even with many similar examples reported in which the bis OMOM geranyl motif was 
successfully removed, it was decided that deprotection should be tested. Compound 51, 
a similar hexa-substituted compound available in-house, was bis protected with MOM 
ethers to compound 156 (Scheme 44) and screened against common reported 
deprotection conditions (Table 5).418 The product was clearly characterised: in 1H NMR 
spectroscopy by the appearance of four singlets corresponding to the MOM ethers and 
by the disappearance of the phenol signals; and by the observation of an accurate mass 
for the molecular ion using HRMS. Happily, two of the deprotection methods were 
successful, and particularly pleasingly, the mild NaHSO4·SiO2 worked cleanly in less than 
10 minutes.   
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Table 5 - Attempted deprotection conditions 
Conditions Deprotected 
THF: 1N HCl  1:1 v/v X 
5 Eq TsOH·H2O, MeOH  
Xs NaI, cat. HCl, acetone X 
NaHSO4·SiO2(2 Eq by weight), DCM  
 
These findings indicated that it should be possible to successfully remove the MOM 
ethers at the end of the synthesis and therefore the proposed route was initiated with 
protection of the orcinol (45) phenols in excellent yield (Scheme 45). The symmetrical 
product (152) clearly showed the addition of two singlets corresponding to the ethers 
by 1H NMR spectroscopy and the correct molecular ion with accurate mass was 
observable by HRMS.    
 
Scheme 45 - Orcinol DMG installation  
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Lithiation methodology 
Initial lithiation attempts were unsuccessful and therefore less well-established, 
alternative methods had to be explored, firstly to confirm formation of the desired 
lithiate and secondly to give the desired product. The first two failed attempts followed 
a method outlined in the literature421 (Scheme 46). This procedure called for the 
application of n-BuLi to compound 152 at 0 °C followed by 90 minutes stirring at room 
temperature before the addition of the electrophile. This method appeared to not 
account for the decomposition of THF in the presence of organolithium reagents. When 
no product was formed, the reactions were repeated at -78 °C and -40 °C, which afforded 
an improved yield of ~50-60%. The reaction mixture became bright yellow upon addition 
of n-BuLi, potentially indicative of formation of the aryl lithiate. Although this colour 
change was also observed in the reaction at 0 °C, it was noted that the colour was 
gradually lost during the hour-long stir.  
It was determined, by eye, that the yellow colour was at its most intense at roughly 20 
minutes and it was found that by quenching the reaction with the desired electrophile 
after 20 min the linker could reproducibly be inserted in excellent yield, and with no 
formation of the undesired Sn2' product. Compound 153 could be clearly identified: by 
a marked shift in Rf; by observation of an exact mass of the molecular ion using HRMS; 
and 1H NMR spectroscopy clearly demonstrated the loss of the 2-CH singlet signal and 
the appearance of the geranyl chain signals. Retention of a single trans alkene 2'-CH 
triplet was also clear from this spectrum and when compared to that of the starting 
geranyl bromide.   
 
Scheme 46 - C-2 directed geranyl installation 
Following this success, consecutive lithiations were attempted to further functionalise 
the ring. Initially the second lithiation was attempted immediately following the addition 
of the geranyl linker in the same pot and by 1H NMR spectroscopy this appeared to have 
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gone to > 95% conversion (Scheme 47). Upon addition of n-BuLi, which was used in 
excess to quench any geranyl bromide still in solution, the reaction turned orange. When 
this was quenched with dry dimethyl formamide (DMF), the desired product (154) was 
obtained in 31% yield with the rest of the mixture comprising of the product of the first 
lithiation (153) and the starting material (152).  
  
Scheme 47 - Consecutive one-pot electrophile additions  
Several attempts were made to improve the yield of the second lithiation step (Table 6). 
1H NMR spectroscopy was used to monitor small-scale reactions to screen different 
solvents, temperatures and additives. Unfortunately, the yield could not be improved.  
 
Table 6 - Conditions attempted to improve formylation yields 
Number Conditions 
1        (i) THF, n-BuLi, -78 ˚C        
    (ii) THF, n-BuLi, 0 ˚C 
2          (i) Et2O, n-BuLi, at -78 ˚C         
 (ii) Et2O, n-BuLi, 0 ˚C 
3    (i) THF, TMEDA, n-BuLi -78 ˚C        
(ii) THF, TMEDA, n-BuLi, 0 ˚C 
4     (i) Et2O, TMEDA, n-BuLi, -78 ˚C      
(ii) Et2O, TMEDA, n-BuLi, 0 ˚C 
5 (i) THF, s-BuLi, -78 ˚C             
 (ii) THF, s-BuLi, 0 ˚C 
6      (i) THF, TMEDA, s-BuLi, -78 ˚C   
(ii)THF, TMEDA, s-BuLi, 0 ˚C 
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It is understood that poor solvation of lithiates can hinder reaction progress390 and so 
TMEDA was added as a co-solvent in an attempt to relieve this, but unfortunately this 
had no observable impact. More donating solvents such as HMPA and HMPT were not 
explored. Unfortunately, no explanation was established as to why the second lithiation 
does not appear to proceed to completion.  
It had been hoped that this second lithiation would allow sufficient scope to react with 
a range of electrophiles prior to deprotection. Disappointingly however, it did not seem 
that this was the case. A batch of the lithiate compound 153 was synthesised and this 
was then split into two and treated separately with CO2 and B(OMe)3 in an attempt to 
form the respective carboxylic and boronic acids. These reactions were unsuccessful 
over several repeats. The boronic acid would have been particularly valuable for use in 
palladium coupling reactions as the bromination of the ring elsewhere in the Ward lab 
had been challenging. In addition, the lithiate itself could potentially have been used to 
transmetallate to the palladium417 in a catalytic cycle, but this was never attempted.  
Although the yield was low, the second lithiation had progressed to some product and 
therefore the third consecutive lithiation was attempted. N-chlorosuccinamide (NCS) 
was utilised as an electrophilic source of chlorine. It was hoped that by using the DMF 
formyl equivalent, compound 157, the aldehyde would be protected as the lithium 
stabilised hemi-aminal (Scheme 48) increasing the likelihood of successful reaction. 
Regrettably however, these attempts to fully functionalise the ring were not successful.  
 
Scheme 48 - Consecutive one-pot chlorination of the formylation intermediate was unsuccessful  
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Functionalisation and Deprotection 
Although conducting the three functionalisations in one pot had proven unsuccessful, 
compound 154 was available and an attempt was made to chlorinate this using NCS. 
Unfortunately, this showed no reaction even at forcing temperatures (140 °C in THF) in 
a microwave. This was not entirely surprising as the aldehyde acts to deactivate the ring 
and the electron donating ability of the phenols is attenuated upon addition of the MOM 
groups. As a result, the aromatic ring exhibits significantly decreased reactivity towards 
electrophiles. 
 
Scheme 49 -Removal of MOM DMGs proved challangeing 
Chlorinations of compound 154 were not forthcoming but it was hoped that the 
deprotected compound 103 might yield better results so the deprotection conditions 
established previously were attempted. Using either reaction conditions the 
deprotection of the 2-OMOM was observed within five minutes at room temperature 
but the other 4-OMOM was unchanged after a day, and when heated or left for more 
time the mixture only turned red-black (Scheme 49). The deprotection of α-carbonyl 
OMOM ethers is documented422 and has been observed previously in the Ward Lab with 
a related SEM protecting group. Potentially the test deprotections had worked only due 
to the presence of two flanking halogens on the 4-phenol of compound 156 and 
therefore deprotection of compound 154 was not possible with the same methods. 
 
Scheme 50 - Inatallation of robust tail analogue 
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To circumvent the difficulties thought to be associated with the presence of the geranyl 
chain compound 158 was synthesised (Scheme 50). This could be used as a simpler 
example on which to test the bis MOM deprotection without the risk of the geranyl chain 
cyclising or interfering in the reaction. This decision to abandon the geranyl motif was 
also informed by the first publication of SAR212 around AF-like compounds. As previously 
outlined in the introduction, the work in this paper showed that extensive changes to 
the lipophilic chain had surprisingly little impact. It appeared that, regarding the tail, the 
changes in activity corresponded only to general changes in the lipophilic hydrophobic 
interactions and it was found that optimal interaction required a tail length of eight 
carbons. It was understandable that having more lipophilic interactions should increase 
the retention of the compound in the lipophilic TAO pocket and active site and afford an 
increase in potency. In contrast, compounds with chains longer than eight carbons may 
be suffering from increased indiscriminate protein binding and decreased solubility or 
the chain may protrude from the protein, thereby exposing it to the polar intra-
mitochondrial fluid.   
Using many conditions reportedly used with similar compounds with a bis MOM geranyl 
motifs, deprotections were again screened ( 
Table 7). Excitingly the neutral deprotection utilising ethylene glycol and heat 
deprotected the C8 chain compound, 158, without degradation and in excellent yield.  
 
Table 7 - Attempted MOM ether deprotection conditions  
Conditions Result 
THF: 1N HCl  1:1 v/v No reaction 
MeOH: 1N HCl  1:1 v/v No reaction 
5 Eq TsOH·H2O, MeOH No reaction 
Xs NaI, cat. HCl, acetone Removed the SM but no clear product 
NaHSO4·SiO2(2 Eq by weight), DCM No reaction 
Conc HCl:THF, 1:2 Slow reaction and no clear product 
Ethylene glycol, 160 °C 87% (conversion after two hours) 
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ZnBr2, n-BuSH Removed the SM but no clear product 
EtSH, THF No reaction 
5mol% AcCl, MeOH No reaction 
 
Compound 158 was also used as a tool to test other potential reactivity of the ring in the 
absence of the geranyl chain. Several reactions were attempted to further elaborate the 
MOM protected ring but none were successful (Scheme 51).  
 
Scheme 51 - MOM protected compound unreactive to elctrophiles 
The deprotection in ethylene glycol proved to be very fruitful initially but encountered 
reproducibility issues that proved insurmountable. Initially, the reaction yields were 
excellent to quantitative but unfortunately application of these methods to another 
batch of compound 158 synthesised only gave a maximum yield of 15%. Every effort was 
made to uncover the reason underpinning this issue and rectify it but no change made 
ever restored the initial success. The combined product obtained from the various 
reactions completed was taken forwards to investigate the subsequent reactions. The 
bisphenol compound (159) was formylated and chlorinated in excellent yields and gave 
a CCB analogue that proved very active against TAO Ki = 0.85 nM. Both compounds were 
fully characterised with the formylation observed by the appearance of salicylic signals 
in the 1H NMR spectrum and the chlorination by disappearance of the aromatic CH. 
Pleasingly, considering the best obtained yields of component reactions, the total yield 
of this CCB analogue from orcinol is 60% (Scheme 52). This constitutes a marked 
improvement over existing syntheses of other CCB and AF-like compounds.  
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Scheme 52 - Complete synthetic route to AF analogues 
 
Benzisoxazole 
While the ortho-lithiation reactions were under investigation, it was discovered that the 
benzisoxazole functionality represents an active alternative for the salicylic motif in 
ascofuranone. The benzisoxazole was first synthesised en route to compound 164, in 
which the nitrile replaces the aldehyde, and this chemistry was reconfirmed with the 
octyl chain analogue (Scheme 53). Oxime (162) formation was achieved 
straightforwardly in methanol, and once activated the nitrogen bound trans-hydroxyl is 
primed for intramolecular displacement by the ortho-phenol; this proceeds 
instantaneously at room temperature on treatment with triphenylphosphine (PPh3) and 
2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to the heterocyclic benzisoxazole 
(163). Following this the base catalysed ring opening of the isoxazole affords the open 
nitrile phenol isomer (164).  
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Scheme 53 - Synthesis of benzisoxazole and nitrile C8 analogues  
Benzisoxazoles like compound 163 represented a genuinely exciting development in the 
search for new TAO AF analogues. The 5,6-heterocycle is more drug-like, having 
removed many of the undesirable functionality of the head group. The benzaldehyde, 
which was a metabolism risk has been replaced, and the phenol which was a toxicity risk 
and might interfere with redox-cycling, has been masked. Importantly the compound 
retains high activity, with Ki = 25 nM, which is not significantly reduced compared to that 
of CCB and AF. Benzisoxazoles exist in drugs already on the market such as the 
antipsychotics Paliperidone and Risperidone. These compounds are generally 
metabolically stable with biological half-lives of approximately 20 hours, indicating that 
this heterocycle has good stability in the human body. It remained to be seen however 
whether such a highly substituted compound incorporating a para-phenol would behave 
in the same manner. 
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Table 8 - TAO inhibition of C8 AF analogues 
Structure Ki (nM) 
 
>1000 
 
92 
 
0.85 
 
130 
 
25 
 
5 
 
The above table (Table 8) summarises the measured activities of the compounds of 
interest from the ortho-lithiation mediated synthesis described above. The inhibition 
constants appear to be in agreement with the SAR findings which were published during 
the course of this work, in that it is essential that an electron withdrawing group is 
incorporated at the aldehyde position.  
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Benzisoxazole stability 
Whilst the benzisoxazole illustrates an exciting breakthrough in this project, there were 
remaining concerns regarding its stability. As it is an intermediate in the synthesis of the 
nitrile and the two exhibit similar activity, it was suggested that the benzisoxazole could 
simply be isomerising to form the nitrile, and that in reality it was this that was the active 
compound. This hypothesis was substantiated when it was noted that the 3-methyl 
benzisoxazole, compound 166, synthesised elsewhere in the Ward lab, had proven 
inactive, while the methyl ketone, compound 165, retained activity (Figure 38). While 
this might represent genuine SAR around the benzisoxazole target, with the methyl 
disrupting a key orientation for the molecule, given that the active nitrile is an available 
isomer of compound 163 it was necessary that the stability was verified.   
 
Figure 38 - Additional methyl containing AF analogues 
An additional concern was the use of DDQ in the preceding synthetic sequence, which if 
present in residual quantities in the samples for biological testing, at levels below 
detection by NMR or LCMS, could potentially result in false positives through redox 
cycling. The C8 benzisoxazole was dissolved in D6-DMSO and numerous 1H NMR spectra 
were taken over the course of two weeks in attempt to monitor any degradation or 
isomerisation. No change was observed. Samples of the benzisoxazole were also 
dissolved in DMSO and separately in a solution of the buffers used in the biological assay, 
and these were followed over two weeks by LCMS. Again there was no detectable 
degradation to the nitrile, which gave us confidence that the benzisoxazole was stable 
under the conditions of the assay, particularly, since synthetically, the nitrile formation 
requires a few hours at room temperature in methanol and in the presence of excess 
NaOMe.  
113 
 
 
Alternative 5, 6-heterocycles 
The benzisoxazole represented a very interesting new scaffold. In addition, the discovery 
that the geranyl could be swapped for the simpler octyl chain without loss of activity 
broadened the spectrum of applicable chemistry. With concerns over the stability of the 
5,6 heterocycles still prevalent it was decided that analogues should be synthesised for 
testing. It was hoped that the indazole could be synthesised from the salicylic motif. This 
was of particular interest as it would afford the same arrangement of heteroatoms as 
the benzisoxazole, although a H-bond donor would replace a H-bond acceptor, but it 
would have no potential to ring open. There are reported examples of direct conversion 
of simple salicylaldehyde structures. The majority of these involve use of Lewis acids to 
activate the phenol, presumably such that it is displaced by the hydrazone formed at the 
benzaldehyde (Scheme 54).  
 
Scheme 54 - Proposed mechanism for indazole formation 
The remaining reactions utilise forcing temperatures and polar solvents with excess 
hydrazine. Unfortunately, none of the desired product, compound 169, was obtained 
using any of the reported conditions. It is plausible that the multitude of electron 
donating functionalities on the fully hexa-substituted ring may make it less amenable to 
attack by the hydrazone. 
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Figure 39 - Dihydrazone dimer 
One potential explanation could be the formation of compound 170 (Figure 39). This 
might compete with formation of the indazole, but it was hoped that, because imine 
formation is reversible, excess hydrazine, heat, time and the presence of water would 
allow the thermodynamic formation of the indazole product. If it was present, its mass 
was not clear via LCMS and there was little shift in the NMR spectrum from the starting 
material but equally there were no observable NH signals. Methyl hydrazine was used 
in place of hydrazine in case this dimer was the cause of the problem as it would be 
unable to form such dimeric compounds. Regrettably, this didn't afford any methyl 
indazole either and it remains unclear why these indazole formations were 
unproductive. At this point there was little remaining material and as a result of the 
problems with both the MOM ether deprotections and indazole formations, another 
route to these compounds was required. 
Conclusion 
The ortho-lithiation approach facilitated the first successful synthesis of biologically 
active compounds achieved in this work, and represents a novel chemical route to AF-
like compounds. In developing this chemistry novel headgroups were discovered, which 
should exhibit improved drug-like properties while hopefully retaining activity. It was 
found that the reactive geranyl chain could be replaced with the simplified octyl whilst 
retaining excellent biological activity. His greatly expanded the range of chemistry 
applicable. The benzisoxazole is a more drug-like headgroup than that of known AF 
analogues, having removed or masked both the benzaldehyde and phenol, which posed 
key metabolic and toxicity risks. To examine the available chemical space it was 
necessary that other bicycle heterocyclic headgroups were synthesised. It was hoped 
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that the indazole, which was of particular interest, could be accessed using this 
chemistry, but unfortunately efforts were unsuccessful.  
At this stage the ortho-lithiation approach was of limited use in obtaining further 
desirable compounds, especially given the reproducibility problems faced with the 
ethylene glycol deprotection. In addition, only a limited number of 5, 6 heterocycles 
were accessible from the bisphenol aromatic motif. A new method was required which 
would enable access of a variety of bicyclic heterocycles and installation of a new 
functionalisable tail. 
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Chapter 4 - Benzisoxazole and Indazole synthesis 
As a result of the irreproducibility problems faced with the ortho-lithiation chemistry 
and the lack of success in attempts to diversify any compounds that were obtained, it 
became imperative that an alternate synthetic route was developed. It was believed that 
use of an aliphatic starting material, compound 48, as opposed to the aromatic 
compounds previously utilized, would enable synthesis of a greater number of novel 
heterocyclic headgroups.  
New synthetic method 
The benzisoxazole synthesised with the simple octane chain, compound 163, showed 
excellent activity against TAO but frustratingly the ortho-lithiation approach utilised had 
become unreliable. In addition, attempts to further elaborate the compounds obtained 
were unsuccessful and the indazole could not be achieved via this route. A new synthetic 
method was required to enable access to the benzisoxazole and indazole and ideally a 
range of additional, correctly decorated heterocycles. Displacement of the salicyl ortho-
phenol had proven unsuccessful but it was noted that the connectivity was identical to 
1,3-diketones, which are prevalent in heterocycle formation. This suggested the 
potential to integrate a late stage aromatisation in any newly proposed synthetic route.  
 
Scheme 55 - Late stage aromatisation reported in AF total synthesis 
This is not an entirely novel concept. In one reported total synthesis of AF254 a 
chlorination and aromatization had been combined in the final step (Scheme 55), 
although this had been very low yielding. In this work a formylation and aromatization 
of compound 48 would instead be employed.  
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Scheme 56 - Retrosynthetic analysis 
With this late stage aromatization in mind, retrosynthetic disconnections suggested 
synthesis via the 1,3-dicarbonyl (48) and early installation of the tail (Scheme 56). An 
appropriate synthetic route was devised from compound 48 as it benefits from being 
commercially available and is relatively cheap. Disappointingly, very little chemistry was 
reported around this compound, although the simpler 1,3-dicyclohexanone was better 
understood. It was sincerely hoped that this lack of published research was coincidental 
and not due to any inherent challenges with reactivity and stability. While in the above 
retrosynthesis the tail is added early in the synthetic route, ideally in order to achieve a 
range of different tails, diversification should be at late stage. The proposed route 
(Scheme 57) suggested protection of the diketone (48) as the enol (176) to confer 
regioselectivity and direct deprotonation at the C-6 position over the otherwise acidic 
C-2 methylene. This would be followed by lithiation, quench with a formyl equivalent, 
then cyclisation and deprotection to afford compounds 180 and 181. The capacity of 
these compounds for both aromatisation and tail addition would then be examined. 
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Scheme 57 - Proposed route to validate and explore headgroup formation from aliphatic precursors 
 
Route Validation  
Initially an attempt was made to doubly deprotonate the unprotected diketone (48) 
using lithium bases. It was anticipated that only the least stable position on the di-
lithiate (186) would attack dimethyl formaldehyde (DMF) and thereby enable selective 
functionalisation without the requirement for protecting groups. These reactions 
(Scheme 58) were repeated several times with lithium diisopropylamide (LDA) in the 
presence of TMEDA but none of the desired product (187) was successfully obtained. 
 
Scheme 58 - Dilithiation failed to yield the desired formylated product. 
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It appeared therefore that it would be necessary to protect compound 48. It was decided 
that a methyl protecting group would be most appropriate as this would be resistant to 
lithiation conditions but also easy to remove prior to aromatisation using a simple 
aqueous acidic solution. 
Initially there were concerns that use of electrophilic methylating reagents such as 
iodomethane might result in selectivity problems in which both the carbonyl and C-2 
position were alkylated. Therefore, milder conditions using acid and dry methanol were 
trialed, but these reactions did not approach completion by TLC or 1H NMR 
spectroscopic evidence. Striving to obtain a more complete conversion several bases 
and procedures were screened and it was found that addition of sodium hydride to a 
stirred solution of compound 48 and dimethylsulfate afforded the product in excellent 
yield (Scheme 59). The product (176) is clearly characterized: with the observation of 
the molecular ion with accurate mass by HRMS; the shift in Rf which correlates with the 
decreased polarity of the product; and in 1H NMR spectroscopy by the appearance of 
singlet with integration of three protons correlating to the methyl ether, the presence 
of the 2-CH vinyl signal and the disappearance of the 2-CH2 signal for the bis-ketone 
tautomer. 
 
Scheme 59 - Methyl enol ether formation 
Lithiation was undertaken with the non-nucleophilic base lithium diisopropylamide 
(LDA) and DMF was used in attempt to introduce the formyl functionality. Although this 
was repeated several times, with different sources of dry DMF, no product was 
successfully obtained. To ensure that the lithiate was being formed, an aliquot was taken 
from the lithiation reaction and quenched in deuterium oxide. A 1H NMR spectrum of 
the product showed a ~50% reduction in the intensity of the C-2 methylene signal 
relative to that of other protons, indicating that the desired lithiate was being 
successfully formed in > 90% yield. It remains unclear why this reaction with DMF failed, 
but fortunately reaction with the methyl formate was found to afford the desired 
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product in > 50% yield. The observation of gentle bubbling upon addition of the formate 
was attributed to decomposition to carbon monoxide and methanol in the presence of 
the lithiate base, which may account for the moderate yields. 
Eventually it was found that application of sodium methoxide to a solution of compound 
176 in dry methyl formate gave the product more easily and in improved yields (Scheme 
60). The product was clearly characterised: with the observation of the molecular ion 
with accurate mass by HRMS; the resulting shift from the Rf of the starting material; and 
in 1H NMR spectroscopy by the appearance of a signal at ~7 ppm, assumed to 
correspond to the vinylic 6-CH proton. By 1H NMR spectroscopy it appeared that the 
compound exists primarily (>90%) as the isomer 177 (Scheme 60). This can be justified 
by the improved stability afforded by the increased potential for H-bond interactions 
and extended conjugation compared to the isomer with the non-conjugated aldehyde. 
The 1H NMR spectrum of this compound also exhibited a broad vinylic signal and a small 
signal at > 8 ppm, likely arising from the aldehyde tautomer, which suggests that the 
tautomers are able to interconvert.  
 
Scheme 60 - Simplified formylation conditions 
It was hoped that this success would extend to enable addition of a range of different 
electrophiles and allow access to other heterocycles, but these reactions were 
unsuccessful. This was particularly regrettable as it was the potential for exploration that 
made this synthetic route so attractive initially. The addition of 2-bromo-1,1-
diethoxyethane was of particular interest because the resulting methylene aldehyde 
compound (188) would have allowed access to rings with a single heteroatom, 
compounds 189-191, which represent unexplored chemical space in TAO inhibitors 
(Scheme 61). It was hoped that in the event that addition of the 2-bromo-1,1-
diethoxyethane was unsuccessful, addition of the alpha halo ester would provide an 
alternate route to the desired compounds after reduction and re-oxidation. In addition, 
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this route should have afforded other distinct heterocyclic derivatives, such as 
compound 194 (Scheme 61).  
Unfortunately, although many reaction conditions were trialed for both electrophiles, 
none of the desired products were successfully obtained. With the prior success in 
addition of the formyl and with limited time available, further development from 
compound 123 was made a priority and the addition of novel electrophiles was 
discontinued. 
 
Scheme 61 - Proposed route to diverse heterocyclic headgroups 
Thankfully, the cyclisation to afford the pyrazole and isoxazole, which was crucial in the 
synthetic route, proved relatively facile. Stirring of compound 177 with hydrazine 
hydrochloride in methanol at room temperature afforded the pyrazole (178) in excellent 
yield within minutes. The isoxazole could not be obtained under the same conditions. 
Different bases and solvents were screened and it was found that stirring compound 
177 in pyridine at 60 °C afforded the isoxazole in one hour (Scheme 62). The correct 
molecular ions of the products were observed by mass spectrometry and in the 1H NMR 
spectrum of each heterocycle there was an indicative shift downfield for the signal 
corresponding to the vinyl/aldehyde. 
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It was plausible that the reactions had yielded the 1-N isoxazole isomer rather that the 
desired 1-O isomer, compound 179, and none of the analytical methods employed were 
capable of distinguishing these. However, there is a strong rationale for selective 
formation of the 1-O isomer (179). Firstly, if a combination of both isomers were present 
this should result in two separate 3-CH signals in the 1H NMR spectrum of the product, 
with this 3-CH proton being adjacent to two different heteroatoms. In this case however, 
only one signal was observed. It is expected that imine formation will occur selectively 
at the aldehyde/enol position, which has lower electron density and is better exposed, 
thereby affording the 1-O isomer. Production of the 1-N isomer would require imine 
formation at the α, β-unsaturated ketone, which has higher electron density due to 
conjugation with the methoxy ether and is more sterically hindered.    
 
Scheme 62 - Straightforward heterocycle formation 
Deprotection of the methyl ether enol proved to be trivial with the product obtained in 
good yield on first attempt. The starting material was stirred in THF: water with 1 M HCl 
added to afford the product (Scheme 63), and work up comprised a simple extraction, 
although frustratingly the products obtained were thick, sap-like gums, which were 
challenging to handle. For both compounds 180 and 181 correct molecular ions were 
observed by mass spectrometry and the 1H NMR spectrum of each demonstrated the 
disappearance of both the methyl ether singlet and vinyl singlet signals as well as the 
appearance of the 7-CH2 geminal signals. 
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Scheme 63 - Trivial methyl enol ether deprotection 
Gratifyingly, following the success of both the cyclisation and deprotection, test 
reactions suggested that the aromatisation would be equally forthcoming. LCMS results 
indicated successful product formation by overnight reaction either with palladium on 
carbon (Pd/C) in toluene at 90 ºC, or with chloranil at room temperature. It was hoped 
that these conditions would prove equally successful in attempts to synthesise 
biologically relevant target compounds.  
Overall this route had so far proven very successful in accessing the intended scaffolds 
with correct decoration and focus turned to the challenge of attaching the tail to 
compounds 180 and 181. Unfortunately, repeated attempts to install a variety of 
different tails all proved unsuccessful. Reactions with bromooctane and allyl bromide 
and 1,4-addition of acrylate esters all failed under a variety of conditions. Fortunately, 
at this point another student tasked with developing the chemistry to attach the octyl 
chain had a breakthrough. It was found that a one pot l-proline catalyzed Knoevenagel 
condensation of octanal followed by sodium cyanoborohydride reduction afforded the 
desired product in nearly quantitative yields.  
These reaction conditions were applied to both of the heterocyclic starting materials, 
180 and 181, and by examination of reaction mixtures using LCMS it appeared that the 
desired products, 195 and 196, had been achieved. Unfortunately however, the 
compounds proved difficult to isolate and samples with the correct retention time and 
molecular ion by LCMS proved to be impure by 1H NMR spectroscopy, even following 
further purification. At first, the Knoevenagel and reduction steps were attempted in 
one pot. With the mass of the indazole product was observed by LCMS but repeated 
attempts at isolation did not yield the desired product. The isoxazole behaved differently 
and by LCMS appeared to have been reduced twice, resulting in addition of 4 Da. A 
stepwise approach was also unsuccessful (Scheme 64).    
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Scheme 64 - Late stage Knovenagel condensation failed to arrive at target compounds 
It was clear that compounds 195 and 196 were identifiable by LCMS. Therefore, despite 
the futility of attempted reduction it was hoped that they could still be utilised in 
synthesis of the benzisoxazole and indazole, but, this was not achieved. Compounds 195 
and 196 already represented a 10 π electron system, which was similar to the 5,6-
heterocyclic targets, but containing an undesirable exocyclic olefin. It was hoped that 
this molecule would be amenable to rearrangement to the target compound. Direct 
intramolecular 1,4-hydride shift was impossible, with the planarity of the molecule 
prohibiting the required orbital overlap of the exocyclic olefin and the hydrogen on the 
4-position. Instead it was hoped that either introduction of an acid or a metal might 
encourage aromatisation. The exocyclic compounds 195 and 196 were heated in the 
presence of acid and palladium on carbon, both separately and in combination.  
Different solvents were screened, but all attempts returned the starting compound, 
which in fact proved highly stable in the presence of heat, acid and/or palladium. 
Unfortunately, at this point material was running low and with a lack of positive results 
in this endeavour the focus was diverted to the less preferred method of primary 
installation of the tail via the established Knoevenagel-reduction chemistry.  
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Synthesis of Octyl analogues 
 
Scheme 65 - Proposed route to indazole and benzisoxazole targets requiring initial installation of the octyl chain 
It was intended that following primary installation of the octyl chain the established 
chemistry would be repeated to resynthesise the benzisoxazole and afford the indazole 
for the first time (Scheme 65). The Knoevenagel condensation and reduction step 
proceeded repeatedly to excellent yields (> 90%) (Scheme 66). The product (201) was 
easily characterised: by the observation of the molecular ion with accurate mass using 
HRMS; the product provoked a distinct change in retention time via LCMS and Rf via TLC; 
and 1H NMR spectrometry clearly exhibits the incorporation of the signals derived from 
the octyl chain alongside those of the starting material. Unfortunately, due to the 
complex mixture of isomers present, the 1H and 13C NMR spectra were not fully assigned, 
but successful onward reaction to the methyl enol ether (202), which was fully 
characterised, confirmed the identity of compound 201. 
 
Scheme 66 - One-pot Knoevenagel condensation and reduction  
Unfortunately, compound 201 proved unstable and quickly decomposed even when 
stored under nitrogen at -20 °C. As such, it was required that as material was generated 
it was immediately used and fortuitously the resulting methyl protected product (202) 
was very stable. The methylated compound 202 was achieved easily and in excellent 
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yield via the established reaction with dimethyl sulfate and the following lithium 
mediated formylation gave compound 203 in moderate yield (Scheme 67). This lithiation 
appeared more temperamental than those previously undertaken, on some occasions 
yielding very little product. This was disappointing but not entirely surprising, given that 
lithiations are often found to be sensitive and inconsistent, but extra care was taken in 
attempt to ensure the qualities of reagents and technique.  Both compounds 202 and 
203 were characterised fully: by the observation of the accurate mass of the molecular 
ion using HRMS; change in retention time via LCMS and Rf via TLC; and by 1H NMR 
spectroscopy where compound 202 was easily identified by the appearance of the 
methoxy singlet for 3H, and compound 203 by the appearance of a broad singlet signal 
at ~7 ppm corresponding to the vinylic proton and the loss of the C-6 methylene protons.  
 
Scheme 67 - Validated protection and formylation methods applied to C8 compounds 
While previously deprotection of the methyl ether had proved trivial, in this case the 
same conditions yielded none of the desired product. By LCMS it appeared that the 
starting material was diminished but with no clear formation of any product and nothing 
was obtained when the mixture was purified by column chromatography. Various 
solvents and acids were screened in hope of improving the outcome but this was 
without success. Further to this, attempts to deprotect the heterocyclic products (205 
and 206) formed in the subsequent cyclisation step were also unsuccessful. While this 
setback was disappointing there was a good chance that, even if the methyl could not 
ultimately be removed, these compounds would retain activity against TAO given that 
the para methoxy phenol of colletochlorin had been demonstrated to have high activity.  
Thankfully, heterocycle formation proceeded in good yield (Scheme 68), although this 
was lower than obtained in the absence of the tail. The molecular ion was observable 
for both compounds 205 and 206, there is a clear shift in retention time by LCMS, and 
1H NMR spectroscopy the vinylic signal is replaced by a distinct aromatic signal. 
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Treatment of 205 and 206 with Pd/C in toluene gave the aromatized compounds 207 
and 208 in excellent yields and were characterised fully: by the observation of the 
accurate mass molecular ion using HRMS; change in retention time via LCMS; and by 1H 
NMR spectroscopy which displayed obvious simplification with the disappearance of 
alkyl ring signals and the appearance of a clear aromatic CH singlet.  
 
Scheme 68 - Validated chemistry successfully afforded target heterocycles 
Although the methylated compounds 207 and 208 are excellent candidates to submit to 
the TAO assay, the free phenol would enable tighter exploration of SAR. Various 
methods were trialed for deprotection: organic and inorganic acids under forcing 
conditions; nucleophilic thiols; BBr3 and TMSI, but all failed to deprotect either 
compounds 207 or 208. At this point material was in low supply and the decision was 
made to focus on other more promising synthetic routes. The deprotection of the 
benzisoxazole was therefore not examined further. 
Disappointingly, at the time of writing this thesis, the compounds synthesised by using 
this chemistry, that are expected to be biologically significant, have not yet been tested 
for TAO activity due to a lack of available TAO protein and collaborators. The isolated 
TAO enzyme assay was previously conducted in-house but unfortunately after the 
original stock of protein was exhausted, unexpected difficulties were encountered in 
expression and purification of a new batch of enzyme, which although now overcome, 
could not produce data in time for this report.  Additionally, new collaborations were 
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being established during the final year of this work to access a wider spectrum of 
phenotypic, whole trypanosome assays, and unfortunately again, these data were not 
available in time to be included in this thesis. 
Diversifiable synthesis  
Having successfully synthesised the octyl compounds, there was a demand for 
compound diversification to enable exploration of the chemical space around the 
benzisoxazole tail. It was also intended that the indazole should be elaborated, although 
this was not yet confirmed active, on the assumption that it is biologically significant and 
because it can be synthesised via the same methodology.  
During this work it became abundantly clear that a single change at any position of the 
multi-substituted aromatic head group could idiosyncratically alter the reactivity of the 
ring. In light of this, it was preferred that the electronics of the tail be disconnected from 
those of the head group and therefore conjugate styrene-like connections were 
discounted. Many different diversifiable tail groups were considered for installation 
(Scheme 69): (1) olefins would allow coupling via metathesis; (2) aldehydes could react 
with partners by reductive amination; (3) esters could be diversified by amide coupling; 
(4) a leaving group such as a halide or activated alcohol could be directly displaced by 
nucleophiles. This list of tail connections is in no way exhaustive but would enable very 
substantial scope for diversification. Unfortunately, at this point in the PhD time was 
very limited, and therefore only one of these options could be further investigated. 
 
Scheme 69 - Selection of potential diversifiable tail groups 
Of the various options available it was decided that the ester represented the best 
opportunity for diversification: the existing olefin in AF was known to be metabolically 
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labile and removing it with a selective hydrogenation was potentially challenging; both 
the alcohol and aldehyde would require specific protection to facilitate the established 
lithiation chemistry, increasing the number of steps required; the ester on the other 
hand would likely be stable under the basic and nucleophilic conditions required for 
lithiation chemistry,  could be deprotected under mild conditions and could be 
diversified to a range of amides. If the synthesis proved facile and plenty of material 
could be produced, the ester also had the potential to be reduced to the aldehyde or 
the alcohol. In addition, synthetic methods to install the ester tail-linker had precedent 
in a successful test reaction between the diketone (48) and ethyl acrylate (Scheme 70), 
which was carried out earlier in this work. Although the compound had not been fully 
characterized, LCMS analysis of the reaction clearly showed product formation.     
 
Scheme 70 - Test reaction for acrylate addition 
The acrylate derived motif has several other desirable features in addition to enabling 
diversification: (1) it separates the head group and tail both electronically and sterically; 
(2) it introduces heteroatoms and increases the polarity, which is necessary in order to 
reduce the log P compared to that of colletochlorin B (CCB), > 6, and its octyl analogue 
compound 161 (Table 8); (3) with the tail already a minimum of four atoms long it is 
straightforward to extend it to achieve the empirically derived ideal length of eight 
atoms using a range of commercially available amines.  
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Scheme 71 - Proposed route to diversifiable compounds utilising established chemical methodology  
It was proposed that a synthesis nearly identical to that of the octyl (Scheme 65) was 
used (Scheme 71). The ethyl acrylate was exchanged for a tert butyl ester in the hope 
that this would impede any reaction between the lithium enolate and the ester, and it 
could then be easily deprotected using acid. 
 
Scheme 72 - Lactone formation a potential risk   
It was anticipated that this should alleviate complications resulting from formation of 
the intramolecular lactone (222) (Scheme 72). It was briefly considered that the lactone 
(223) (Figure 40) could be utilised as a more elegant means of protecting both the enol 
and ester throughout the synthesis. However, in the six-membered lactone (Figure 40) 
the lone-pairs of the oxygen are not correctly orientated to enable orbital overlap with 
the carbonyl π* anti-bonding orbital, and it was feared that the resulting reduction of 
electron density at the carbonyl would lower the pKa of the adjacent alpha hydrogens. 
It was thought that increasing the acidity of this alpha position could afford a competing 
site for deprotonation and lithiation as an alternative to the desired C-6 position. With 
131 
 
these concerns, and with limited time available, the use of the lactone was left 
unexplored. 
 
Figure 40 - Lactone functionality considered as a protection strategy  
The proposed synthesis (Scheme 71) was not ideal. There was valid criticism of the 
continued use of the methyl ether protecting group which had repeatedly proved 
difficult or impossible to remove. The decision to retain this methyl protection was 
based principally on advancing the synthesis and avoiding problems associated with the 
development of unexplored chemistry. As previously stated, it was also anticipated that 
the methyl phenol derivatives would have similar potency to the free phenols and 
therefore, whilst the preference was to be able to biologically characterise both the 
methyl ether and free phenol derivatives, valuable information could be gained from 
the ethers alone in the event of an unsuccessful deprotection. Alternative protections 
of the initial diketone compound 48 utilising TBDMSCl and TIPSCl were attempted with 
no success. This was most likely reagent result of poor quality of reagents and choice of 
reaction conditions but this was not examined further. 
Unfortunately, the synthesis outlined was plagued with repeated setbacks which would 
delay progress for weeks at a time. Small-scale test reactions to compounds 213 and 
214, prior to aromatization, were successful but not reproducible on larger scale. 
Installation of the t-Bu acrylate ester was developed and for a period of time proved 
high yielding. While it appeared that the reaction with ethyl acrylate (Scheme 70) 
proceeded successfully in THF, a quick solvent screen demonstrated that the reaction 
with the tert butyl equivalent was only effective in DMF. This reaction was amenable to 
scale up and a reaction using 20 g of the diketone (48) formed the product in excellent 
yield >90%. The ability to simply use diethyl ether to extract the product from the 
reaction mixture followed by a recrystallization expedited this reaction on scale. The 1H 
NMR spectrum of the product (210) has a very broad alkyl region but clearly shows the 
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t-Bu signal and the doublet ascribed to the methyl on the ring. Observation of an 
accurate molecular ion by HRMS also confirmed successful product formation. 
Unfortunately, due to the instability of compound 210, the product was not further 
characterised, but, successful onward reaction to the methyl enol ether (211) which was 
fully characterised confirmed the identity of 210. 
Due to downstream problems in the synthesis it was necessary to repeat this reaction 
many times and infuriatingly, upon purchase of a new batch of starting material, 
compound 48, the reaction became unreliable. Another batch was sourced but this too 
proved ineffectual. A solvent screen was conducted in attempt to circumvent the 
problem but with no success. The same diketone (48) was reordered from a variety of 
different suppliers and by screening these it was established that one example showed 
excellent conversion in dimethylacetamide (DMA). The whole process was time 
consuming and the solution unsatisfactory, especially considering that the cause 
remains unknown. LCMS and NMR spectroscopy could identify no fault in the starting 
materials. 
The following protection step with dimethyl sulfate and NaH proceeded reliably 
(Scheme 73) in good yield. The product (211) was characterised fully: the 1H NMR 
spectrum is simplified in comparison to that of the starting material, resulting from the 
lack of available tautomers and there is a distinct addition of a singlet at ~4 ppm 
corresponding to the methyl ether; there change in LCMS retention time and TLC Rf shift; 
and the accurate mass of the molecular ion is clearly observable using HRMS.  
 
Scheme 73 - Acrylate addition and methylation  
Lithiation by the established methyl formate method (Scheme 74) proved unreliable and 
difficult to reproduce. While the majority of reactions proceeded in good yield, around 
a third would fail to afford more than 10% of the desired product and the starting 
material could not be recovered even after careful column chromatography. 
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Accordingly, on a few occasions, large scale lithiations on over 15 g, gave very limited 
product necessitating synthesis of more starting material. The product obtained in 
successful reactions was characterised: in 1H NMR spectroscopy by the appearance of 
the vinylic CH at 7 ppm and the disappearance of the two alkyl ring signals; by the change 
in retention time in LCMS and Rf in TLC; and by the accurate mass of the molecular ion 
is clearly observable using HRMS.   
 
Scheme 74 - Unreliable formylation reaction 
Approximately 10 g of the pre-divergent compound 212 was synthesised in several 
batches, which was then used to produce the pyrazole and isoxazole. The majority was 
used to in attempt to synthesise the benzisoxazole, which has confirmed activity against 
TAO and the remainder to be converted to the indazole in the hope that this would 
retain activity and to enable exploration of SAR. As observed previously, both 
heterocycle formations (Scheme 75) proceeded to product but the pyrazole formed in 
higher yield than the isoxazole. Both compounds 213 and 214 were characterised in 
their 1H NMR spectra by a shift in the exo-vinylic proton signal to generate a new singlet 
further downfield and by observation of the correct molecular ion mass using LCMS. 
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Scheme 75 - Heterocycle formation successful in presence of tert butyl ester 
Around 5 g of the isoxazole (214) and 2 g of the pyrazole (213) were successfully 
synthesised but unfortunately, despite the apparent stability of the test samples, these 
larger samples decomposed when left for just two days to form unidentified products. 
Neither sample could be retrieved by column purification so disappointingly they had to 
be abandoned. As such the entire synthetic route had to be repeated.  
The pyrazole had been obtained in sufficient quantities from smaller test reactions, 
which had not decomposed, to facilitate attempted diversification to some of the amide 
final products and the isoxazole was successfully resynthesised. The pyrazole and 
isoxazole were successfully aromatized using DDQ in toluene at room temperature to 
afford the indazole (215) and benzisoxazole (216) in excellent yield. The deprotection of 
the tert butyl ester proved similarly facile using trifluoroacetic acid in dichloromethane 
to produce the free acids 217 and 218 in excellent yield (Scheme 76). The products of 
both steps were clearly identified using 1H NMR spectroscopy. The aromatised 
compounds 215 and 216 gave a clear 5-CH singlet and a singlet for the tolyl CH3 with the 
distinct absence of the alkyl ring protons, whereas the carboxylic acids (217 and 218) 
lacked the characteristic tert butyl signal present throughout the synthesis. Both 
carboxylic acid compounds could also be identified by a change in LCMS retention time 
and Rf and by observation of the accurate molecular ion mass using HRMS. 
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Scheme 76 - Aromatisation and deprotection proceeded in excellent yield  
Amide synthesis 
It was hoped that diversification of the tailgroup would enable tuning of the PSA and log 
P of the compound to improve the pharmacokinetic profile while retaining the activity 
afforded separately by the headgroup. This may be overly simplified considering the 
increase in potency which results simply from non-specific lipophilic tail-group 
interactions, as observed with the octyl compounds 160-164, but nonetheless the 
compounds (Table 9) will enable exploration of SAR and optimisation against both the 
TAO protein and the whole organism.  
Table 9 - Log P and PSA values for the preliminary range of amide coupled compounds423 
Amine Log P, PSA (Å2) 
of benzisoxazole amide 
 
Log P, PSA (Å2) 
of indazole amide 
 
 
0.84, 71 0.77, 74 
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0.96, 60 0.89, 64 
 
1.68, 51 1.60, 54 
 
2.37, 60 2.29, 63 
 
2.88, 51 2.98, 54 
 
3.71, 60 3.64,63 
 
5.06, 72 4.98, 75 
 
With a vast number of amines available for coupling to the carboxylic acid compounds 
217 and 218, criteria were applied to narrow the selection. Firstly, for expedience it was 
decided that the amines should be selected from the 111 available in-house, which we 
were confident represented an appropriate initial diversity set. Secondly, the most 
diverse of these amines should be selected whilst excluding undesirable and reactive 
functionalities. Finally, the coupled amide products should encompass a wide range of 
log P and PSA values to enable assessment of how these factors influence the inhibition 
of the TAO protein and whole parasite. With only a limited quantity of the free acids, 
217 and 218, available, only seven amines were selected for trial (Table 9).  
 
Scheme 77 - Coupling reagents screened for amide formation 
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In order to determine suitable reaction conditions the simple amine pyrrolidine was 
utilised in a screen of amide coupling reagents (Scheme 77): HBTU; HATU; DCC; T3P; 
EDAC; and oxalyl chloride. HBTU was found to give the best result and was therefore 
used in coupling all the amines selected. The amides formed in these initial reactions 
proved difficult to isolate via flash column chromatography so an alternate method of 
purification was necessary. The optimum process (Scheme 78) ultimately developed 
required that the reactions were executed in 1 mL of DMF and transferred directly to a 
mass directed auto-purification HPLC. In this way the coupled product was retrieved in 
much greater purity than other attempted methods.  
 
Scheme 78 - Coupling conditions employed in mini-library generation 
Positively, for the majority of the reactions coupling preceded successfully, however, 
unfortunately there was a rather complex array of different products obtained in many 
cases, summarised below (Table 10). Four of the couplings with the indazole and six with 
the isoxazole gave clean LCMS traces containing the accurate molecular ion masses. Of 
the compounds obtained, three indazoles and three isoxazoles, 231-236, were 
characterised by 1H NMR but the others could not be assigned. In addition to the major 
peaks, the indazoles exhibited a second smaller set of indazole signals that could not be 
removed by purifying. More disappointingly it was determined that in every example 
the isoxazole had reacted to form the ring opened ortho-phenol nitrile isomer.  
 
 
 
 
Table 10 - Results of preliminary amide couplings 
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Amine coupled Benzisoxazole reaction result 
 
Indazole reaction result 
 
 
 
Product Obtained 
Clear LCMS, HRMS 
Ambiguous 1H NMR 
 
Product Obtained 
Clear LCMS, HRMS 
Ambiguous 1H NMR 
 
 
Nitrile Product Obtained 
Clear LCMS, HRMS, 1H NMR 
 
Product Obtained 
Clear LCMS, HRMS,  
Uninterruptable 1H NMR 
 
 
Nitrile Product Obtained 
Clear LCMS, HRMS, 1H NMR 
 
Product Obtained 
Clear LCMS, HRMS, 1H 
NMR 
 
 
Nitrile Product Obtained 
Clear LCMS, HRMS, 1H NMR 
Product Obtained 
Clear LCMS, HRMS, 1H 
NMR 
 
 
Product Obtained 
Clear LCMS, HRMS 
Ambiguous 1H NMR 
Failed 
 
Failed Failed 
 
Product Obtained 
Clear LCMS, HRMS 
Ambiguous 1H 
Failed 
 
Those compounds successfully obtained, 231-236, were characterised by 1H NMR 
spectroscopy and confirmed by a combination of the appropriate amide signals and 
well-established heterocycle signals, and by HRMS where the exact mass of each 
molecular ion was observable, which confirmed the atomic composition of the products; 
they were not characterised further due to time restraints. Evidently this coupling 
reaction requires further optimisation but this was beyond the scope of this work. The 
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six compounds (Figure 41) synthesised represent the first exploration of this 5,6-
heterocycle for the inhibition of TAO and examination of their activity is eagerly 
anticipated. 
 
Figure 41 - Amides successfully observed and partially characterised 
 
Conclusion 
The limitations of the ortho-lithiation synthesis required the development of new 
synthetic methods to allow for both the synthesis of novel heterocyclic headgroups and 
the installation and diversification of a suitable tail. These goals were successfully 
achieved from the commercially available aliphatic diketone (48) as an alternative to the 
aromatic compounds (45 and 51) utilised previously. This choice greatly facilitated 
heterocycle formation, and by employing a late stage aromatisation an entirely novel 
range of drug-like AF analogues were synthesised.  
Initial validation of this new synthesis was promising and confirmed that late stage 
aromatisation represented a viable method for constructing the 4-methyl-6-phenol 
indazole and benzisoxazole motifs, although regrettably other heterocyclic cores proved 
inaccessible. Attention then turned to synthesis of the octyl chain AF analogues for the 
indazole (199) and benzisoxazole (200). The successful synthesis of these compounds 
further validated the synthetic method and gave the first indazole ascofuranone 
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analogue, compound 207. Finally, focus shifted to the synthesis of diversifiable 
analogues of the two heterocyclic cores, compounds 215 and 216. Despite a plethora of 
synthetic challenges, the two carboxylic acid compounds 217 and 218 were synthesised 
in sufficient yield to enable development of an amide coupling reaction, which afforded 
a set of six novel amide compounds.  
This work represents the preliminary exploration of this chemical space and although 
the products obtained were modest in number and potentially more complex than 
desired, they serve to validate this method for access to novel AF analogues. These 
methods permit synthesis of a variety of heterocycles, afford compounds with the 
required aromatic ornamentation and, in addition, facilitate installation of diverse tail 
groups. Another student has begun further investigation of this chemistry and 
elucidation of the SAR around these new analogues will add to this work and be 
published accordingly. 
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Chapter 5 - Experimental 
All reactions were conducted under an atmosphere of nitrogen unless otherwise stated. 
Anhydrous solvents were used as purchased or were purified under nitrogen as follows 
using activated molecular sieves. 
  
Thin layer chromatography was performed on glass plates pre-coated with Merck silica 
gel 60 F254. Visualisation was achieved with U.V. fluorescence (254 nm) or by staining 
with a phosphomolybdic acid dip or a potassium permanganate dip. Flash column 
chromatography was carried out using pre-packed columns filled with Aldrich silica gel 
(40-63 µm) on an ISCO Combiflash Rf, or a Biotage Isolera Prime. 
  
Proton nuclear magnetic resonance spectra were recorded at 500 MHz on a Varian 500 
spectrometer (at 30 °C), using residual isotopic solvent (CHCl3, δH = 7.27 ppm, DMSO 
δH = 2.50 ppm, 3.33 ppm (H2O), MeOH δH = 3.31 ppm, 4.87 ppm (H2O)) as an internal 
reference. Chemical shifts are quoted in parts per million (ppm). Coupling constants (J) 
are recorded in Hertz (Hz). 
  
Carbon nuclear magnetic resonance spectra were recorded at 125 MHz on a Varian 
500 spectrometer and are proton decoupled, using residual isotopic solvent (CHCl3, δC = 
77.00 ppm, DMSO δC = 39.52 ppm) as an internal reference. Carbon spectra assignments 
are supported by DEPT editing and chemical shifts (δC) are quoted in ppm. 
  
Infrared spectra were recorded on a Perkin Elmer FT-IR Spectrum One spectrometer as 
a neat sample. Absorption maxima are reported in wave numbers (cm-1). Only significant 
absorptions are presented in the data, with key stretches identified in brackets. 
  
LCMS data was recorded on a Waters 2695 HPLC using a Waters 2487 UV detector and 
a Thermo LCQ ESI-MS. Samples were eluted through a Phenomenex Lunar 3µ C18 50 
mm × 4.6 mm column, using acetonitrile and water (3 : 7 to 7 : 3) acidified by 0.01% 
formic acid 
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HPLC data and purification was performed on an Agilent 1100 series HPLC spectrometer, 
using a Phenominex Luna 10 µ C18 150 mm ×15 mm column, eluted using acetonitrile 
and water (3 : 7 to 7 : 3) 
  
High resolution mass spectrometry data (ESI) were recorded on Bruker Daltonics Apex 
III ESI-MS, with an Apollo ESI using a methanol spray. Only molecular ions, fractions from 
molecular ions and other major peaks are reported as mass/charge (m/z) ratios. 
 
Microwave reactions were performed using a Biotage Initiator 8+ microwave reactor in 
sealed reaction vials. Specific conditions for each reaction are reported separately.  
 
Melting points were taken on a Griffin melting point apparatus. 
 
Compounds were primarily bought from Sigma Aldrich however compound 24 was 
purchased from Acros Organic when the batch from Sigma Aldrich was found to not yield 
consistent results. 
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Methyl 3-chloro-4,6-dihydroxy-2-methylbenzoate260 (81) 
 
A dropping funnel was charged with sulfuryl chloride (0.82 mL, 10 mmol) in anhydrous 
diethyl ether (5 mL). This solution was added in a drop-wise manner to a solution of 
methyl 2,4-dihydroxy-6-methylbenzoate (1.87 g, 10.3 mmol) in diethyl ether (30 mL). 
The reaction was stirred for 1 hour at room temperature and then refluxed for 2 hours. 
Upon completion the reaction was allowed to cool to room temperature then water (15 
mL) added and stirred for 5 minutes. The diethyl ether was separated and the aqueous 
layer extracted with diethyl ether (2 x 15 mL). The organic fractions were combined, 
dried over magnesium sulfate, filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (25 g silica), eluting with a gradient of 40-
60 °C petrol ether: ethyl acetate (100:0) to (90:10), gave the title compound as a cream 
coloured solid (0.79 g, 36%): MS (EI) m/z (%): 216 (72), 218 (62), 220 (22) [M]+; Rf 0.35 
(10% ethyl acetate / 90% 40-60 °C petrol ether); 1H NMR (500 MHz, chloroform-d) δ 
11.40 (1 H, s, 6-OH), 6.53 (1 H, s, 5-CH), 6.16 (1 H, s, 4-OH), 3.95 (3 H, s, 1-CH3), 2.62 (3 
H, s, 6-CH3).  
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Methyl 3-chloro-4,6-dihydroxy-5-iodo-2-methylbenzoate (82)  
 
Benzyltrimethylammonium dichloroiodonate (2.66 g, 7.64 mmol) and potassium 
hydrogen carbonate (2.29 g, 20.8 mmol) were added to a stirred solution of methyl 3-
chloro-4,6-dihydroxy-2-methylbenzoate (1.50 g, 6.94 mmol), methanol (40 mL) and 
dichloromethane (50 mL) then the reaction was left to stir for 16 hours. The reaction 
was diluted with water (50 mL) and the organic layer separated. The remaining aqueous 
layer was washed with dichloromethane (2 x 60 mL). The organic extracts were then 
combined, dried over magnesium sulfate, filtered and concentrated under reduced 
pressure. Purification by flash column chromatography (25 g silica), eluting with a 
gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to (85:15), gave the title 
compound as a white solid (1.96 g, 83%): mp 98-103 °C; Rf 0.26 (10% ethyl acetate / 90% 
40-60 °C petrol ether); HRMS-ESI m/z [M+Na]+ calcd for C9H9ClINaO4: 364.9048, found: 
364.9050; 1H NMR (500 MHz, chloroform-d) δ 12.40 (1 H, s, 6-OH), 6.53 (1 H, s, 4-OH), 
3.98 (3 H, s, 1-CH3), 2.60 (3 H, s, 6-CH3); 13C NMR (125 MHz, chloroform-d) δ 171.2 (C), 
161.4 (C), 155.7 (C), 139.7 (C), 112.9 (C), 106.8 (C), 72.0 (C), 52.8 (CH3), 20.0 (CH3); IR 
(neat, νmax) cm-1 3441, 1647, 1444, 1380, 1298, 1217, 1124, 1088, 799, 712. 
 
 
 
 
 
 
 
  
145 
 
± Methyl 2-hydroxy-6-methyl-4-oxocyclohex-2-enecarboxylate261 (42) 
 
Sodium metal (5.75 g, 250 mmol) was fully dissolved in methanol (150 mL) at 0 ˚C.  
Methylacetoacetate (26.9 mL, 250 mmol) and methylcrotonate (26.4 mL, 250 mmol) 
were added and the reaction mixture was refluxed for 3 days. The reaction was allowed 
to cool to room temperature, the majority of the methanol was removed under reduced 
pressure and the remaining was diluted with water (70 mL) and acidified with 1 M 
aqueous hydrogen chloride solution (20 mL). The acidified mix was then extracted with 
ethyl acetate (3 x 100 mL). The combined organic extracts were dried over magnesium 
sulfate, filtered and concentrated under reduced pressure. Recrystallisation from 
diethyl ether afforded the title compound as a white powder (29.1 g, 64%): Rf 0.44 (100% 
ethyl acetate); HRMS-ESI m/z [M+H]+ calcd for C9H13O4: 185.0808, found: 185.0809; 1H 
NMR (400 MHz, dmso-d6) 5.19 (1 H, s, 3-CH), 3.61 (3 H, s, 1-CH3), 3.07 (1 H, d, J = 11 Hz, 
1-CH), 2.38-2.14 (3 H, m, 5-CH2 and 6-CH), 0.93 (3 H, d, J = 6 Hz, 6-CH3).  
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Methyl 3-bromo-2,4-dihydroxy-6-methylbenzoate243 (43) 
 
A solution of bromine (5.35 mL, 110 mmol) in acetic acid (40 mL) was added drop-wise 
to a stirred solution of methyl 2-hydroxy-6-methyl-4-oxocyclohex-2-enecarboxylate 
(10.1 g, 55.6 mmol) in acetic acid (40 mL) and the reaction was stirred at room 
temperature for 15 hours. The reaction was poured onto ice and the precipitated 
filtered off. Purification of this precipitate by flash column chromatography (100 g silica), 
eluting with a gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to (85:15), gave 
the title compound as a white solid (10.0 g, 69%): Rf 0.16 (10% ethyl acetate / 90% 40-
60 °C petrol ether); HRMS-ESI m/z [M+Na]+ calcd for C9H9BrNaO4: 282.9576, found: 
282.9578; 1H NMR (500 MHz, chloroform-d) δ 12.54 (1 H, s, 2-OH), 6.48 (1 H, s, 5-CH), 
5.97 (1 H, s, 4-OH), 3.97 (3 H, s, 1-CH3), 2.50 (3 H, s, 6-CH3); 13C NMR (125 MHz, 
chloroform-d) δ 171.9 (C), 161.0 (C), 156.8 (C), 142.6 (C), 110.6 (CH), 106.2 (C), 96.6 (C), 
52.3 (CH3), 24.1 (CH3); IR (neat, νmax) cm-1 3397, 2953, 1626, 1577, 1440, 1439, 1308, 
1260, 1208, 1074, 1022, 958, 794.  
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Methyl 3-bromo-5-chloro-2,4-dihydroxy-6-methylbenzoate243 (51) 
 
Methyl 3-bromo-2,4-dihydroxy-6-methylbenzoate (1.00 g, 3.71 mmol) was dissolved in 
dichloromethane (20 mL) and cooled to 0 °C. Sulfryl chloride (0.38 mL, 4.6 mmol) was 
added and the reaction allowed warm to room temperature over and was stirred for 3 
hours. The reaction was quenched with saturated aqeous sodium hydrogen carbonate 
(20 mL) and the organic layer separated. The aqeous layer was extracted with 
dichloromethane (2 x 20 mL). The organics were dried over magnesium sulfate, filtered 
and concentrated under reduced pressure. This gave the title compound as a white solid 
(1.07 g, 98%): mp 68-72 °C; HRMS-ESI m/z [M+Na]+ calcd for C9H8BrClNaO4: 318.9167, 
found: 318.9160; 1H NMR (500 MHz, chloroform-d) 12.18 (1 H, s, 2-OH), 6.46 (1 H, s, 4-
OH), 3.99 (3 H, s, 1-CH3), 2.63 (3 H, s, 6-CH3). 
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Methyl 2,4-dihydroxy-6-methylbenzoate262 (88) 
 
Iodine (1.95 g, 7.60 mmol) was added to a stirred solution of methyl 2-hydroxy-6-
methyl-4-oxocyclohex-2-enecarboxylate (0.70 g, 3.8 mmol) in acetic acid (7.5 mL) and 
the reaction was stirred at room temperature for 15 hours. The reaction was diluted 
with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined extracts 
were washed with a saturated aqueous sodium bicarbonate solution (3 x 30 mL), brine 
(30 mL) and dried over magnesium sulfate. Purification by flash column chromatography 
(50 g silica), eluting with a gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to 
(90:10), gave the title compound as a colourless solid (0.31 g, 44%): Rf 0.48 (10% ethyl 
acetate / 90% 40-60 °C petrol ether); MS (EI) m/z (%): 182 (72), 183 (10) [M]+; 1H NMR 
(500 MHz, chloroform-d) δ 11.70 (1 H, s, 2-OH), 6.28 (1 H, s, 3-CH), 6.23 (1 H, s, 5-CH), 
5.08 (1 H, s, 4-OH), 3.94 (3 H, s, 9-CH3), 2.53 (3 H, s, 7-CH3). 
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Methyl 3-bromo-5-chloro-2,4-dimethoxy-6-methylbenzoate263 (83) 
 
Dimethylsulfate (0.81 mL, 8.5 mmol) was added to a stirred suspension of methyl 5-
bromo-3-chloro-4,6-dihydroxy-2-methylbenzoate (1.00 g, 3.40 mmol), potassium 
carbonate (1.07 g, 8.46 mmol) and acetone (10 mL). The reaction was refluxed for 3 
hours then allowed to cool to room temperature and concentrated under reduced 
pressure. The concentrated mixture was transferred to a separating funnel with ethyl 
acetate (15 mL) and washed with a 1 M aqueous sodium hydroxide solution (3 x10 mL). 
The organics were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure. Purification by flash column chromatography (10 g silica), eluting with 
a gradient of 40-60 °C petrol ether: ethyl acetate  (100:0) to (90:10), gave the title 
compound as a colourless oil (0.90 g, 83%): Rf 0.16 (10% ethyl acetate / 90% 40-60 °C 
petrol ether); HRMS-ESI m/z [M+Na]+ calcd for C11H12BrClNaO4: 344.9500, found: 
344.9497;  1H NMR (500 MHz, chloroform-d) δ 3.95 (3H, s, 1-CH3), 3.90 (3H, s, 4-CH3), 
3.88 (3H, s, 2-CH3), 2.30 (3H, s, 6-CH3); 13C NMR (125 MHz, chloroform-d) δ 166.9 (C), 
155.1 (C), 153.5 (C), 134.4 (C), 127.2 (C), 125.7 (C). 111.2 (C), 62.3 (CH3), 60.5 (CH3), 52.6 
(CH3), 17.5 (CH3). 
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Methyl 3-chloro-5-iodo-4,6-dimethoxy-2-methylbenzoate (85) 
 
Dimethylsulfate (0.81 mL, 4.8 mmol) was added to a stirred suspension of methyl 3-
chloro-4,6-dihydroxy-5-iodo-2-methylbenzoate (0.750 g, 2.19 mmol), potassium 
carbonate (0.67 g, 4.8 mmol) and acetone (10 mL). The reaction was refluxed for 5 hours 
then was allowed to cool to room temperature and concentrated under reduced 
pressure. The concentrated mixture was transferred to a separating funnel with ethyl 
acetate (15 mL) and washed with a 1 M aqueous sodium hydroxide solution (3 x 10 mL). 
The organics were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure. Purification by flash column chromatography (10 g silica), eluting with 
a gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to (90:10), gave the title 
compound as a clear oil with a yellow hue (0.62 g, 77%): Rf 0.50 (10% ethyl acetate / 90% 
40-60 °C petrol ether); HRMS-EI m/z [M+Na]+ calcd for C11H12ClINaO4: 392.9361, found: 
392.9358; 1H NMR (500 MHz, chloroform-d) δ 3.95 (3 H, s, 1-CH3), 3.88 (3 H, s, 4 or 6-
CH3), 3.85 (3 H, s, 4 or 6-CH3), 2.31 (3 H, s, 2-CH3); 13C NMR (125 MHz, chloroform-d) δ 
166.9 (C), 157.6 (C), 156.1 (C), 135.9 (C), 126.7 (C), 124.7 (C), 87.5 (C), 62.6 (CH3), 60.5 
(CH3), 52.7 (CH3), 17.5 (CH3); IR (neat, νmax) cm-1 2940, 1723, 1373, 1256, 1083, 961, 926, 
708. 
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Methyl 3-chloro-4,6-dimethoxy-2-methyl-5-(3-methylbut-2-en-1-yl)benzoate (86) 
 
Methyl 3-chloro-5-iodo-4,6-dimethoxy-2-methylbenzoate (100 mg, 0.27 mmol), 3-
methyl-2-butenylboronic acid pinacol ester (66 mg, 0.34 mmol) and an aqueous 1 M 
potassium carbonate solution (0.81 mL) was were combined in dioxane (0.8 mL). 
Nitrogen gas was bubbled through the reaction mixture for 10 minutes to degas the 
reaction. Pd(dppf)Cl2 (22 mg, 0.03 mmol) was added and the reaction was heated to 100 
°C for 2 hours. The reaction was allowed to cool to room temperature then transferred 
to a separating funnel with water (10 mL) and ethyl acetate (10 mL). The organic layer 
was separated and the aqueous layer was extracted further with ethyl acetate (2 x 10 
mL). The combined organic extracts were washed with brine (20 mL), dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. Purification by 
flash column chromatography (10 g silica), eluting with a gradient of 40-60 °C petrol 
ether: ethyl acetate (100:0) to (90:10), gave the title compound (42 mg, 49%) as a 
colourless oil: 1H NMR (500 MHz, chloroform-d) δ 5.19-5.12 (1 H, m, 2’-CH), 3.93 (3 H, s, 
1-CH3), 3.82 (3 H, s, 4 or 6-CH3), 3.76 (3 H, s, 4 or 6-CH3), 3.36 (2 H, d, J = 7 Hz, 1’-CH2), 
2.29 (3 H, s, 2-CH3), 1.77 (3 H, s, 3’ or 4’-CH3), 1.68 (3 H, s, 3’ or 4’-CH3).  
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Methyl 3-bromo-2,4-dimethoxy-6-methylbenzoate264 (99) 
 
Dimethylsulfate (0.76 mL, 8.0 mmol) was added to a stirred suspension of methyl 3-
bromo-4,6-dihydroxy-5-2-methylbenzoate (830 mg, 3.20 mmol), potassium carbonate 
(1.10g, 7.97 mmol) and acetone (10 mL). The reaction was refluxed for 3 hours then 
allowed to cool to room temperature and concentrated under reduced pressure. The 
concentrated mixture was transferred to a separating funnel with ethyl acetate (25 mL) 
and washed with a 1 M aqueous sodium hydroxide solution (3 x 15 mL). The organics 
were dried over magnesium sulfate, filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (10 g silica), eluting with a gradient of 40-
60 °C petrol ether: ethyl acetate (100:0) to (90:10), gave the title compound as a 
colourless oil (0.82 g, 89%): Rf 0.34 (10% ethyl acetate / 90% 40-60 °C petrol ether); MS 
(EI) m/z (%): 288 (70), 290 (65) [M]+; 1H NMR (500 MHz, chloroform-d) δ 6.52 (1 H, s, 5-
CH), 3.91 (3 H, s, 2-CH3), 3.89 (3 H, s, 4-CH3), 3.88 (3 H, s, 1-CH3), 2.30 (3 H, s, 6-CH3).  
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Methyl 4-acetoxy-2-hydroxy-6-methylbenzoate (116) 
 
Methyl 2,4-dihydroxy-6-methylbenzoate (520 mg, 2.86 mmol) and triethylamine (400 
µL, 2.86 mmol) were dissolved in dichloromethane (10 mL). The mixture was cooled to 
0 ˚C and acetyl chloride (205 µL, 2.86 mmol) was added. The reaction was stirred at 0 ˚C 
for 30 minutes and then allowed to come to room temperature and stirred for 1 hour. 
The reaction was diluted with brine (20 mL) and the organic layer separated. The 
aqueous phase was washed with dichloromethane (2 x 15 mL) and the combined organic 
extracts were dried over magnesium sulfate, filtered and concentrated under reduced 
pressure onto silica gel (1 g). Purification by flash column chromatography (10 g silica), 
eluting with a gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to (90:10), gave 
the title compound as a white powder (0.52 g, 81%): mp 56-60 °C; Rf 0.74 (20% ethyl 
acetate / 80% 40-60 °C petrol ether); HRMS-EI m/z [M+H]+ calcd for C11H13O5: 225.0757, 
found: 225.0757;  1H NMR (500 MHz, chloroform-d) δ 11.50 (1 H, s, 2-OH), 6.62 (1 H, s, 
3-CH), 6.50 (1 H, s, 5-CH), 3.96 (3 H, s, 1-CH3) , 2.54 (3 H, s, 6-CH3), 2.29 (3 H, s, 4-CH3); 
13C NMR (126 MHz, chloroform-d) 171.7 (C), 168.5 (C), 164.2 (C), 154.7 (C), 143.1 (C), 
116.4 (CH), 110.1 (C), 108.5 (CH), 52.1 (CH3), 24.01 (CH3), 21.01 (CH3); IR (neat, νmax) cm-
1 2957, 1761, 1656, 1316, 1264, 1190, 1136, 1066. 
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Methyl 4-acetoxy-3-chloro-6-hydroxy-2-methylbenzoate (117) 
 
Methyl 3-chloro-4,6-dihydroxy-2-methylbenzoate (400 mg, 1.85 mmol) was dissolved in 
a solution of dichloromethane (4 mL) and triethylamine (270 µL, 1.94 mmol). The 
reaction mixture was cooled to 0 °C, acetyl chloride (139 µL, 1.94 mmol) was added 
drop-wise and the reaction was stirred for 1 hour. The solution was transferred to a 
separating funnel, diluted with ethyl acetate (20 mL) then washed with water (20 mL) 
and brine (20 mL). The organic layer was dried with magnesium sulfate, filtered, and 
concentrated under reduced pressure. Purification by flash column chromatography (10 
g silica), eluting with a gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to (90:10), 
gave the title compound as a white/yellow solid (230 mg, 48%): mp 60-61 °C; Rf 0.32 
(20% ethyl acetate / 80% 40-60 °C petrol ether); MS (EI) m/z (%): 258 (20), 260 (7) [M]+ 
HRMS-ESI m/z [M+H]+ calcd for C11H12ClO5: 259.0368, found:  259.0370; 1H NMR (500 
MHz, chloroform-d) δ 11.02 (1 H, s, 6-OH), 6.55 (1 H, s, 5-CH), 3.92 (3 H, s, 1-CH3), 2.58 
(3 H, s, 6-CH3), 2.30 (3 H, s, 4-CH3); 13C NMR (125 MHz, chloroform-d) δ 171.0 (C), 167.9 
(C), 161.3 (C), 151.5 (C), 140.2 (C), 119.7 (C), 112.4 (C), 110.7 (C), 52.6 (CH3), 20.7 (CH3), 
19.8 (CH3); IR (neat, νmax) cm-1 2960, 1776, 1662, 1312, 1167, 1112, 1015, 885, 801. 
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 (E)-Methyl 4-acetoxy-2-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-6-methylbenzoate (118) 
 
Geranyl bromide (500 mg, 2.31 mmol) was added to a suspension of methyl 4-acetoxy-
2-hydroxy-6-methylbenzoate (260 mg, 1.16 mmol), potassium carbonate (481 mg, 3.48 
mmol) and potassium iodide (18 mg, 0.12 mmol) in N,N-dimethylforamide (3 mL). The 
reaction was left stirring for 16 hours then diluted with water (10 mL) and it was 
extracted with diethyl ether (2 x 20 mL). The combined organic extracts were dried over 
magnesium sulfate, filtered and concentrated under reduced pressure onto silica gel (1 
g). Purification by flash column chromatography (10 g silica), eluting with a gradient of 
40-60 °C petrol ether: ethyl acetate (100:0) to (90:10), gave the tile compound as a 
colourless oil (280 mg, 73%): Rf 0.82 (20% ethyl acetate / 80% 40-60 °C petrol ether); 1H 
NMR (500 MHz, chloroform-d) δ 6.52 (1 H, s, 5-CH), 6.50 (1 H, s, 3-CH), 5.40-5.35 (1 H, 
m, 2’-CH), 5.08-5.03 (1 H, m, 6’-CH), 4.50 (2 H, d, J = 6 Hz, 1’-CH2), 3.85 (3 H, s, 1-CH3), 
2.25 (3 H, s, 6-CH3), 2.01 (3 H, s, 4-CH3), 1.67 (3 H, s, 3'-CH3), 1.65 (3 H, s, 8’ or 10’-CH3), 
1.58 (3 H, s, 8’ or 10’-CH3); 13C NMR (126 MHz, chloroform-d) δ 171.0 (C), 168.2 (C), 156.8 
(C), 151.8 (C), 141.1 (C), 137.6 (C), 131.7 (C), 123.7 (CH), 121.9 (C), 119.1 (-CH), 115.3 
(CH), 104.2 (CH), 66.0 (CH2), 52.0 (CH3), 39.4 (CH2), 26.2 (CH2), 25.5 (CH3), 20.9 (CH3), 
19.3 (CH3), 17.6 (CH3), 16.6 (CH3). 
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(E)-Methyl 4-acetoxy-3-chloro-6-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-2-
methylbenzoate (119) 
 
Geranyl bromide (500 mg, 2.31 mmol) was added to a suspension of methyl 4-acetoxy-
3-chloro-6-hydroxy-2-methylbenzoate (260 mg, 1.16 mmol), potassium carbonate (481 
mg, 3.48 mmol) and potassium iodide (18 mg, 0.12 mmol) in N,N-dimethylforamide (3 
mL). The reaction was left stirring for 16 hours then diluted with water (10 mL) and 
extracted with diethyl ether (2 x 20 mL). The combined organic extracts were dried over 
magnesium sulfate, filtered and concentrated under reduced pressure onto silica gel (1 
g). Purification by flash column chromatography (10 g silica), eluting with a gradient of 
40-60 °C petrol ether: ethyl acetate (100:0) to (90:10), gave the title compound as a 
colourless oil (311 mg, 65%): Rf 0.57 (20% ethyl acetate / 80% 40-60 °C petrol ether); 
HRMS-ESI m/z [M+Na]+ calcd for C21H27ClNaO5: 417.1439, found: 417.1443; 1H NMR (500 
MHz, chloroform-d) δ 6.60 (1 H, s, 5-CH), 5.38 (1 H, t, J = 6 Hz, 2'-CH), 5.07 (1 H, t, J = 7 
Hz, 6'-CH), 4.52 (2 H, d, J = 6 Hz, 1'-CH2), 3.89 (3 H, s, 1-CH3), 2.33 (3 H, s, 2-CH3), 2.31 (3 
H, s, 4-CH3), 2.14-2.01 (4 H, m, 4' and 5'-CH2), 1.68 (3 H, s, 3'-CH3), 1.67 (3 H, s, 7' or 8'-
CH3), 1.60 (3 H, s, 7' or 8'-CH3); 13C NMR (125 MHz, chloroform-d) δ 168.0 (C), 167.4 (C), 
154.5 (C), 148.2 (C), 141.6 (C), 135.5 (C), 131.7 (C), 123.7  (CH), 123.7 (C), 119.2  (CH), 
118.8  (CH), 106.3 (CH2), 66.3 (CH3), 52.2 (CH2), 26.3 (CH2), 25.6 (CH3), 20.6 (CH3), 17.6 
(CH3), 17.4 (CH3), 16.6 (CH3); IR (neat, νmax) cm-1 2924, 1779, 1733, 1590, 1256, 1185, 
1105, 1033. 
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(E)-Methyl 4-acetoxy-3-(3,7-dimethylocta-2,6-dien-1-yl)-2-hydroxy-6-methylbenzoate 
(120) 
 
(E)-Methyl 4-acetoxy-2-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-6-methylbenzoate (145 
mg, 0.36 mmol) was dissolved in toluene (8 mL) and florisil 100-200 mesh (1.45 g) added. 
The reaction was heated to 100 ˚C for 4 hours, cooled to room temperature, filtered and 
the filtrate was concentrated under reduced pressure. Purification by flash column 
chromatography (10 g silica), eluting with a gradient of 40-60 °C petrol ether: ethyl 
acetate (100:0) to (90:10), gave title compound as a colourless oil (50 mg, 21%): Rf 0.30 
(10% ethyl acetate / 90% 40-60 °C petrol ether); HRMS-ESI m/z [M+Na]+ calcd for 
C21H28NaO5: 383.1829, found: 383.1834; 1H NMR (500 MHz, chloroform-d) δ 11.82 (1 H, 
s, 2-OH), 6.46 (1 H, s, 5-CH), 5.15 (1 H, t, J = 7 Hz, 2’-CH), 5.07 (1 H, t, J = 7 Hz, 6’-CH), 
3.95 (3 H, s, 1-CH3), 3.29 (2 H, d, J = 7 Hz, 1’-CH2), 2.50 (3 H, s, 6-CH3), 2.30 (3 H, s, 4-CH3), 
2.09-2.01 (2 H, m, 5’-CH2), 2.01-1.94 (2 H, m, 4’-CH2), 1.75 (3 H, s, 3’-CH3), 1.66 (3 H, s, 8’ 
or 10’ CH3), 1.58 (3 H, s, 8’ or 10’ CH3); 13C NMR (126 MHz, chloroform-d) δ 172.2 (C), 
168.7 (C), 162.5 (C), 152.8 (C), 139.7 (C), 135.6 (C), 131.3 (C), 124.3 (CH), 121.3 (CH), 
120.0 (C), 116.8 (CH), 110.0 (C), 52.1 (C), 39.7 (CH2), 26.6 (CH2), 25.6 (CH3), 24.0 (CH3), 
22.9 (CH2), 20.9 (CH3), 17.6 (CH3), 16.1 (CH); IR (neat, νmax) cm-1 3328, 1653, 1439, 1368, 
1317, 1245, 1191, 1139. 
 
158 
 
(E)-Methyl3-chloro-5-(3,7-dimethylocta-2,6-dien-1-yl)-4,6-dihydroxy-2-
methylbenzoate265 (126) 
 
(E)-Methyl 4-acetoxy-3-chloro-6-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-2-
methylbenzoate (240 mg, 0.67 mmol) was dissolved in toluene (8 mL) and florisil 100-
200 mesh (2.40 g) added. The reaction was heated to 100 ˚C for 4 hours, cooled to room 
temperature and filtered. The filtrate was concentrated under reduced pressure. 
Purification by flash column chromatography (10 g silica), eluting with a gradient of 40-
60 °C petrol ether: ethyl acetate (100:0) to (90:10), gave title compound as a colourless 
oil (26 mg, ap 20%): HRMS-ESI m/z [M+H]+ calcd for C19H26ClO4: 353.1514, found: 
253.1308; 1H NMR (500 MHz, chloroform-d) δ 11.63 (1 H, s, 6-OH), 6.21 (1 H, s, 4-OH), 
5.25 (1 H, t, J = 7 Hz, 2’-CH), 5.07 (1 H, t, J = 7 Hz, 6’-CH), 3.95 (3 H, s, 1-CH3), 3.43 (2 H, 
d, J = 7 Hz, 1’-CH2), 2.60 (3 H, s, 2-CH3), 2.13-2.03 (2 H, m, 5’-CH2), 2.03-1.92 (2 H, m, 4’-
CH2), 1.80 (3 H, s, 3’-CH3), 1.66 (3 H, s, 7’ or 8’-CH3), 1.58 (3 H, s, 7’ or 8’-CH3). 
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1-(2,4-Dihydroxyphenyl)-2,2,2-trifluoroethanone266 (135) 
 
Trifluoroacetic acid anhydride (16.3 mL, 115 mmol) was added drop-wise to a stirred 
suspension of resorcinol (10.0 g, 91 mmol) and aluminum chloride (39.5 g, 296 mmol) in 
dichloromethane (750 mL) at 0 ˚C. The reaction was allowed to come to room 
temperature and was stirred for 15 hours. The mixture was poured onto ice (300 g), 
transferred to separating funnel and the organic layer separated. The aqueous layer was 
then washed with dichloromethane (3 x 300 mL). The combined organics were 
neutralised with a saturated aqueous sodium bicarbonate solution (200 mL), washed 
with a saturated brine solution (200 mL), dried over magnesium sulfate and 
concentrated under reduced pressure. Purification by flash column chromatography (70 
g silica), eluting with a gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to (75:25), 
gave the title compound as a pale yellow powder (15.4 g, 83%): MS (EI) m/z (%): 207 (15) 
[M+H]+; 1H NMR (500 MHz, chloroform-d) δ 11.49 (1 H, s, 2-OH), 7.75 (1 H, d, J = 9 Hz, 6-
CH), 6.49 (1 H, d, J = 9 Hz, 5-CH), 6.47 (1 H, s, 3-CH), 5.63 (1 H, s, 4-OH).   
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1-(2,4-Dihydroxy-3-iodophenyl)-2,2,2-trifluoroethanone (136)  
 
Iodine (4.61 g, 18.2 mmol) and potassium iodate (1.54 g, 7.2 mmol) were added to a 
stirred solution of 1-(2,4-dihydroxyphenyl)-2,2,2-trifluoroethanone (4.35 g, 21.1 mmol) 
in ethanol (50 mL) and the mixture was stirred for 16 hours. The reaction was diluted 
with water (50 mL) and a 1M hydrochloric acid solution added until pH 4 achieved. The 
solution was then extracted with diethyl ether (3 x 50 mL) and the combined organic 
layers were washed with a saturated aqueous sodium thiosulfate solution (50 mL) and 
a saturated brine solution (50 mL). The organics were dried over magnesium sulfate, 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (50 g silica, eluting with a gradient of 40-60 °C petrol: ethyl acetate 
(100:0) to (80:20), gave the title compound as an white/brown powder (4.60 g, 68%): 
mp 56-59 °C; Rf  0.58 (20% ethyl acetate / 80% 40-60 °C petrol ether); MS (EI) m/z (%): 
332 (56) [M]+; 1H NMR (500 MHz, chloroform-d) δ 12.43 (1 H, s, 2-OH), 7.77 (1 H, d, J = 
9 Hz, 6-CH), 6.72 (1 H, d, J = 9 Hz, 5-CH), 6.50 (1 H, br s, 4-OH); 13C NMR (125 MHz, 
chloroform-d) 182.09 (q, 2JFC = 36 Hz, C), 165.71 (C), 163.92 (C), 132.85 (q, 3JFC = 4 Hz, 
CH), 116.32 (q, 1JFC = 289 Hz, C), 108.45 (CH), 108.31 (C), 77.49 (C); IR (neat, νmax) cm-1 
3399, 1607, 1481, 1363, 1287, 1130, 1016, 957, 783. 
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4-(5',5'-Dimethyl-1',3'-dioxan-2'-yl)phenol267 (149) 
 
2, 2 Dimetyl 1, 3 propanediol (4.26 g, 40.9 mmol) was added to a stirred solution of para-
hydroxybenzaldehyde (2.00 g, 16.4 mmol) in dry dichloromethane (15 mL) containing 4 
Ȧ activated molecular sieves. Para-toluylsulfonic acid (150 mg, 0.82 mmol) was added 
and the reaction was refluxed for 14 hours. The reaction was cooled to room 
temperature, transferred to a separating funnel and washed with saturated aqueous 
sodium bicarbonate (20 mL). The layers were separated and the aqueous layer washed 
with ethyl acetate (2 x 20 mL). The combined extracts were dried over magnesium 
sulfate, filtered, concentrated under reduced pressure. Purification by flash column 
chromatography (20 g silica), eluting with a gradient of 40-60 °C petrol ether: ethyl 
acetate (100:0) to (70:30), gave the title compound as an impure product that was used 
directly in the next reaction to 2-(4-(methoxymethoxy)phenyl)-5,5-dimethyl-1,3-
dioxane (2.66 g, ap 78%): HRMS-ESI m/z [M+H]+ calcd for C12H17O3: 209.1172, found:  
209.1173; 1H NMR (500 MHz, chloroform-d) δ 7.38 (2 H, d, J = 9 Hz), 6.78 (2 H, d, J = 9 
Hz), 5.36 (1 H, s), 3.77 (2 H, d, J = 11 Hz), 3.65 (2 H, d, J = 11 Hz), 1.31 (3 H, s), 0.80 (3 H, 
s). 
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2-(4-(Methoxymethoxy)phenyl)-5,5-dimethyl-1,3-dioxane (150) 
 
4-(5',5'-Dimethyl-1',3'-dioxan-2'-yl)phenol (1.95 g, 9.46 mmol) was dissolved in dry 
tetrahydrofuran (15 mL) and cooled to 0 ˚C. 60% sodium hydride on mineral oil (454 mg, 
11.4 mmol) was added to the reaction in three portions and stirred for 30 minutes. 
Chloromethyl methyl ether (790 µL, 10.4 mmol) was added drop-wise via syringe and 
the reaction was allowed come up to room temperature over 30 minutes. Saturated 
aqueous sodium bicarbonate (20 mL) was added and the solution was extracted with 
ethyl acetate (3 x 30 mL). The combined organic extracts were, dried over sodium 
sulfate, filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (20 g silica), eluting with a gradient of 40-60 °C petrol ether: ethyl 
acetate (100:0) to (85:15), gave the title compound as a clear oil (1.67 g, 71%): Rf 0.30 
(20% ethyl acetate / 80% 40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for 
C14H21O4: 253.1434, found: 253.1432; 1H NMR (500 MHz, chloroform-d) δ 7.46 (2 H, d, J 
= 8 Hz, 2 and 6-CH), 7.06 (2 H, d, J = 8 Hz, 3 and 5-CH), 5.37 (1 H, s, 2’-CH), 5.17 (2 H, s, 
4-CH2), 3.77 (2 H, d, J = 11 Hz, 4’-CH2), 3.64 (2 H, d, J = 11 Hz, 4’-CH2), 3.46 (3 H, s, 4-CH3), 
1.31 (3 H, s, 5’-CH3), 0.80 (3 H, s, 5’-CH3); 13C NMR (126 MHz, chloroform-d) δ 157.6 (C), 
132.4 (C), 127.4 (CH), 116.0 (CH), 101.5 (CH), 94.4 (CH2), 77.6 (CH2), 55.8 (CH3), 30.1 (C), 
23.1 (CH3), 21.9 (CH3). 
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(E)-2-(3-(3,7-Dimethylocta-2,6-dien-1-yl)-4-(methoxymethoxy)phenyl)-5,5-dimethyl-1,3-
dioxane (151) 
 
2.0 M n-butyl lithium (297 µL, 0.60 mmol) was added drop-wise to a 0 ˚C stirred solution 
of 2-(4-(methoxymethoxy)phenyl)-5,5-dimethyl-1,3-dioxane (100 mg, 0.4 mmol) and 
N1,N1,N2,N2-tetramethylethane-1,2-diamine (90 µL, 0.60 mmol) in dry tetrahydrofuran 
(3 mL). This was allowed come to room temperature over 30 minutes and was cooled 
again to 0 ˚C before the addition of geranyl bromide (174 mg, 0.80 mmol) drop-wise. 
The reaction was allowed to come to room temperature, brine added (10 mL) and this 
was extracted with diethyl ether (3 x 10 mL). The combined organics were washed with 
brine (2 x 10 mL), dried over sodium sulfate and concentrated under reduced pressure. 
Purification by flash column chromatography (10 g silica), eluting with a gradient of 40-
60 °C petrol ether: ethyl acetate (100:0) to (95:5), gave the title compound as a clear oil 
(79 mg, 65%): 1H NMR (500 MHz, chloroform-d) δ 7.33-7.28 (2 H, m, 2 and 6-CH), 7.09-
7.01 (1 H, d, J = 9 Hz, 5-CH), 5.36-5.29 (2 H, m, 2’’ and 2’-CH), 5.19 (2 H, s, CH2), 5.12 (1 
H, t, J = 7 Hz, 6’-CH), 3.76 (2 H, d, J = 11 Hz, 6’’ and 4’’-CH2), 3.63 (2 H, d, J = 11 Hz, 6’’ and 
4’’-CH2), 3.46 (3 H, s, 5-CH3), 3.37 (2 H, d, J = 7 Hz, 1’-CH2), 2.17-2.06 (2 H, m, 5’-CH2), 
2.06-1.98 (2 H, m, 4’-CH2), 1.73 (3 H, s, 3’-CH3), 1.69 (3 H, s, 7’ or 8’-CH3), 1.61 (3 H, s, 7’ 
or 8’-CH3), 1.30 (3 H, s, 5’’-CH3), 0.80 (3 H, s, 5’’-CH3); 13C NMR (126 MHz, chloroform-d) 
δ 155.3 (C), 135.83 (C), 131.93 (C), 131.33 (C), 130.7 (C), 127.5 (CH), 124.7 (CH), 124.4 
(CH), 122.5 (CH), 113.7 (CH), 101.8 (CH), 94.4 (CH2), 77.7 (CH2), 55.8 (CH3), 39.8 (CH2), 
30.2 (C), 28.7 (CH2), 26.7 (CH2), 25.7 (CH3), 23.0 (CH3), 21.9 (CH3), 17.6 (CH3), 16.1 (CH3).  
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Methyl 3-bromo-5-chloro-2,4-bis(methoxymethoxy)-6-methylbenzoate (156) 
 
60% sodium hydride on mineral oil (267 mg, 6.76 mmol) was added in three portions to 
a stirred solution of methyl 3-bromo-5-chloro-2,4-dihydroxy-6-methylbenzoate (1.00 g, 
3.41 mmol) in dry tetrahydrofuran (15 mL) at 0 ˚C. This was stirred for 40 minutes and 
methyl chloromethoxy ether (506 µL, 76.8 mmol) added drop-wise. The reaction was 
stirred for 16 hours and then diluted with water (100 mL) and extracted with diethyl 
ether (3 x 100 mL). The combined ether fractions were dried over sodium sulfate, 
filtered and concentrated, under reduced pressure. Purification by flash column 
chromatography (20 g silica), eluting with a gradient of 40-60 °C petrol ether: ethyl 
acetate (100:0) to (95:5), gave the title compound as a clear colourless  oil (878 mg, 
68%): Rf 0.34 (20% ethyl acetate / 80% 40-60 °C petrol ether); HRMS-ESI m/z [M+Na]+ 
calcd for C13H16BrClNaO6: 404.9711, found: 404.9700 ; 1H NMR (500 MHz, chloroform-
d) δ 5.19 (2 H, s, 2-CH2), 5.10 (2 H, s, 4-CH2), 3.94 (3 H, s, 1-CH3), 3.71 (3 H, s, 4-CH3), 3.58 
(3 H, s, 2-CH3), 2.32 (3 H, s, 6-CH3) ; 13C NMR (126 MHz, chloroform-d) δ 166.6 (C), 152.6 
(C), 150.6 (C), 134.6 (C), 127.8 (C), 126.2 (C), 112.1 (C), 100.4 (CH2), 99.6 (CH2), 58.4 (CH3), 
57.9 (CH3), 52.6 (CH3), 17.9 (CH3); IR (neat, νmax) cm-1 1733, 1588, 1487, 1184, 1159, 1024, 
879, 753, 689, 588. 
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Methyl 3-bromo-5-chloro-2,4-dihydroxy-6-methylbenzoate243 (51) 
 
Various conditions were attempted to deprotect the methyl 3-bromo-5-chloro-2,4 
bis(methoxymethoxy)-6-methylbenzoate esters on a 50 mg scale. Reactions were 
monitored over 24 hours and deprotection determined via 1H NMR: mp 68-72 °C; HRMS-
ESI m/z [M+Na]+ calcd for C9H8BrClNaO4: 318.9167, found: 318.9160; 1H NMR (500 MHz, 
chloroform-d) 12.18 (1 H, s, 2-OH), 6.46 (1 H, s, 4-OH), 3.99 (3 H, s, 1-CH3), 2.63 (3 H, s, 
6-CH3). 
Conditions Result 
Tetrahydrofuran (2 mL) and 1M HCl (2 mL) 
Paratoluylsulfonic acid (121 mg) and 
methanol (5 mL) 
 
Catalytic HCl, NaI (100 mg) and acetone (5 
mL) 

1:1 NaHSO4:SiO2 (50 mg)  
Acetic acid (1 mL) and methanol (4 mL) 
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1,3-Bis(methoxymethoxy)-5-methylbenzene255 (152) 
 
60% sodium hydride on mineral oil (742 mg, 18.5 mmol) was added in three portions to 
a stirred solution of orcinol (1.00 g, 8.06 mmol) in dimethylformamide (20 mL) at 0 ˚C. 
This was stirred for 40 minutes and methyl chloromethoxy ether (1.35 mL, 17.7 mmol) 
added drop-wise. The reaction was stirred for 16 hours and then diluted with water (100 
mL) and extracted with diethyl ether (3 x 100 mL). The combined organics were washed 
with 1 M sodium hydroxide solution (2 x 50 mL), saturated brine solution (50 mL), dried 
over sodium sulfate, filtered and concentrated under reduced pressure. Purification by 
flash column chromatography (20 g silica), eluting with a gradient of 40-60 °C petrol 
ether: ethyl acetate (100:0) to (95:5), gave the title compound as a clear oil (1.59 g, 93%): 
HRMS-ESI m/z [M+H]+ calcd for C11H17O4: 213.1121, found: 213.1120; 1H NMR (500 MHz, 
chloroform-d) δ 6.56 (1 H, s, 2-CH), 6.54 (2 H, s, 4 and 6-CH), 5.15 (4 H, s, 1 and 3-CH2), 
3.49 (6 H, s, 1 and 3-CH3), 2.31 (3 H, s, 5-CH3). 
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(E)-2-(3,7-Dimethylocta-2,6-dienyl)-1,3-bis(methoxymethoxy)-5-methylbenzene (153) 
 
3-Bis(methoxymethoxy)-5-methylbenzene (2.50 g, 11.8 mmol) was dissolved in dry 
tetrahydrofuran (90 mL) and cooled to 0 ˚C. 2.1 M n-butyl lithium (8.41 mL, 17.7 mmol) 
was added drop-wise and the reaction was left to stir for 1 hour at 0 ˚C. Geranyl bromide 
(4.48 g, 20.6 mmol) was added to the reaction mixture in a drop-wise manner, this was 
stirred for 1 hour and allowed to come to room temperature. The reaction was diluted 
with water (300 mL) and extracted with diethyl ether (3 x 200 mL). The combined 
organics were dried over sodium sulfate, filtered and concentrated under reduced 
pressure. Purification by flash column chromatography (50 g silica), eluting with a 
gradient of 40-60 °C petrol ether: ethyl acetate (100:0) to (95:5), gave the title 
compound as a colourless clear oil (3.70 g, 90%): Rf 0.60 (20% ethyl acetate / 80% 40-60 
°C petrol ether); HRMS-ESI m/z [M+H]+ calcd for C21H33O4: 349.2373, found: 349. 2376;  
1H NMR (500 MHz, chloroform-d) δ 6.60 (2 H, s, 4 and 6-CH), 5.22 (1 H, t, J = 7 Hz, 2’-CH), 
5.18 (4 H, s, 1 and 3-CH2), 5.08 (1 H, t, J = 7 Hz, 6’-CH), 3.48 (6 H, s, 1 and 3-CH3), 3.38 (2 
H, d, J = 7 Hz,  1’-CH2), 2.31 (3 H, s, 5-CH3), 2.09-2.02 (2 H, m, 4’ or 5’-CH2), 1.99-1.92 (2 
H, m, 4’ or 5’-CH2), 1.79 (3 H, s, 3’-CH3), 1.66 (3 H, s, 7’ or 8’-CH3), 1.58 (3 H, s, 7’ or 8’-
CH3); 13C NMR (125 MHz, chloroform-d) δ 155.6 (C), 136.8 (C), 134.3 (C), 131.1  (C), 124.4 
(CH), 123.1 (C), 117.4 (CH), 108.9 (CH), 94.5 (CH2), 55.9 (CH3), 39.8 (CH2), 26.8 (CH2), 25.6 
(CH3), 22.4 (CH2), 21.7 (CH3), 17.6 (CH3), 16.0 (CH3); IR (neat, νmax) cm-1 2952, 2900, 1464, 
1356, 1297, 1215, 1162, 1094, 1000, 904, 876, 704, 685, 674. 
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(E)-3-(3,7-Dimethylocta-2,6-dienyl)-2,4-bis(methoxymethoxy)-6-methylbenzaldehyde 
(154)  
 
3-Bis(methoxymethoxy)-5-methylbenzene (2.50 g, 11.8 mmol) was dissolved in dry 
tetrahydrofuran (90 mL) and cooled to 0 ˚C.  2.1 M n-butyl lithium (8.41 mL, 17.7 mmol) 
was added drop-wise and the reaction was left to stir for 1 hour at 0 ˚C. Geranyl bromide 
(4.48 g, 20.6 mmol) was added to the reaction mixture in a drop-wise manner. This was 
stirred for 1 hour and allowed to come to room temperature. The reaction was cooled 
to 0 ˚ C again and 2.1 M n-butyl lithium (8.41 mL, 17.67 mmol) added followed by another 
1 hour stirring at 0 ˚C. Excess dry N, N-dimethylformamide was added and the reaction 
was allowed to come to room temperature over 1 hour. The reaction was diluted with 
water (300 mL) and extracted with diethyl ether (3 x 200 mL). The combined organics 
were dried over sodium sulfate, filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (50 g silica), eluting with a gradient of 40-
60 °C petrol ether: ethyl acetate (100:0) to (95:5), gave the title compound as a yellow 
tinted clear oil (1.28 g, 31%): HRMS-ESI m/z [M+Na]+ calcd for C23H32NaO5: 399.2142, 
found:  399.2147; 1H NMR (500 MHz, chloroform-d) δ 10.38 (1 H, s, 1-CH), 6.74 (1 H, s, 
5-CH), 5.24 (2 H, s, 2 or 4-CH2), 5.17 (1 H, t, J = 7 Hz, 2’-CH), 5.04 (2 H, s, 2 or 4-CH2), 5.01 
(1 H, t, J = 6 Hz, 6’-CH), 3.57 (3 H, s, 2 or 4-CH3), 3.46 (3 H, s, 2-CH3 or 4-CH3), 3.36 (2 H, 
d, J = 7 Hz,  1’-CH2), 2.57 (3 H, s, 5-CH3), 2.07-2.01 (2 H, m, 4’ or 5’-CH2), 1.99-1.93 (2 H, 
m, 4’ or 5’-CH2), 1.76 (3 H, s, 3’-CH3), 1.63 (3 H, s, 7’ or 8’-CH3), 1.56 (3 H, s, 7’ or 8’-CH3); 
IR (neat, νmax) cm-1 2932, 1682, 1595, 1560, 1440, 1375, 1315, 1284, 1220, 1152, 1039, 
1007, 924. 
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1,3-Bis(methoxymethoxy)-5-methyl-2-octylbenzene (158) 
 
3-Bis(methoxymethoxy)-5-methylbenzene (2.00 g, 9.42 mmol) was dissolved in dry 
tetrahydrofuran (60 mL) and cooled to 0 ˚C. 2.5 M n-butyl lithium (4.90 mL, 12.3 mmol) 
was added drop-wise and the reaction was left to stir for 1 hour at 0 ˚C. Bromooctane 
(2.44 mL, 14.1 mmol) was added to the reaction mixture and this was stirred for 1 hour 
at 0 ˚C before being allowed to come to room temperature. The reaction was diluted 
with water (100 mL) and extracted with diethyl ether (3 x 100 mL). The organic fractions 
were dried over sodium sulfate, filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (25 g silica), eluting 40-60 °C petrol ether: 
ethyl acetate (100:0) to (95:5), gave the title compound as a colourless oil (2.75 g, 83%): 
Rf 0.79 (10% ethyl acetate / 90% 40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for 
C19H32NaO4: 347.2193, found: 347.2187; 1H NMR (500 MHz, chloroform-d) 6.59 (2 H, s, 
4 and 6-CH), 5.17 (4 H, s, 1 and 3-CH2), 3.49 (6 H, s, 1 and 3-OMe), 2.64 (2 H, t, J = 8 Hz, 
1’-CH2), 2.30 (3 H, s, 5-CH3), 1.55-1.46 (2 H, m, 2’-CH2), 1.39-1.23 (10 H, m, 3’ to 7’CH2), 
0.89 (3 H, t, J = 7 Hz, 8’-CH3); 13C NMR (126 MHz, chloroform-d) δ 155.7 (C), 136.6 (C), 
118.4 (C), 108.7 (CH), 94.5 (CH2), 56.0 (CH3), 31.9 (CH2), 29.8 (CH2), 29.7 (CH2), 29.5 (CH2), 
29.3 (CH2), 23.2 (CH2), 22.7 (CH2), 21.8 (CH3), 14.1 (CH3); IR (neat, νmax) cm-1 2924, 2854, 
1612, 1586, 1463, 1394, 1154, 1122, 1036, 923, 823;  
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5-Methyl-2-octylbenzene-1,3-diol (159) 
 
1,3-bis(methoxymethoxy)-5-methyl-2-octylbenzene (350 mg, 1.08 mmol) was 
suspended in ethylene glycol (10 mL) and heated to 160 °C by microwave irradiation for 
5 hours in a sealed vial. The reaction mixture was diluted with water (40 mL) and 
extracted with diethyl ether (3 x 30 ml). The combined extracts were washed with water 
(30 mL), dried over magnesium sulfate, filtered and concentrated under reduced 
pressure. Purification by flash column chromatography (10 g silica), eluting 40-60 °C 
petrol ether: ethyl acetate (100:0) to (70:30), gave the title compound as an 
orange/white powder (255 mg, quant.): mp 63-65 °C; Rf 0.32 (10% ethyl acetate / 90% 
40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for C15H25O2: 237.1849, found: 
237.1853; 1H NMR (500 MHz, chloroform-d) δ 6.23 (2 H, s, 4 and 6-CH), 4.69 (2 H, s, 1 
and 3-OH), 2.59 (2 H, t, J = 8 Hz, 1’-CH2), 2.22 (3 H, s, 5-CH3), 1.60-51 (2 H, m, 2’-CH2), 
1.43-1.23 (10 H, m, 3’ to 7’-CH2), 0.89 (3 H, t, J = 7 Hz, 8’-CH3); 13C NMR (126 MHz, 
chloroform-d) δ 154.4 (C), 137.0 (C), 112.4 (C), 108.7 (CH), 75.4 (CH2), 31.9 (CH2), 29.8 
(CH2), 29.5 (CH2), 29.3 (CH2), 23.0 (CH2), 22.7 (CH2), 21.0 (CH3), 14.1 (CH3); IR (neat, νmax) 
cm-1 3427, 3280, 2956, 2918, 2850, 1635, 1584, 1522, 1467, 1328, 1268, 1160, 1112, 
829, 534. 
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2,4-Dihydroxy-6-methyl-3-octylbenzaldehyde (160) 
 
5-methyl-2-octyl-benzene-1,3-diol (500 mg, 2.12 mmol) was dissolved in dry  N, N-
dimethylformamide (4.1 mL, 53 mmol)  and cooled to  0 oC. Phosphorus oxychloride 
(0.39 mL, 4.2 mmol) was added slowly by syringe and the reaction was then allowed to 
come to room temperature. After 2 hours the reaction was cooled to 0 oC and diluted 
with 1M aqueous sodium hydroxide solution (10 mL). This was stirred for 10 minutes 
then acidified with 1M aqueous hydrogen chloride solution (30 mL) and transferred to 
a separating funnel. The mixture was extracted with diethyl ether (3 x 40 mL). The 
combined organic layers were washed with water (50 mL) and brine (50 mL), dried over 
magnesium sulfate and concentrated under reduced pressure. Purification by flash 
column chromatography (10g silica), eluting 40-60 °C petrol ether: ethyl acetate (100:0) 
to (80: 20), gave the title compound as an orange/white powder (0.54 g, 92%): mp 101-
103 °C; Rf 0.18 (10% ethyl acetate / 90% 40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ 
calcd for C16H25O3: 265.1798, found: 265.1805; 1H NMR (500 MHz, chloroform-d) δ 12.63 
(1 H, s, 2-OH), 10.09 (1 H, s, 1-CH), 6.20 (1 H, s, 5-CH), 5.52 (1 H, s, 4-OH), 2.60 (2 H, d, J 
= 7 Hz, 1’-CH2), 2.50 (3 H, s, 6-CH3), 1.59-1.47 (2 H, m, 2’-CH2), 1.42-1.21 (10 H, m, 3’ to 
7’-CH2), 0.89 (3 H, d, J = 7 Hz, 8’-CH3); 13C NMR (126 MHz, chloroform-d) δ 193.0 (CH), 
164.2 (C), 161.0 (C), 141.5 (C), 114.0 (C), 113.4 (C), 110.2 (CH), 31.9 (CH2), 29.7 (CH2), 
29.5 (CH2), 29.3 (CH2), 28.7 (CH2), 22.6 (CH2), 22.0 (CH2), 17.9 (CH3), 14.1 (CH3); IR (neat, 
νmax) cm-1 3111, 2916, 2849, 1605, 1509, 1466, 1284, 1250, 1216, 1135, 829, 773, 644, 
567.  
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3-Chloro-4,6-dihydroxy-2-methyl-5-octylbenzaldehyde (161) 
 
2,4-dihydroxy-6-methyl-3-octylbenzaldehyde (70 mg, 0.27 mmol) was dissolved in dry 
diethyl ether (5 mL) and sulfuryl chloride (32 µL, 0.40 mmol) added. The reaction was 
stirred for 1 hour at room temperature before being quenched with saturated aqueous 
sodium hydrogen bicarbonate solution (25 mL). The mixture was then extracted with 
diethyl ether (2 x 15 mL). The combined organic phases were dried over magnesium 
sulfate, filtered and concentrated onto celite (1 g). Purification by flash column 
chromatography over silica (10 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to 
(80:20) gave the title compound as a colourless powder (67 mg, 84%): mp 64-66 °C; Rf 
0.58 (10% ethyl acetate / 90% 40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for 
C16H24ClO3: 299.1408, found: 299.1421; 1H NMR (500 MHz, chloroform-d) δ 12.65 (1 H, 
s, 2-OH), 10.14 (1 H, s, 1-CH), 6.34 (1 H, s, 4-OH), 2.69 (2 H, d, J = 7 Hz, 1’-CH2), 2.60 (3 H, 
s, 6-CH3), 1.54--1.47 (2 H, m, 2’-CH2), 1.30-1.23 (10 H, m, 3’ to 7’-CH2), 0.88 (3 H, d, J = 7 
Hz, 8’-CH3); 13C NMR (126 MHz, chloroform-d) δ 193.1 (CH), 162.5 (C), 156.2 (C), 137.2 
(C), 115.8 (C), 113.5 (C), 113.0 (C), 31.9 (CH2), 29.6 (CH2), 29.5 (CH2), 29.3 (CH2), 28.4 
(CH2), 22.9 (CH2), 22.6 (CH2), 14.4 (CH3), 14.1 (CH3); IR (neat, νmax) cm-1 3327, 2924, 2856, 
1606, 1452, 1416, 1374, 1233, 1132, 791, 767, 710, 555. 
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3-Chloro-4,6-dihydroxy-2-methyl-5-octylbenzaldehyde oxime (162) 
 
3-chloro-4,6-dihydroxy-2-methyl-5-octylbenzaldehyde (250 mg, 0.84 mmol), 
hydroxylamine monohydrochloride (178 mg, 2.51 mmol) and sodium acetate (275 mg, 
3.35 mmol) were dissolved in a mixture of tetrahydrofuran: ethanol: water (2:3:2) (2 mL) 
and stirred for 16 hours at room temperature. The reaction mixture was diluted with 
diethyl ether (10 mL), this mixture was dried over magnesium sulfate, filtered and 
concentrated on celite (1 g). Purification by flash column chromatography over silica (10 
g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (90: 10) gave the title compound 
as a white powder (243 mg, 92%): mp 68-70 °C; Rf 0.40 (10% ethyl acetate / 90% 40-60 
°C petrol ether); HRMS-ESI m/z [M+H]+ calcd for C16H25ClNO3: 314.1517, found: 
314.1527;  1H NMR (500 MHz, chloroform-d) δ 10.60 (1 H, s, 2-OH), 8.54 (1 H, s, 1-CH), 
7.14 (1 H, s, 1-OH), 5.88 (1 H, s, 4-OH), 2.69 (2 H, t, J = 7 Hz, 1’-CH2), 2.43 (3 H, s, 6-CH3), 
1.58-1.52 (2 H, m, 2’-CH2), 1.30-1.21 (10 H, m, 3’ to 7’-CH2), 0.91-0.87 (3 H, m, 8’-CH3); 
13C NMR (126 MHz, chloroform-d) δ 156.2 (C), 151.5 (C), 151.0 (CH), 132.5 (C), 115.6 (C), 
112.6 (C), 108.5 (C), 31.9 (CH2), 29.7 (CH2), 29.5 (CH2), 29.3 (CH2), 28.7 (CH2), 23.7 (CH2), 
22.7 (CH2), 15.9 (CH3), 14.1 (CH3); IR (neat, νmax) cm-1 3290, 2912, 2850, 1604, 1466, 1360, 
1314, 1287, 1211, 1183, 1119, 853, 764, 722, 593.  
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5-Chloro-6-hydroxy-4-methyl-7-octylbenzo[d]isoxazole (163) 
 
Triphenylphosphine (220 mg, 0.84 mmol) was dissolved in dry dichloromethane (3 mL) 
and 2,3-dichloro-5,6-dicyanobenzoquinone (190 mg, 0.84 mmol) added. A 3-chloro-4,6-
dihydroxy-2-methyl-5-octylbenzaldehyde oxime (175 mg, 0.56 mmol) solution in 
dichloromethane (3 mL) was prepared and added in one portion. The reaction was 
stirred for 5 minutes at room temperature then concentrated under reduced pressure 
onto celite (1 g). Purification by flash column chromatography over silica (10 g) eluting 
40-60 °C petrol ether: ethyl acetate (100:0) to (90:10) gave the title compound as a white 
powder (150 mg, 90%): mp 102-103 °C; Rf 0.55 (10% ethyl acetate / 90% 40-60 °C petrol 
ether); HRMS-ESI m/z [M+H]+ calcd for C16H23ClNO2: 296.1412, found: 296.1424; 1H NMR 
(500 MHz, chloroform-d) δ 8.60 (1 H, s, 1-CH), 6.00 (1 H, s, 4-OH), 2.94 (2 H, t, J = 7 Hz, 
1’-CH2), 2.43 (3 H, s, 6-CH3), 1.70-1.59 (2 H, m, 2’-CH2), 1.37-1.25 (10 H, m, 3’ to 7’-CH2), 
0.92-0.88 (3 H, m, 8’-CH3); 13C NMR (126 MHz, chloroform-d) δ 160.7 (C), 150.4 (C), 145.0 
(CH), 126.9 (C), 118.1 (C), 115.2 (C), 109.2 (C), 31.8 (CH2), 29.5 (CH2), 29.3 (CH2), 29.2 
(CH2), 28.7 (CH2), 24.5 (CH2), 22.6 (CH2), 16.7 (CH3), 14.0 (CH3); IR (neat, νmax) cm-1 3386, 
2926, 2857, 1604, 1508, 1419, 1328, 1238, 1122, 973, 950, 723, 639. 
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3-Chloro-4,6-dihydroxy-2-methyl-5-octylbenzonitrile (164) 
 
5-Chloro-4-methyl-7-octylbenzo[d]isoxazol-6-ol (50 mg, 0.17 mmol) was dissolved in a 
mixture of ethanol (10 mL) and 1 M aqueous sodium hydroxide (1.7 mL) and stirred for 
2 hours at room temperature. The reaction was acidified with 1 M aqueous hydrogen 
chloride (3 mL) and extracted with diethyl ether (3 x 20 mL). The combined organic 
phases were dried over magnesium sulfate, filtered and concentrated under reduced 
pressure onto celite (1 g). Purification by flash column chromatography over silica (10 
g), eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (85:15), gave the title 
compound as a white powder (16 mg, 31%): mp 68 °C; Rf  0.42 (10% ethyl acetate / 90% 
40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for C16H23ClNO2: 296.1412, found: 
296.1422; 1H NMR (500 MHz, chloroform-d) δ 6.13 (2 H, s, 2 and 4-OH), 2.70-2.63 (2 H, 
m, 1’-CH2), 2.51 (3 H, s, 6-CH3), 1.57-1.49 (2 H, m, 2’-CH2), 1.37-1.23 (10 H, m, 3’ to 7’-
CH2), 0.89 (3 H, s, 8’-CH2); 13C NMR (126 MHz, chloroform-d) δ 156.3 (C), 154.0 (C), 137.0 
(C), 115.7 (C), 115.4 (C), 113.4 (C), 93.8 (C), 31.8  (CH2), 29.5 (CH2), 29.4 (CH2), 29.2 (CH2), 
28.4 (CH2), 23.8 (CH2), 22.6 (CH2), 18.8 (CH3), 14.0 (CH3);  IR (neat, νmax) cm-1 2924, 2855, 
2234, 1592, 1487, 1185, 1026, 864, 750, 688, 591. 
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3-Methoxy-5-methylcyclohex-2-enone268 (176) 
 
5-Methylcyclohexane-1,3-dione (10.0 g, 79.3 mmol) and dimethylsulfate (7.5 mL, 79 
mmol) were dissolved in anhydrous tetrahydrofuran (30 mL) and 60% sodium hydride 
on mineral oil (3.5 g, 87 mmol) was added in portions. The reaction was stirred for 18 
hours at room temperature concentrated under reduced pressure, diluted with ethyl 
acetate (20 mL), quenched with water (20 mL) and transferred to a separating funnel. 
The organics were washed with water (30 mL) and brine (30 mL), dried over magnesium 
sulfate, filtered and concentrated under reduced pressure onto celite (2 g). Purification 
by column chromatography over silica (50 g), eluting with a gradient of 40-60 °C petrol 
ether: ethyl acetate (100:0) to (50:50) and concentration under reduced pressure, gave 
the title compound as a white solid (10.8 g, 72%): HRMS-ESI m/z [M+Na]+ calcd for 
C9H12NaO3: 163.0730, found: 163.0727;  1H (500 MHz, chloroform-d) δ 5.37 (1 H, s, 2-
CH), 3.70 (3 H, s 3-CH3), 2.44 (1 H, t, J = 5 Hz, 6-CH), 2.41 (1 H, t, J = 5 Hz, 4-CH), 2.28- 
2.20 (1 H, m, 5-CH), 2.15 (1 H, dd, J = 17, 10 Hz, 4-CH), 2.05 (1 H, dd, J = 16, 11 Hz, 6-CH), 
1.09 (3 H, d, J = 6 Hz, 5-CH3). 
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(Z)-6-(Hydroxymethylene)-3-methoxy-5-methylcyclohex-2-enone (177) 
 
3-Methoxy-5-methyl-cyclohex-2-en-1-one (2.50 g, 17.8 mmol) was dissolved in methyl 
formate (20 mL, 0.32 mol).  Sodium methoxide (4.8 g, 89 mmol) was added and the 
reaction was stirred for 20 hours. The reaction was concentrated under reduced 
pressure, diluted with water (20 mL) and neutralised by careful addition of 1M aqueous 
hydrochloric acid. The neutral solution was extracted with ethyl acetate (3 x 20 mL). The 
combined organics were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure onto celite (2 g). Purification by flash column chromatography over 
silica (25 g) 40-60 °C petrol ether: ethyl acetate (100:0) to (70:30) gave the title 
compound as a clear yellow oil (1.83 g, 61%): Rf 0.30 (20% ethyl acetate / 80% 40-60 °C 
petrol ether); HRMS-ESI m/z [M+H]+ calcd for C9H13O3: 169.0859, found: 169.0858; 1H 
(500 MHz, chloroform-d) δ 7.24 (1 H, s, 6-CH), 5.35 (1 H, s, 2-CH), 3.74 (3 H, s, 3-CH3), 
2.76 (1 H, h, J = 7 Hz, 5-CH), 2.54 (1 H, dd, J = 17, 6 Hz, 4-CH2), 2.19 (1 H, dd, J = 17, 7 Hz, 
4-CH2), 1.16 (3 H, d, J = 7 Hz, 3-CH3); 13C NMR (126 MHz, cdcl3) δ 192.7 (C), 175.8 (C), 
161.6 (CH), 111.7 (C), 100.0 (CH), 55.8 (CH3), 36.6 (CH2), 28.6 (CH), 20.3 (CH3); IR (neat, 
νmax) cm-1 2962, 1635, 1598, 1406, 1383, 1167, 1000, 831. 
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6-Methoxy-4-methyl-4,5-dihydro-1H-indazole (178) 
 
4-Methoxy-6-methyl-2-oxo-cyclohex-3-ene-1-carbaldehyde (1.75 g, 10.4 mmol) was 
dissolved in dry methyl alcohol (6 mL) and hydrazine monohydrochloride (855 mg, 12.5 
mmol) added to this solution and stirred at room temperature for 1 hour. The reaction 
was concentrated under reduced pressure to near dryness, diluted with ethyl acetate 
(15 mL), transferred to a separating funnel and was washed with water (3 x 10 mL). The 
organics were dried over magnesium sulfate, filtered and concentrated under reduced 
pressure onto celite (2 g).  Purification by flash column chromatography over silica (10 
g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (50:50) gave the title compound 
as a dark red gum (1.66 g, 96%): HRMS-ESI m/z [M+H]+ calcd for C9H13N2O: 165.1022, 
found: 165.1023; 1H (500 MHz, chloroform-d) δ 9.33 (1 H, s, 1-NH), 7.21 (1 H, s, 3-CH), 
5.64 (1 H, s, 7-CH), 3.67 (3 H, s, 6-CH3), 3.11-2.98 (1 H, m, 4-CH), 2.44 (1 H, dd, J = 16, 7 
Hz, 5-CH2), 2.22 (1 H, dd, J = 16, 11 Hz, 5-CH2), 1.26 (3 H, d, J = 7 Hz, 4-CH3). 
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6-Methoxy-4-methyl-4,5-dihydrobenzo[d]isoxazole (179) 
 
4-Methoxy-6-methyl-2-oxo-cyclohex-3-ene-1-carbaldehyde (2.00 g, 11.9 mmol) and 
hydroxylamine hydrochloride (825 mg, 11.9 mmol) were dissolved in pyridine (7 mL) and 
heated to 70 °C for 2 hours. The reaction was concentrated under reduced pressure then 
diluted with ethyl acetate (30 mL) and washed with 1M aqueous hydrogen chloride 
solution (30 mL). The combined organics were dried over magnesium sulfate, filtered 
and concentrated under reduced pressure onto celite (2 g). Purification by flash column 
chromatography over silica (25 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to 
(50:50) gave the title compound as a viscous red oil (1.85 g, 94%): MS (ESI) m/z (%): 166 
(100) [M+H]+; 1H (500 MHz, chloroform-d) δ 7.98 (1 H, s, 3-CH), 5.62 (1 H, s 7-CH), 3.71 
(3 H, s, 6-CH3), 3.08-2.99 (1 H, m. 4-CH), 2.60 (1 H, dd, J = 17, 8 Hz, 5-CH2), 2.31 (1 H, dd, 
J = 17, 10 Hz, 5-CH2), 1.24 (3 H, d, J = 7 Hz, 4-CH3). 
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4-Methyl-4,5-dihydro-1H-indazol-6(7H)-one (180) 
 
6-Methoxy-4-methyl-4,5-dihydro-1H-indazole (750 mg, 4.57 mmol) was suspended 
in water (4 mL), 12 M aqueous hydrogen chloride (0.5 mL, 5 mmol) added and the 
reaction stirred for 16 hours at room temperature. The reaction was neutralised with 
excess saturated aqueous sodium hydrogen carbonate solution (20 mL) and extracted 
with ethyl acetate (3 x 20 mL). The combined organics were dried over magnesium 
sulfate, filtered and concentrated under reduced pressure giving the product as a dark 
red gum (643 mg, 94%): HRMS-ESI m/z [M+H]+ calcd for C8H11N2O: 151.0866, found: 
151.0871; 1H (500 MHz, chloroform-d) δ 7.47 (1 H, s, 3-CH), 7.04 (1 H, s, 1-NH), 3.68-3.50 
(2 H, m, 7-CH2), 3.23-3.12 (1 H, m, 4-CH), 2.72 (1 H, dd, J = 14, 5 Hz, 5-CH2), 2.36 (1 H, dd, 
J = 14, 9 Hz, 5-CH2), 1.33 (3 H, d, J = 7 Hz, 4-CH3); 13C NMR (126 MHz, chloroform-d) δ 
207.6 (C) 143.0 (C), 127.5 (CH), 121.1 (C), 48.1 (CH2), 37.8 (CH2), 26.1 (CH), 21.5 (CH3). 
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4-Methyl-4,5-dihydrobenzo[d]isoxazol-6(7H)-one (181) 
 
 6-Methoxy-4-methyl-4,5-dihydro-1,2-benzoxazole (900 mg, 5.45 mmol) was suspended 
as an oil in water (3 mL) and concentrated hydrochloric acid (0.45 mL, 5.5 mmol) was 
added. The reaction was stirred for 16 hours and was then extracted with ethyl acetate 
(2 x 20 mL). The organics were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure onto celite (2 g).  Purification by flash column chromatography 
over silica (20 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (50:50) gave the 
title compound as a yellow gum (764 mg, 93%): MS (EI) m/z (%): 151 (51), 152 (8) [M]+; 
1H (500 MHz, chloroform-d) δ 8.21 (1 H, s, 3-CH), 3.69-3.50 (2 H, m, 7-CH2), 3.17-3.04 (1 
H, m, 4-CH), 2.77 (1 H, dd, J = 14, 6 Hz, 5-CH2), 2.38 (1 H, dd, J 14, 8 Hz, 5-CH2), 1.31 (3 H, 
d, J = 7 Hz, 4-CH3); 13C NMR (126 MHz, chloroform-d) δ 204.2 (C), 163.1 (C), 148.1 (CH), 
117.5 (C), 47.2 (CH2), 37.7 (CH2), 24.6(CH), 21.2 (CH3). 
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 5-Methyl-2-octylcyclohexane-1,3-diol (201) 
 
5-Methylcyclohexane-1,3-dione (10.3 g, 81.9 mmol), octanal (8.54 mL, 54.6 mmol) and 
L-proline (1.26 g, 10.9 mmol) were dissolved in ethanol (150 mL) and stirred for 1 hour. 
Sodium cyanoborahydride (3.43 g, 54.6 mmol) and molecular sieves (350 mg per mmol 
of aldehyde) were added and the reaction heated to 80 °C for 2 hours. The reaction was 
poured onto ice (100 g) and the white solid suspension that formed was vacuum filtered. 
The solids were dissolved in ethyl acetate (40 mL) and washed with water (2 x 40 mL). 
The organics were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure to give the title compound as a white powder (11.9 g, apparent yield 
91%) Product was a complex mixture of isomers and full characterisation was confirmed 
after successful subsequent reaction to 3-methoxy-5-methyl-2-octylcyclohex-2-enone: 
Rf 0.12 (20% ethyl acetate / 80% 40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for 
C15H27O2: 239.2006, found: 239.2005 
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3-Methoxy-5-methyl-2-octylcyclohex-2-enone (202) 
 
5-Methyl-2-octyl-cyclohexane-1,3-dione (567 mg, 2.38 mmol) and dimethylsulfate (0.23 
mL 2.4 mmol) were dissolved in anhydrous tetrahydrofuran (30 mL) and 60% sodium 
hydride on mineral oil (3.49 g, 87.1 mmol) was added in portions. The reaction was 
stirred for 18 hours at room temperature concentrated under reduced pressure, diluted 
with ethyl acetate (20 mL), quenched with water (20 mL) and transferred to a separating 
funnel. The organics were washed with water (30 mL) and brine (30 mL), dried over 
magnesium sulfate, filtered and concentrated under reduced pressure onto celite (2 g). 
Purification by column chromatography over silica (50 g), eluting with a gradient of 40-
60 °C petrol ether: ethyl acetate (100:0) to (50:50) and concentration under reduced 
pressure, gave the title compound as a yellow oil (508 mg, 85%): Rf 0.26 (20% ethyl 
acetate / 80% 40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for C16H29O2: 253.2162, 
found: 253.2163; 1H (500 MHz, chloroform-d) δ 3.80 (3 H, s, 3-CH3), 2.71-2.61 (1 H, m, 4 
or 6-CH), 2.44 (1 H, dd, J = 16, 3 Hz, 4 or 6-CH), 2.28-2.11 (4 H, m, 4 or 6-CH, 5-CH and 1’-
CH2), 2.07-1.98 (1 H, m, 4 or 6-CH), 1.26 (12 H, s, 2’ to 7’-CH2), 1.10 (3 H, d, J = 6 Hz, 5-
CH2), 0.88 (3 H, t, J = 7 Hz, 8’-CH3); 13C NMR (126 MHz, chloroform-d) δ 198.0 (C), 170.8 
(C), 119.6 (C), 54.9 (CH3), 44.8 (CH2), 33.0 (CH2), 31.8 (CH2), 29.6 (CH2), 29.4 (CH2), 29.2 
(CH2), 28.6 (CH2), 28.4(CH), 22.6(CH2), 21.9 (CH2), 21.1 (CH3), 13.9 (CH3); IR (neat, νmax) 
cm-1 2924, 1709, 1377, 1230, 1128, 1061, 1033, 722. 
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4-Methoxy-6-methyl-3-octyl-2-oxocyclohex-3-enecarbaldehyde (203) 
 
N-Isopropylpropan-2-amine (2.67 mL, 19.0 mmol) was dissolved in dry tetrahydrofuran 
(150 mL), cooled to -78 °C and n-butyllithium (6.18 mL, 15.5 mmol) added. The mixture 
was allowed to come to room temperature. This was cooled to -78 °C again and a 
solution of 3-methoxy-5-methyl-2-octyl-cyclohex-2-en-1-one (3.00 g, 11.9 mmol) in dry 
tetrahydrofuran (5 mL) was added via syringe. This was stirred for 1 hour and then 
dry methyl formate (1.47 mL, 23.8 mmol) was added and the reaction was allowed to 
come to room temperature overnight slowly. The reaction mixture was concentrated 
under reduced pressure and diluted with ethyl acetate (30 mL). This was neutralised 
with 1 M aqueous hydrogen chloride, the organics separated and washed with water 
(30 mL). The organics were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure onto celite (2 g). Purification by flash column chromatography 
over silica (25 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (90:10) gave the 
title compound as a clear yellow oil (2.25 g, 68%): Rf 0.46 (20% ethyl acetate / 80% 40-
60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for C17H29O3: 281.2111, found: 
281.2113; 1H (500 MHz, chloroform-d) δ 7.19 (1 H, d, J = 1 Hz, 1-CH), 3.79 (3 H, s, 4-CH3), 
2.75 (1 H, q, J = 7 Hz, 5-CH), 2.65 (1 H, dd, J = 17, 6 Hz, 5-CH), 2.37-2.27 (3 H, m, 1’-CH2 
and 6-CH), 1.39-1.32 (2 H, m, 2’-CH2), 1.32-1.23 (10 H, m, 3’ to 7’-CH2), 1.18 (3 H, d, J = 7 
Hz, 6-CH3), 0.88 (3 H, t, J = 7 Hz, 8’-CH3); 13C NMR (126 MHz, chloroform-d) δ 191.9 (C), 
169.3 (C), 160.5 (CH), 111.3 (CH3), 55.0 (CH2), 31.9 (CH2), 31.8 (CH2), 29.6 (CH2), 29.4 
(CH2), 29.2 (CH2), 28.6 (CH2), 28.3 (CH), 22.6 (CH2), 21.6 (CH2), 20.4 (CH3), 14.0 (CH3); IR 
(neat, νmax) cm-1 2923, 1608, 1378, 1238, 1159, 1130, 1006, 953.  
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6-Methoxy-4-methyl-7-octyl-4,5-dihydro-1H-indazole (205) 
 
4-Methoxy-6-methyl-3-octyl-2-oxo-cyclohex-3-ene-1-carbaldehyde (500 mg, 1.78 
mmol) was dissolved in methanol (5 mL), hydrazine monohydrochloride (134 mg, 1.96 
mmol) was added and the reaction was stirred at room temperature for 2 hours. 
The reaction was concentrated to near dryness under reduced pressure, diluted with 
water (30 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organics were 
dried over magnesium sulfate, filtered and concentrated under reduced pressure onto 
celite (2 g). Purification by flash column chromatography over silica (10 g) eluting 40-60 
°C petrol ether: ethyl acetate (100:0) to (75:25) gave the title compound as a red gum 
(481 mg, 97%). Product unstable, full characterisation after subsequent reaction to 6-
methoxy-4-methyl-7-octyl-1H-indazole: MS (ESI) m/z (%): 171 (100) [M+H]+; 1H NMR 
(500 MHz, chloroform-d) δ 7.25 (1 H, s, 3-CH), 3.64 (3 H, s, 6-CH3), 3.09-2.96 (1 H, m, 4-
CH), 2.57 (1 H, dd, J = 16, 7 Hz, 5-CH), 2.49 (2 H, t, J = 8 Hz, 1’-CH2), 2.22 (1 H, dd, J = 16, 
10 Hz, 5-CH), 1.58-1.47 (2 H, m, 2’-CH2), 1.40-1.14 (13 H, m, 4-CH3 and 3’ to 7’-CH2), 0.87 
(3 H, t, J =  7 Hz, 8’-CH3). 
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6-Methoxy-4-methyl-7-octyl-4,5-dihydrobenzo[d]isoxazole (206) 
 
4-Methoxy-6-methyl-3-octyl-2-oxo-cyclohex-3-ene-1-carbaldehyde (375 mg, 1.34 
mmol) was dissolved in pyridine (6 mL) and hydroxylamine hydrochloride (102 mg, 1.47 
mmol) added. The reaction was heated to 100 °C in a microwave for 1 hour then 
concentrated under reduced pressure to near dryness. The residue was diluted with 
ethyl acetate (30 mL) and this was washed with 1 M aqueous hydrochloric acid (2 x 20 
mL) then water (2 x 30 mL). The organics were dried over magnesium sulfate, filtered 
and concentrated under reduced pressure onto celite (2 g).  Purification by flash column 
chromatography over silica (10 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to 
(90:10) gave the title compound as a clear viscous oil (224 mg, 61%). Product unstable, 
full characterisation after subsequent reaction to 6-methoxy-4-methyl-7-
octylbenzo[d]isoxazole: MS (ESI) m/z (%): 178 (100) [M+H]+; 1H (500 MHz, chloroform-
d) δ 7.99 (1 H, s, 3-CH), 3.69 (3 H, s, 6-CH3), 3.14-2.99 (1 H, m, 4-CH), 2.71 (1 H, dd, J = 
17, 8 Hz, 5-CH), 2.44 (2 H, t, J = 8 Hz, 1’-CH2), 2.32 (1 H, dd, J = 17, 10 Hz, 5-CH), 1.55-1.46 
(2 H, m, 2’-CH2), 1.36-1.20 (13 H, m, 3’ to 7’-CH2 and 4-CH3), 0.88 (3 H, t, J  = 7 Hz, 8’-
CH3). 
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6-Methoxy-4-methyl-7-octyl-1H-indazole (207) 
 
6-Methoxy-4-methyl-7-octyl-4,5-dihydro-1H-indazole (50 mg, 0.18 mmol) and 
palladium on carbon 60% (3.2 mg, 0.02 mmol) were added to toluene (5 mL)  and the 
reaction was heated to 100 °C for 15 hours. The reaction was cooled, filtered and 
concentrated under reduced pressure to give the title compound as a pale yellow solid 
(44 mg, 89%): mp 55-58 °C; Rf 0.28 (20% ethyl acetate / 80% 40-60 °C petrol ether);  
HRMS-ESI m/z [M+H]+ calcd for C17H27N2O: 275.2118, found: 275.2112; δ H (500 MHz, 
chloroform-d) 8.06 (1 H, s, 3-CH), 7.28-7.25 (1 H, m, 1-NH), 6.75 (1 H, s, 5-CH), 3.92 (3 H, 
s, 6-CH3), 2.86 (2 H, t, J = 8 Hz, 1’-CH2), 2.59 (3 H, s, 4-CH3), 1.68-1.60 (2 H, m, 2’-CH2), 
1.47-1.14 (10 H, m, 3’-7’-CH2), 0.88 (3 H, t, J =7 Hz, 8’-CH3); 13C NMR (126 MHz, 
chloroform-d) δ 156.1 (C), 141.0 (C), 133.7 (CH), 129.2 (C), 118.8 (C), 109.0 (CH), 108.4 
(C), 56.9 (CH3), 31.9 (CH2), 29.8 (CH2), 29.5 (CH2), 29.3 (CH2), 29.2 (CH2), 25.0 (CH2), 22.6 
(CH2), 18.7 (CH3), 14.0 (CH3); IR (neat, νmax) cm-1 2921, 2852, 1619, 1460, 1219, 949, 839. 
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6-Methoxy-4-methyl-7-octylbenzo[d]isoxazole (208) 
 
6-Methoxy-4-methyl-7-octyl-4,5-dihydrobenzo[d]isoxazole (50 mg, 0.18 mmol) and 
palladium on carbon 60% (3.2 mg, 0.02 mmol) were added to toluene (5 mL) and the 
reaction was heated to 100 °C for 15 hours. The reaction was cooled, filtered and 
concentrated under reduced pressure to give the title compound as a clear pale yellow 
oil (46 mg, 93%): mp 48-50 °C; Rf 0.47 (10% ethyl acetate / 90% 40-60 °C petrol ether); 
HRMS-ESI m/z [M+H]+ calcd for C17H26NO2: 276.1958, found: 276.1950; 1H (500 MHz, 
chloroform-d) δ 8.59 (1 H, s, 3-CH), 6.74 (1 H, s, 5-CH), 3.91 (3 H, s, 6-CH3), 2.92-2.82 (2 
H, m, 1’-CH2), 2.54 (3 H, s, 4-CH3), 1.71-1.59 (2 H, m, 2’-CH2), 1.46-1.18 (10 H, m, 3’ to 7’-
CH2), 0.88 (3 H, t, J = 7 Hz, 8’-CH3); 13C NMR (126 MHz, chloroform-d) δ 162.4 (C), 158.8 
(C), 145.1 (CH), 129.9 (C), 115.4 (C), 110.0 (C), 109.6 (CH), 56.5 (CH3), 31.9 (CH2), 29.6 
(CH2), 29.4 (CH2), 29.2 (CH2), 29.1 (CH2), 23.6 (CH2), 22.6 (CH2), 18.7 (CH3), 14.1 (CH3); IR 
(neat, νmax) cm-1 2953, 2851, 2919, 1623, 1600, 1461, 1314, 1219. 
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Ethyl 3-(2-hydroxy-4-methyl-6-oxocyclohex-1-en-1-yl)propanoate (209) 
 
60% Sodium hydride on mineral oil (698 mg, 17.4 mmol) was dissolved in dry N, N-
dimethylformamide (30 mL). A dropping funnel was charged with 5-methylcyclohexane-
1,3-dione (2.00 g, 15.8 mmol) in N, N-dimethylformamide (10 mL) and was added drop-
wise over 5 minutes. The reaction was left to stir for 1 hour before the addition of ethyl 
acrylate (1.90 mL, 17.4 mmol). The reaction was stirred for a further 2 hours then 
neutralised with 1 M aqueous hydrogen chloride and diluted with water (50 mL). The 
quenched solution was transferred to a separating funnel and extracted with diethyl 
ether (3 x 100 mL). The combined organics were washed with water (2 x 50 mL) followed 
by saturated brine solution (50 mL). The organics were dried over magnesium sulfate, 
filtered and concentrated under reduced pressure onto celite (3 g). Purification by flash 
column chromatography over silica (25 g), eluting petrol ether: ethyl acetate (100: 0) to 
(50: 50), gave the title compound as a white powder (2.01 g, 56%): HRMS-ESI m/z 
[M+Na]+ calcd for C12H18NaO4: 249.1097, found: 249.1102; 1H (500 MHz, chloroform-d) 
δ 9.47 (1 H, s, 5-OH), 4.22-4.16 (1 H, m, 1-CH2), 2.63-2.39 (6 H, m, 2, 6 and 8-CH2), 2.23-
2.10 (2 H, m, 3-CH2), 2.08-1.96 (1 H, m, 7-CH), 1.27 (3 H, t, J = 7 Hz, 1-CH3), 1.06 (3 H, d, 
J = 6 Hz, 7-CH3). 
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Tert-butyl 3-(4-methyl-2,6-dioxocyclohexyl)propanoate (210) 
 
5-Methylcyclohexane-1,3-dione (2.00 g, 15.9 mmol) and tert butyl acrylate (2.55 mL, 
17.4 mmol) were dissolved in  N,N-dimethylformamide (10 mL)  and  sodium hydride 
(635 mg, 15.8 mmol)  added slowly. The reaction was stirred for 1 hour at room 
temperature then heated to 80 °C for 16 hours. The reaction was allowed cool to room 
temperature, acidified to pH 4 with acetic acid then neutralised and diluted with 
saturated aqueous sodium hydrogen carbonate solution (30 mL). This was extracted 
with ethyl acetate (3 x 30 mL). The combined organics were washed with saturated 
aqueous sodium hydrogen carbonate (30 mL), dried over magnesium sulfate, filtered 
and concentrated under reduced pressure onto celite (4 g).  Purification by flash column 
chromatography over silica (25 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to 
(60:40) gave the title compound as a pale yellow powder (2.94 g, 73%). Product 
unstable, full characterisation after subsequent reaction to tert-butyl 3-(2-methoxy-4-
methyl-6-oxocyclohex-1-en-1-yl)propanoate: HRMS-ESI m/z [M+Na]+ calcd for 
C14H22NaO4: 277.1410, found: 277.1415; 1H (500 MHz, chloroform-d) δ 2.49-2.36 (6 H, 
m), 2.18-2.02 (3 H, m), 1.42 (9 H, s, 1'-tBu), 1.02 (3 H, d, J = 6 Hz, 4-CH3) 
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Tert-butyl 3-(2-methoxy-4-methyl-6-oxocyclohex-1-en-1-yl)propanoate (211)   
 
Tert-butyl 3-(2-hydroxy-4-methyl-6-oxo-cyclohexen-1-yl)propanoate (16.0 g, 62.9 
mmol) and  dimethyl sulfate (7.1 mL, 76 mmol)  were dissolved in  tetrahydrofuran (200 
mL) and 60% sodium hydride on mineral oil (3.0 g, 76 mmol) added slowly. The reaction 
was stirred at room temperature for 3 hours then the reaction was concentrated under 
reduced pressure and rediluted with ethyl acetate (25 mL) and water (25 mL). This 
mixture was neutralised using excess sodium phosphate monobasic. The ethyl acetate 
was separated and the aqueous layer extracted with ethyl acetate (2 x 30 mL). The 
combined organics were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure onto celite (2 g).  Purification by flash column chromatography over 
silica (100 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (80:20) gave the title 
compound as a clear colourless oil (15.2 g, 90%): Rf 0.17 (20% ethyl acetate / 80% 40-60 
°C petrol ether); HRMS-ESI m/z [M+Na]+ calcd for C15H24NaO4: 291.1567, found: 
291.1572; 1H (600 MHz, chloroform-d) 3.78 (3 H, s, 2-CH3), 2.69-2.58 (1 H, m, 3 or 5-CH3), 
2.55-2.43 (2 H, m, 3’-CH2), 2.43-2.34 (1 H, m, 3 or 5-CH3), 2.24-2.17 (2 H, m, 2’-CH3), 2.17-
2.09 (2 H, m, 3 or 5-CH2 and 4-CH), 2.05-1.93 (1 H, m, 3 or 5-CH2), 1.40 (9 H, s, 1’-tBu), 
1.07 (3 H, d, J = 6 Hz, 4-CH2); 13C NMR (126 MHz, chloroform-d) δ 197.6 (C), 172.9 (C), 
171.5 (C), 117.7 (C), 79.6 (C), 55.1 (C), 44.7 (CH2), 34.3 (CH2), 33.0 (CH2), 28.4 (CH), 28.1 
(CH3), 21.1 (CH3), 17.8 (CH2); IR (neat, νmax) cm-1 2973, 1723, 1611, 1367, 1233, 1148, 
1084, 846. 
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(Z)-Tert-butyl 3-(5-(hydroxymethylene)-2-methoxy-4-methyl-6-oxocyclohex-1-en-1-
yl)propanoate (212) 
 
Diisopropylamine (4.6 mL, 32 mmol) was dissolved in dry tetrahydrofuran (550 mL), 
cooled to -78 °C and 2.5 M n-butyllithium (12.2 mL, 30.4 mmol)  added. The reaction was 
warmed to room temperature then cooled to -78 °C and tert-butyl 3-(2-methoxy-4-
methyl-6-oxo-cyclohexen-1-yl)propanoate (6.80 g, 23.4 mmol) added. The reaction was 
stirred for 1 hour at -78 °C then methyl formate (2.34 mL, 38.0 mmol) was added and 
the reaction was allowed to warm to room temperature overnight. The reaction was 
concentrated under reduced pressure, diluted water (50 mL) and neutralised by careful 
addition of 1M aqueous hydrogen chloride solution.  The organics were dried over 
magnesium sulfate, filtered and concentrated under reduced pressure onto celite (5 
g).  Purification by flash column chromatography over silica (100 g) eluting 40-60 °C 
petrol ether: ethyl acetate (100:0) to (70:30) gave the title compound as a yellow oil 
(4.41 g, 59%): Rf 0.26 (20% ethyl acetate / 80% 40-60 °C petrol ether); HRMS-ESI m/z 
[M+H]+ calcd for C16H24NaO5: 319.1510, found: 319.1521; 1H NMR (500 MHz, 
chloroform-d) 7.21-7.07 (1 H, m, 5-CH), 3.79 (3 H, s, 2-CH3), 2.76-2.69 (1 H, m, 4-CH), 
2.67-2.60 (1 H, m, 3-CH2), 2.60-2.56 (2 H, m, 3’-CH2), 2.35-2.25 (3 H, m, 2’-CH and 3-CH2), 
1.41 (9 H, s, 1’-tBu), 1.16 (3 H, d, J = 7 Hz, 4-CH3); 13C NMR (126 MHz, chloroform-d) δ 
191.7 (C), 172.7 (C), 170.0 (C), 160.3 (CH), 116.5 (C), 111.2 (C), 79.7 (C), 55.2 (CH3), 34.3 
(CH2), 32.0 (CH2), 28.3 (CH), 28.1 (CH3), 20.3 (CH3), 17.5 (CH2); IR (neat, νmax) cm1 2973, 
1723, 1611, 1367, 1233, 1148, 1084, 846.  
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Tert-butyl 3-(6-methoxy-4-methyl-4,5-dihydro-1H-indazol-7-yl)propanoate (213) 
 
(Z)-Tert-butyl 3-(5-(hydroxymethylene)-2-methoxy-4-methyl-6-oxocyclohex-1-en-1-yl) 
propanoate (3.25 g, 11.0 mmol) was dissolved in methanol (15 mL), hydrazine 
monohydrochloride (0.939 g, 13.7 mmol) was added and the reaction was stirred at 
room temperature for 2 hours. The reaction was concentrated to near dryness under 
reduced pressure, diluted with water (30 mL) and extracted with ethyl acetate (2 x 30 
mL). The combined organics were dried over magnesium sulfate, filtered and 
concentrated under reduced pressure onto celite (2 g). Purification by flash column 
chromatography over silica (10 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to 
(80:20) gave the title compound as a yellow gum (2.80 g, 87%). Product unstable, full 
characterisation after subsequent reaction to tert-butyl 3-(6-methoxy-4-methyl-1H-
indazol-7-yl)propanoate: MS (ESI) m/z (%): 237 (47) 293 (100) [M+H]+;  1H NMR (500 
MHz, chloroform-d) δ 7.25 (1 H, s, 3-CH), 3.65 (3 H, s, 6-CH3), 3.10-2.95 (1 H, m, 4-CH), 
2.76 (2 H, t, J = 8 Hz, 3’-CH3), 2.57 (1 H, dd, J = 16, 7 Hz, 5-CH2), 2.49 (2 H, t, J = 8 Hz, 
2’CH3), 2.21 (1 H, dd, J = 16, 11 Hz, 5-CH2), 1.43 (9 H, s, 1’-tBu), 1.28 (3 H, d, J=  7 Hz, 4’-
CH3). 
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Tert-butyl 3-(6-methoxy-4-methyl-4,5-dihydrobenzo[d]isoxazol-7-yl)propanoate (214) 
 
4-Methoxy-6-methyl-3-octyl-2-oxo-cyclohex-3-ene-1-carbaldehyde (3.00 g, 10.3 
mmol) was dissolved in pyridine (10 mL) and hydroxylamine hydrochloride (880 mg, 
12.6 mmol) added. The reaction was heated to 100 °C in a microwave for 1 hour then 
concentrated under reduced pressure to near dryness. The residue was diluted with 
ethyl acetate (30 mL) and this was washed with 1 M aqueous hydrochloric acid (20 mL) 
and water (2 x 30 mL). The organics were dried over magnesium sulfate, filtered and 
concentrated under reduced pressure onto celite (2 g). Purification by flash column 
chromatography over silica (10 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to 
(90:10) gave the title compound as a yellow oil (1.86 g, 61%). Product unstable, full 
characterisation after subsequent reaction to tert-butyl 3-(6-methoxy-4-
methylbenzo[d]isoxazol-7-yl)propanoate: MS (ESI) m/z (%): 238 (47), 294 (52) [M+H]+; 
1H NMR (500 MHz, chloroform-d) δ 7.99 (1 H, s, 3-CH), 3.71 (3 H, s, 6-CH3), 3.11-2.97 (1 
H, m, 4-CH), 2.77-2.67 (3 H, m, 5-CH2 and 3’-CH2), 2.49-2.41 (2 H, m, 2’-CH2), 2.32 (1 H, 
dd, J  = 17, 10 Hz, 5-CH2), 1.42 (9 H, s, 1’-tBu), 1.25 (3 H, d, J  = 7 Hz, 4-CH3). 
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Tert-butyl 3-(6-methoxy-4-methyl-1H-indazol-7-yl)propanoate (215) 
 
Tert-butyl 3-(6-methoxy-4-methyl-4,5-dihydro-1H-indazol-7-yl)propanoate (600 mg, 
2.05 mmol) was dissolved in toluene (20 mL) and 2,3-dichloro-5,6-dicyano-p-
benzoquinone (583 mg, 2.57 mmol) added. The reaction was stirred for 16 hours at 
room temperature then diluted with ethyl acetate (50 mL) and washed with water (5 x 
50 mL). The organics were dried over magnesium sulfate, filtered and concentrated 
under reduced pressure on to celite (2 g). Purification by flash column chromatography 
over silica (100 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (80:20) gave the 
title compound as a white/yellow gum (576 mg, 97%): Rf 0.28 (20% ethyl acetate / 80% 
40-60 °C petrol ether); MS (ESI) m/z (%): 175 (54), 217 (18), 235 (32), 291 (100) [M+H]+;  
1H (500 MHz, chloroform-d) 8.03 (1 H, s, 3-H), 6.69 (1 H, s, 5-CH), 3.91 (3 H, s, 6-CH3), 
3.13 (2 H, t, J = 7 Hz, 3’-CH2), 2.61-2.56 (5 H, m, 2’CH2 and 4-CH3), 1.37 (9 H, s, 1’-tBu); 
13C NMR (126 MHz, chloroform-d) 174.0 (C), 156.20 (CH), 141.10 (C), 133.40 (C), 130.10 
(C), 118.80 (C), 108.40 (CH), 106.60 (C), 80.8, 56.60 (CH3), 35.00 (CH2), 28.0 (CH3), 20.1 
(CH2), 18.7(CH3); IR (neat, νmax) cm1 2971, 2936, 1705, 1624, 1603, 1276, 1232, 1118, 
862, 767. 
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3-(6-Methoxy-4-methyl-1H-indazol-7-yl)propanoic acid (217) 
 
Tert-butyl 3-(6-methoxy-4-methyl-1H-indazol-7-yl)propanoate (250 mg, 0.86 mmol) was 
dissolved in dichloromethane and trifluoroacetic acid (0.25 mL, 3.3 mmol) added. The 
reaction was stirred at room temperature for 16 hours and then concentrated under 
reduced pressure onto celite (1 g). Purification by flash column chromatography over 
silica (100 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) to (80:20) gave the title 
compound as a white/brown solid (189 mg, 93%): mp 153-159 °C; Rf 0.10 (50% ethyl 
acetate / 50% 40-60 °C petrol ether); HRMS-ESI m/z [M+H]+ calcd for C12H15N2O3: 
235.1077, found:  235.1068; 1H (500 MHz, dmso-d6) δ 7.97 (1 H, s, 3-CH), 6.73 (1 H, s, 5-
CH), 3.83 (3 H, s, 6-CH3), 3.08-2.85 (2 H, m, 3’-CH2), 2.46-2.40 (2 H, m, 2’-CH2); 13C NMR 
(126 MHz, dmso-d6) 174.4 (C), 155.5 (C), 140.9 (C), 133.1 (CH), 129.3 (C), 119.2 (C), 108.6 
(CH), 106.2 (C), 57.1 (CH3), 33.7 (CH2), 20.7 (CH2), 18.9 (CH3); IR (neat, νmax) cm1 2921, 
1716, 1623, 1297, 1215, 1033, 827. 
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Tert-butyl 3-(6-methoxy-4-methylbenzo[d]isoxazol-7-yl)propanoate (216) 
 
Tert-butyl 3-(6-methoxy-4-methyl-4,5-dihydro-1H-indazol-7-yl)propanoate (1.75 g, 5.97 
mmol) was dissolved in toluene (20 mL) and 2,3-dichloro-5,6-dicyano-p-benzoquinone 
(1.69 g, 7.46 mmol) added. The reaction was stirred for 3 hours at room temperature 
then diluted with ethyl acetate (50 mL) and washed with water (5 x 50 mL). The organics 
were dried over magnesium sulfate, filtered and concentrated under reduced pressure 
on to celite (2 g). Purification by flash column chromatography over silica (100 g) eluting 
40-60 °C petrol ether: ethyl acetate (100:0) to (80:20) gave the title compound as a white 
solid (1.61 g, 93%): mp 63-66 °C; Rf 0.15 (20% ethyl acetate / 80% 40-60 °C petrol ether 
MS (ESI) m/z (%): 176 (25), 218 (12), 236 (100), 292 (9) [M+H]+; 1H (500 MHz, chloroform-
d) 8.60 (1 H, s, 3-CH), 6.74 (1 H, s, 5-CH), 3.92 (3 H, s, 6-CH3), 3.19-3.13 (2 H, m, 3’-CH2), 
2.63-2.57 (2 H, m, 2’-CH), 2.55 (3 H, s, 4-CH3), 1.42 (9 H, s, 1’-tBu); 13C NMR (126 MHz, 
chloroform-d) 172.3 (C), 162.2 (C), 159.0 (C), 145.1 (C), 130.8 (CH), 115.5 (C), 109.5 (CH), 
107.7 (C), 80.1 (C), 56.5 (CH3), 34.5 (CH2), 28.0 (CH3), 19.5 (CH2), 18.7 (CH3). 
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3-(6-Methoxy-4-methylbenzo[d]isoxazol-7-yl)propanoic acid (218) 
 
Tert-butyl 3-(6-methoxy-4-methylbenzo[d]isoxazol-7-yl)propanoate (320 mg, 1.10 
mmol) was dissolved in dichloromethane and trifluoroacetic acid (0.32 mL, 4.2 mmol) 
added. The reaction was stirred at room temperature for 16 hours and then 
concentrated under reduced pressure onto celite (1 g). Purification by flash column 
chromatography over silica (100 g) eluting 40-60 °C petrol ether: ethyl acetate (100:0) 
to (80:20) gave the title compound as a white solid (235 mg, 91%): mp 143-147 °C; Rf 
0.25 (50% ethyl acetate / 50% 40-60 petrol ether); HRMS-ESI m/z [M+H]+ calcd for 
C12H14NO4: 236.0917, found:  236.0915; 1H (500 MHz, chloroform-d) δ 8.61 (1 H, s, 3-
CH), 6.75 (1 H, s, 5-CH), 3.92 (3 H, s, 6-CH3), 3.26-3.19 (2 H, m, 3’-CH2), 2.76-2.71 (2 H, m, 
2’-CH2), 2.56 (3 H, s, 4-CH3); 13C NMR (126 MHz, chloroform) δ 178.2 (C), 162.1 (C), 159.0 
(C), 145.1 (CH), 131.1 (C), 115.5 (C), 109.5 (CH), 107.1 (C), 56.5 (CH3), 32.9 (CH2), 19.1 
(CH2), 18.8 (CH3); IR (neat, νmax) cm-1 2924, 1695, 1304, 1221, 1173, 1125, 835, 826, 658, 
645. 
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General amide coupling procedure: 
The desired carboxylic acid (20 mg) was dissolved in N, N-dimethyl formamide (1 mL), 
triethylamine (3 Eq) was added and this was stirred for 20 minutes. N,N,N′,N′-
Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (2.2 Eq) and the 
selected amine (2.5 Eq) were added and the reaction stirred for 20 hours. Direct 
purification of reaction mixture by a mass directed auto purification HPLC machine gave 
the coupled products below:    
2-Hydroxy-4-methoxy-6-methyl-3-(3-morpholino-3-oxopropyl)benzonitrile (232) 
 
White/brown solid (11 mg, 42%): HRMS-ESI m/z [M+H]+ calcd for C16H20N2O4: 305.1496, 
found:  305.1495; 1H (500 MHz, chloroform-d) δ 6.33 (1 H, s, 5-CH), 3.85 (3 H, s, 4-CH3), 
3.78-3.52 (6 H, m, 4’ and 5’-CH2), 3.47-3.40 (2 H, m, 4’-CH2), 2.95-2.85 (2 H, m, 1’ or 2’-
CH2), 2.67-2.59 (2 H, m, 1’ or 2’-CH2), 2.46 (3 H, s, 6-CH3). 
 
2-Hydroxy-4-methoxy-6-methyl-3-(3-oxo-3-(pyrrolidin-1-yl)propyl)benzonitrile (233) 
 
White solid (9 mg, 37%): HRMS-ESI m/z [M+H]+ calcd for C12H14NO4: 236.0917, found:  
236.0915; 1H (500 MHz, chloroform-d) δ 6.31 (1 H, s, 5-CH), 3.84 (3 H, s), 3.47 (2 H, t, J = 
7 Hz), 3.34 (2 H, t, J = 7 Hz), 2.98-2.84 (2 H, m), 2.64-2.55 (2 H, m), 2.46 (3 H, s, 6-CH3), 
1.95 (2 H, ap p, J = 7 Hz, 5’-CH2), 1.85 (2 H, ap p, J = 7 Hz, 5’-CH2). 
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N-Butyl-3-(3-cyano-2-hydroxy-6-methoxy-4-methylphenyl)propanamide (234) 
 
White/brown solid (8 mg, 32%): HRMS-ESI m/z [M+H]+ calcd for C16H23N2O3: 291.1703, 
found:  291.1703; 1H (500 MHz, chloroform-d) δ (500 MHz, cdcl3) 10.41 (1 H, br s, 3’-NH), 
6.32 (1 H, s, 5-CH), 5.52 (1 H, br s, 2-OH), 3.83 (3 H, s, 6-CH3), 3.33-3.18 (2 H, m, 4’-CH2), 
2.93-2.81 (2 H, m, 1’ or 2’-CH2), 2.60-2.51 (2 H, m, 1’ or 2’-CH2), 2.46 (3 H, s, 4-CH3), 1.51-
1.40 (2 H, m, 5’-CH2), 1.34-1.24 (2 H, m, 6’-CH2), 0.91 (3 H, t, J = 7 Hz, 7’-CH3). 
 
3-(6-Methoxy-4-methyl-1H-indazol-7-yl)-1-morpholinopropan-1-one (235) 
 
White solid (15 mg, 59%): HRMS-ESI m/z [M+H]+ calcd for C16H21N3O3: 304.1656, found: 
304.1655; 1H (500 MHz, chloroform-d) δ 8.05 (1 H, s, 3-H), 6.70 (1 H, s, 5-CH), 3.92 (3 H, 
s, 6-CH3), 3.59-3.53 (2 H, m, 4’-CH2), 3.49-3.45 (2 H, m, 4’-CH2), 3.40-3.31 (4 H, m, 5-CH2), 
3.26 (2 H, t, J = 6 Hz, 1’ or 2’-CH2), 2.67 (2 H, t, J = 6 Hz, 1’ or 2’-CH2), 2.59 (3 H, s, 4-CH3). 
 
 
3-(6-Methoxy-4-methyl-1H-indazol-7-yl)-1-(pyrrolidin-1-yl)propan-1-one (231) 
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Brown solid (6 mg, 25%): HRMS-ESI m/z [M+H]+ calcd for C16H22N3O2: 288.1707, found:  
288.1705;  1H (500 MHz, chloroform-d) δ 8.04 (1 H, s, 3-CH), 6.70 (1 H, s, 5-CH), 3.93 (3 
H, s, 6-CH3), 3.43 (2 H, t, J = 7 Hz, 1’-CH2), 3.28 (4 H, ap q, J = 7 Hz, 4’-CH2), 2.64-2.60 (2 
H, m, 2’-CH2), 2.59 (3 H, s, 4-CH2), 1.85 (2 H, ap p, J = 7, 6 Hz, 5’-CH2), 1.78 (2 H, ap p, J = 
8, 7 Hz, 5’-CH2). 
 
N-(2-Hydroxyethyl)-3-(6-methoxy-4-methyl-1H-indazol-7-yl)-N-methylpropanamide 
(236) 
 
White /brown solid (11 mg, 45%): HRMS-ESI m/z [M+H]+ calcd for C15H23N3O3: 292.1656, 
found:  292.1653;  1H (500 MHz, chloroform-d) δ 8.05 (1 H, s), 6.70 (1 H, s), 3.93 (3 H, s), 
3.73 (2 H, t, J = 5 Hz), 3.54 (2 H, t, J = 5 Hz), 3.29-3.21 (2 H, m), 2.99 (3 H, s), 2.71 (2 H, t, 
J = 7 Hz), 2.59 (3 H, s). 
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Overview and Future work 
When this work was initiated it was expected that the development of synthetic 
methods would occupy no more than two years, leaving time to develop SAR around 
ascofuranone. The synthesis proved a great deal more challenging than anticipated, 
expanding to fill the entire PhD and therefore much remains to be investigated around 
these compounds. Whilst the aromatic head group structure looks deceptively simple, 
the presence of substituents on most, if not all, constituent atoms often frustrated 
attempts to transfer developed routes between different headgroup analogues. This 
was not aided by the difficulty encountered in deprotections across various routes 
employed. Particularly the para phenol, which was discovered to be vital for activity, 
was challenging to deprotect. In spite of these problems the aims outlined initially were 
largely achieved. 
There was a lack of synthetic means available when commencing and many potential 
routes were explored. Early forays into palladium chemistry and Fries-like 
rearrangement afforded only limited results although attachment of the tail to the 
headgroup was higher yielding than previously reported syntheses. A combination of 
ortho lithiation chemistry and late stage aromatisaiton of aliphatic heterocycles were 
more successful and allowed the synthesis of a range of novel inhibitors. 
The entire ascofuranone molecule required modification to remove the undesirable 
metabolically labile functionalities. The discovery in the Ward lab of the active 
benzisoxazole headgroup seemingly addresses the aldehyde and bisphenol which were 
at the greatest risk of metabolic alteration. The indazoles synthesised have yet to be 
confirmed as active compounds, however if inhibition of TAO is confirmed then these 
compounds will be another exciting novel class of TAO inhibitors. 
These 5, 6-hetercyclic compounds were developed further and synthetic methods were 
established to allow diversification of these headgroups. Ultimately little time remained 
for exploration of the SAR however the synthetic methods validated will allow future 
exploration of the chemical space around these compounds. 
Clearly further exploration is required of the chemical space around the heterocycles 
with the amide tail. A range of amides should be synthesised with a diverse array of 
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chemical functionalities in attempt to optimise the medicinal chemistry parameters such 
as log P and PSA. It is hoped that compounds could be identified which lack the 
undesirable lipophilicity and metabolic instability associated with the ascofuranone lead 
compound but which retain activity. 
Given that the benzisoxazole appears to isomerise under amide coupling conditions it 
has become imperative that the activity of the indazoles against TAO be ascertained. If 
this compound retains activity it would be prudent to shift focus to the indazole core, 
given that it has proven more easily achievable. If x-ray crystal structures of sufficient 
quality could be achieved, a computationally guided exploration of point changes on the 
indazole and benzisoxazole headgroup would be compelling and novel.   
Further work to access a range of other heterocycles from the diketone starting material 
would be of great interest and was underexplored in this work due to time constraints. 
Of particular interest are the mono heteroatomic indole and thiophene due to their 
improved stability and common use in pharmaceutical drugs at present. Elsewhere in 
the Ward lab Beckmann rearrangement of the salicylic motif has successfully generated 
the benzoxazole and synthesis of a colletochlorin B octyl analogue is underway.   
If the heterocyclic compounds synthesised prove to be active inhibitors of TAO it would 
be necessary to conduct a counter screen against other electron transport chain 
enzymes to assess selectivity. 
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